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ABSTRACT 
PURIFICATION AND CHARACTERIZATION OF Plasmodium falciparum 
HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE 
 
Edwin Kimathi Murungi 
 
MSc minithesis, Faculty of Natural Sciences, University of the Western Cape and Faculty 
of Health Sciences, University of Cape Town. 
 
Malaria remains the most important parasitic disease worldwide. It is estimated that over 
500 million infections and more than 2.7 million deaths arising from malaria occur each 
year. Most (90%) of the infections occur in Africa with the most affected groups being 
children of less than five years of age and women. This dire situation is exacerbated by 
the emergence of drug resistant strains of Plasmodium falciparum. As a result, novel 
antimalarials are urgently needed to combat the disease.  
 
The purine salvage enzyme, hypoxanthine phosphoribosyltransferase of Plasmodium 
falciparum (PfHPRT) catalyses the conversion of phosphoribosyl pyrophosphate and 
hypoxanthine (or guanine) into inosine (or guanosine) monophosphate and 
pyrophosphate. The nucleotides are needed for DNA and RNA synthesis. As such, the 
enzyme is essential for parasite survival and is a recognized drug target. Previous work in 
this laboratory developed methodology for expressing the protein in Escherichia coli and 
partial purification. Also, the laboratory has identified a group of chalcones that 
accelerate catalytic turnover, activate an inactive to active transition of the enzyme, and 
potently inhibit enzyme turnover under select conditions. One objective has been to 
crystallize the chalcone/enzyme complex.   
 
The work reported in this thesis focuses on improving the purification of PfHPRT by 
investigating the characteristics of anion exchange DE-52 chromatography (the first stage 
of the purification), developing an HPLC gel filtration method for examining the 
quaternary structure of the protein and possible end stage purification, and initial 
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crystallization trials. A homology model of the open, unliganded PfHPRT is constructed 
using the atomic structures of human, T. cruzi and S. typhimurium HPRT as templates.  
A method for the synthesis of [γ-32P]TNP-8N3-ITP is developed for use as a photoaffinity 
probe of the active site.    
 
The original purification protocol involved a relatively short DE-52 column placed in 
tandem with a Reactive Red 120 column. PfHPRT does not bind to the first column, but 
binds to the second and can be eluted with pyrophosphate. This study found that about 
half of the PfHPRT was eluted during the wash stage and that the pH rose to about 11. A 
well-equilibrated column maintained the pH at 8.9, but had little effect on the protein 
elution characteristics. Increasing the length of the column and thoroughly equilibrating 
the resin resulted in the elution of a rather pure PfHPRT component without retardation 
on the column. The subsequent Reactive Red 120 chromatography was found to be 
effective in eliminating key contaminants and undesirable forms of PfHPRT. 
 
HPLC gel filtration was found to be effective in distinguishing between tetrameric and 
dimeric forms of PfHPRT, the equilibrium of these two forms dependent on salt 
concentration, with the tetramer stable at low salt and the dimer predominating at high 
salt. Preparations of PfHPRT were shown to contain significant amounts of undesirable 
dimer even at low salt concentrations. HPLC gel filtration was shown to be an effective 
method of purifying tetrameric PfHPRT on a preparative scale. 
 
Attempts were made to crystallize PfHPRT alone, in complex with a chalcone, GMP or 
IMP. Despite varying the concentrations of ligands, precipitant, pH, divalent cations, and 
protein, and additionally employing various crystallization methods such as vapour 
diffusion (both the hanging drop and the sitting drop) and microbatch, no protein crystals 
were obtained. Instead, numerous salt/ligand crystals were obtained as judged by 
methylene blue dye test, prick test and diffraction patterns. 
 
Only one crystal structure of PfHPRT complexed with a transition state analog inhibitor, 
ImmucillinHP, PPi, and two Mg2+ has been solved. The substrates and Mg2+ are tightly 
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enclosed by several protein loops. A model of an open, unliganded form of PfHPRT was 
constructed based on sequence homology to the human, T. cruzi and S. typhimurium 
HPRT using the program MODELLER. The active site of the open structure is much 
larger and will be useful for docking of inhibitors, such as the chalcone.  
 
Synthesis of 2',3',4'-O-(2,4,6-trinitrophenyl)-8-azidoinosine triphosphate (TNP-8N3-ITP) 
was achieved by nitrous acid-induced deamination of 2',3',4'-O-(2,4,6-trinitrophenyl)-8-
azidoadenosine triphosphate (TNP-8N3-ATP). The yield was good enough to effect the 
synthesis of highly radioactive [γ-32P]TNP-8N3-ITP with minimal purification.  
Photoaffinity labeling experiments showed that both the adenine and inosine probes 
bound with high affinity (K0.5 = 2-5 μM), but derivatized the protein with rather poor 
efficiency. Nevertheless, the probes could be useful for determining the Kd values for 
inhibitor binding to the active site through competitive inhibition of probe binding.  
 
Overall, the impurity of the protein may explain why no crystals were obtained. 
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CHAPTER ONE: LITERATURE REVIEW 
 
1.1 Introduction  
Malaria is the most important of the parasitic diseases of humans. More than three billion 
people live in malarious areas and the disease causes between one and three million 
deaths each year (Breman et al., 2004). Snow and co-workers (2005) further estimate the 
global falciparum malaria morbidity burden to be about 515 million cases. Sub-Saharan 
Africa suffers the vast majority (90%) of this toll with children below 5 years of age and 
pregnant women being the most affected groups (Breman, 2001). Pregnant women are 
highly susceptible largely because the transient depression of their cell-mediated 
immunity that allows retention of the fetal allograft also interferes with resistance to 
infections (Ismaili et al., 2003). Resurgence of the disease in many parts of the tropics, 
mainly due to the parasites’ resistance to drugs and the vectors’ resistance to insecticides, 
together with the ever looming danger of importation to nonmalarious countries 
aggravates the situation. Other factors implicated in the increase in malaria burden, 
especially in Africa, include war and civil disturbance, environmental changes, climatic 
changes and population increase (Greenwood and Mutabingwa, 2002). 
 
The disease remains a growing threat to the economic development of countries in the 
tropical and subtropical regions of the world. Majority of countries with endemic malaria 
are poor with low annual economic growth rates. Miller et al. (2002) argue that malaria is 
a disease of poverty and underdeveloped countries. This view is echoed by Sachs and 
Malaney (2002) who show a correlation between malaria and poverty. Results obtained  
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 earlier by Gallup and Sachs (2001) show that between 1965 and 1990, countries with a 
high intensity of malaria experienced an average growth in per-capita GDP of 0.4% per 
year compared with 2.3% for non-malarious countries. 
 
Human malaria is caused by infection with intracellular parasites of the genus 
Plasmodium, namely Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and 
Plasmodium malariae, which are transmitted by female Anopheles gambiae mosquitoes 
(Clark et al., 2004). The Anopheles gambiae complex of species has a remarkable 
tendency towards human biting (anthropophily). Plasmodium falciparum and, to a much 
lesser extent, Plasmodium vivax accounts for the majority of instances of morbidity and 
mortality (Miller et al., 2002). Exposure to infected blood products (transfusion malaria) 
and congenital transmission (Trampuz et al., 2003) are alternative routes of infection.  
 
1.2 Life cycle of Plasmodium 
Although the different species of Plasmodium exhibit genetic and phenotypic differences, 
their life cycles are similar (Khan and Waters, 2004). The life cycle of P. falciparum, 
shown in Figure 1.0, involves two hosts. During a blood meal, mosquitoes inject 
sporozoites into the human subcutaneous tissue, and less-frequently directly into the 
blood stream from where they travel to the liver (Miller et al., 2002). In the liver, 
sporozoites move through several hepatocytes before infecting the ultimate one with the 
formation of a vacuole around the sporozoites (Mota et al., 2001).  
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Figure 1.0: The life cycle of the malaria parasite (adapted from Phillips, 2001) 
 
The migration through host cells induces the Ca2+ dependent exocytosis of sporozoite’s 
apical organelles (rhoptries, micronemes and dense granules), a prerequisite for infection 
(Mota et al., 2002). Host cells traversed by sporozoites would in turn be recognized by 
the host’s immune system as being infected, thus creating false targets. This mechanism 
may aid the parasite to escape the host’s immune response (Mota and Rodriguez, 2001). 
Inside the hepatocytes, sporozoites develop into mature schizonts (tissue schizogony) 
which rupture and release merozoites that infect erythrocytes. In P.vivax and P.ovale a  
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 dormant hepatocyte stage (hypnozoites) can persist and cause relapses weeks or years 
later. Binding of parasite ligands to erythrocytic receptors is a prerequisite to invasion of 
the erythrocytes by the parasite. Numerous molecules, (including glycophorin A, B and 
C, EBA-175), implicated in the invasion process have been identified on both the 
merozoite and erythrocyte surfaces (Gaur et al., 2004). The invasion process proceeds as 
follows; first, merozoites reversibly attach to the erythrocyte surface and reorient their 
apices. This is followed by the formation of an irreversible junction, a parasitophorous 
vacuole, entry into the vacuole by movement of the junction and finally resealing of the 
vacuolar and erythrocytic membranes (Pasvol, 2003; Gaur et al., 2004). Within the 
erythrocytes, merozoites undergo asexual multiplication (erythrocytic schizogony) 
whereby they develop through the ring, trophozoite and schizont stages. Upon rupture, 
schizonts release merozoites that infect fresh erythrocytes. Approximately 15 hours into 
this asexual reproductive phase, there is a gradual increase in the permeability of the 
erythrocyte plasma membrane to a range of small molecules and ions. (Kirk, 2004; 
Staines et al., 2005). This occurs due to the induction of new permeation pathways (NPP) 
by the internal parasite. These pathways aid in the uptake of nutrients and removal of 
both lactate and excess amino acids from the erythrocyte (Staines et al., 2005).  
 
Some merozoites differentiate into gametocytes (Trampuz et al., 2003). Male 
(microgametocytes) and female (macrogametocytes) are ingested by the insect vector 
during a blood meal. Microgametes differentiate into several individual gametes  
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 (exflagellating of microgametocyte). Gamete formation is followed by fertilization, 
resulting in the diploid zygote. After one round of meiotic division, the zygote develops 
into a motile ookinete that penetrates the cells of the midgut and traverses the midgut 
wall to form an oocyst on the basolateral lamina. Sporozoites develop within the oocyst 
and, on release, migrate via the haemolymph to invade the salivary glands. When the 
slender, haploid sporozoites are inoculated into a new human host, they invade the 
hepatocytes within minutes and develop into exoerythrocytic forms (liver schizonts) 
which rupture and release merozoites that infect erythrocytes and perpetuate the cycle.   
 
1.3 The pathogenesis of malaria 
Malaria presents as a complex syndrome affecting many organs. Central to the pathology 
of the disease are the repeated cycles of parasite invasion and destruction of human 
erythrocytes. In response, host mononuclear cells secrete cytokines, such as tissue 
necrotic factor (TNF), pro-inflammatory interleukins, oxygen free radicals and nitric 
oxide (Maitland and Marsh, 2004) which result in damage to host endothelium and 
tissues.  
 
Microvascular occlusion in falciparum malaria is related to two properties of the parasite: 
adhesion of parasitized erythrocytes to endothelial cells-cytoadherence, and agglutination 
of nonparasitized erythrocytes around erythrocytes containing trophozoites and schizonts 
of P. falciparum- rosetting (Udomsangpetch et al., 1992). Several host ligands have been 
identified as potential mediators of cytoadhesion and include thrombospondin (TSP)  
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 (Roberts et al., 1985) endothelial leukocyte adhesion molecule 1 (ELAM-1), vascular cell 
adhesion molecule (VCAM-1) (Ockenhouse et al., 1992), platelet GP1V (CD36), platelet 
endothelial cell adhesion molecule 1 (CD31), chrondroitin sulfate A and hyaluronic acid 
and intercellular adhesion molecule 1 (ICAM-1) (Berendt et al., 1989). Infected 
erythrocytes may rosette uninfected ones using complement receptor 1 (CD35). 
Cytoadherence and rosetting result in the formation of erythrocyte aggregates and intra 
vascular sequestration of erythrocytes in vital organs such as the brain, heart and 
placenta. This interferes with microcirculation and metabolism and allows parasite 
development away from the host defense system, a phenomenon referred to as splenic 
processing and filtration (Reeder et al., 1999).      
 
Infection results in a wide spectrum of clinical manifestations which are primarily due to 
schizont rupture and destruction of erythrocytes. Symptoms include fever, chills, 
headaches, diaphoresis, dizziness, malaise, myalgia, abdominal pain, nausea, vomiting, 
mild diarrhea and dry cough (Trampuz et al., 2003). Additional signs include tachycardia, 
jaundice, pallor, orthostatic hypotension, hepatomegally and splenomegally. The major 
complications of severe malaria include cerebral malaria, pulmonary edema, acute renal 
failure, severe anemia, metabolic acidosis, hypoglycemia (Garg, 2000), circulatory 
collapse, repeated generalized convulsions, hyperbilirubinemia and hypovolaemia 
(WHO, 2000).  
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 1.4 Drugs used in malaria treatment 
Preventive and/or curative drug therapies play an important role in the control malaria 
(Gregson and Plowe, 2005). Although drugs in use target different stages of the malaria 
life cycle, majority of them act on the asexual, intra-erythrocytic stage: the phase 
responsible for the clinical symptoms of disease (Maitland et al., 2004). The choice of an 
anti-malarial agent largely depends on the patient’s level of immunity, the drug’s side 
effect profile, cost and the site where the infection was acquired - an indicator of a 
particular drug’s resistance probability (White, 2004). Quinolines, folate antagonists, 
antibiotics, artemisinin derivatives and hydroxynapthoquinones are the main classes of 
antimalarial drugs. Each class of drugs exhibit unique properties as explained below.  
 
1.4.1 Quinolines 
This class is comprised of: (i) the 4-aminoquinolines (chloroquine and amodiaquine), (ii) 
the quinoline methanols (quinine, quinidine and mefloquine), (iii) the phenathrene 
methanols (halofantrine and lumefantrine). Drugs in this class exert their action on the 
parasite’s food vacuole (Maitland et al., 2004). Predominantly in the trophozoite and 
early schizont stages, hemoglobin is ingested with the cytoplasm of the host erythrocyte 
by a phagocytosis-like mechanism into the food vacuole where it is degraded to generate 
free heme (Ginsburg et al., 1999). Free heme is potentially toxic through an oxidative 
mechanism and is therefore disposed of by conversion into long insoluble polymers of 
hemozoin (heme polymerization). An alternative heme degradation pathway is through 
it’s reaction with hydrogen peroxide generated by the spontaneous oxidation of the  
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 released heme from a ferrous to a ferric state (Loria et al., 1999). Famin et al. (1999) 
have also found out that some of the heme diffuses into the cytoplasm of the parasite 
where it is likely destroyed by reduced glutathione. Heme polymerization and the 
oxidative and glutathione-dependent heme degradation pathways are inhibited by the 
quinolines. They bind to heme through a π-π stacking of their planar aromatic structures 
(Ridley et al., 1997). Moreover, mefloquine and quinine have been shown to block the 
uptake of hemoglobin from the host cell (Famin and Ginsburg, 2002). The activity of 
quinolines seems to depend on the weak base effect whereby presence of a basic amino 
function enables concentration of the drug in the acidic food vacuole in its membrane-
impermeable protonated form (Ginsburg et al., 1989). 
 
Members of this class are widely used in malaria treatment as exemplified by the use of 
chloroquine as a first line agent in many African countries for a long time before the 
emergence of chloroquine resistance (Winstanley, 2000). Although generally safe, 
several adverse effects which include pruritis, retinopathy, shock, cardiac arrhythmias, 
psoriasis, leukopenia and aplastic anaemia have been reported for chloroquine (Khoo et 
al., 2005). Amodiaquine through its active metabolites has been shown to cause hepatitis 
and agranulocytosis (Winstanley et al., 1990).  
 
Parenteral quinine is the drug of choice for severe malaria as compliance with oral 
quinine is poor due its bitter taste (Newton and White, 1999). The therapeutic index for 
quinine is narrow and severe side effects such as hypoglycemia, coma, hemolytic- 
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 uraemic syndrome and cardiovascular disorders may arise. Cinchonism, (characterized by 
tinnitus, deafness, dizziness, nausea and visual problems) is, however, the commonest 
side effect.  
 
Mefloquine, mostly used in prophylaxis due to its long terminal half-life (14-21 days) has 
been linked with neuropsychotic side effects (Mai et al., 1996). Halofantrine by 
prolonging the QT interval causes ventricular arrhythmias (Monlun et al., 1993). By 
targeting the dormant liver forms (hypnozoites) of P. vivax and P. ovale infections, the 8-
amino quinoline, primaquine, prevents relapses of these infections. Primaquine is, 
however, contraindicated in glucose 6-phosphate dehydrogenase deficient patients in 
whom it causes hemolysis.  
 
1.4.2 Folate antagonists 
Inhibition of enzymes of the folate pathway results in decreased pyrimidine synthesis and 
consequently reduced DNA, serine and methionine formation (Olliaro, 2001). Available 
antifolates include synergistic mixtures such as pyrimethamine-sulfadoxine (Fansidar®), 
chlorproguanil-dapsone (LapDap®), sulfalene-pyrimethamine (metakelphin®) and 
proguanil-atovaquone (Malarone®). These combinations are carefully selected for 
matching pharmacokinetics to maximize the synergy. 
 
Classification of the antifolates is based on the enzyme inhibited in the folate synthesis 
pathway. Type 1 antifolates (sulfonamides and sulfones) by mimicking p-aminobenzoic  
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 acid (PABA), compete for the active site of the bifunctional enzyme dihydropteroate 
synthase (DHPS) and block the formation of dihydropteroate from 
hydroxymethyldihydropterin, a reaction catalyzed by DHPS. This enzyme is encoded by 
the same gene as dihydro-6-hydroxymethylpterin pyrophosphokinase. Type 2 antifolates 
(pyrimethamine, biguanides and quinazolines) on the other hand inhibit dihydrofolate 
reductase (DHFR), also a bifunctional enzyme in plasmodia coupled with thymidylate 
synthase, and inhibit the NADPH-dependent reduction of dihydrofolate to 
tetrahydrofolate (Olliaro, 2001). Tetrahydrofolate serves as an essential methyl donor in 
the conversion of 2´-deoxyribosyluracil monophosphate to 2´-deoxyribosylthymine 
monophosphate. Malaria parasites are particularly susceptible to inhibition of DHFR 
because unlike mammalian cells, transcriptional inhibition (mediated by the protein 
binding to its own message) is not relieved by the accumulation of substrate that occurs 
in the presence of inhibitor (Zhang and Rathod, 2002). 
 
Apart from the severe allergic reactions caused by the sulfonamides, few side effects 
have been reported for the antifolates. The classical condition of antifolates toxicity is the 
Stevens - Johnson syndrome, also referred to as toxic epidermal necrolysis. 
 
1.4.3 Artemisinins 
This class consists of a unique family of sesquiterpene lactone endoperoxides. The parent 
compound, artemisinin, was first extracted from the Chinese herb Artemisia annua 
(qinghao). Several semisynthetic derivatives which include artemether, arteether,  
 10
 
 
 
 
 artelinate and artesunate are in use. They are metabolized to dihydroartemisinin which is 
the main active agent in the body (Ridley, 2002). Members of this group act on all phases 
of the asexual intra-erythrocytic schizogonic cycle and also possess gametocytocidal 
activity (Ridley, 2002; Newton and White, 1999). Although the mechanism of action is 
not known with certainty, the prevailing hypothesis is that the essential pharmacophore, 
an endoperoxide bridge, undergoes reductive cleavage by ferroheme ferrous-
protoporphyrin IX (Fe(II)PPIX) to generate carbon-centered free radicals that alkylate 
protein and damage parasites’ microorganelles and membranes (Meshnick et al, 1996). 
Recent studies show that artemisinin may also inhibit the SERCA orthologue (PfATP6) 
of Plasmodium falciparum as evidenced by thapsigargin (a sesquiterpene lactone and 
highly specific SERCA inhibitor) antagonism of parasiticidal activity of artemisinin 
(Eckstein-Ludwig et al., 2003).  Chelation of iron by desferrioxamine abrogates the 
antimalarial activity of artemisinins and correspondingly attenuates inhibition of PfATP6 
(Wei and Sadrzadeh, 1994; Eckstein-Ludwig et al., 2003).  
 
As a class, artemisinins are fast acting and potent but due to their short half-lives, they are 
currently used in combination with longer half-life drugs. This strategy forms the basis of 
artemisinin combined therapies (ACTs) and is hoped to improve individual compliance 
and prevent or retard the development of drug resistance. Several combinations are 
already in the market and include artemether-lumefantrine (Coartem®), 
dihydroartemisinin-piperaquine (Artekin®) and the triple combination of chlorproguanil-
dapsone-artesunate  undergoing phase II trials in Malawi (Maitland et al., 2004). 
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 Although relatively lacking in adverse effects, embryonic toxicity has been reported for 
this class of antimalarials in China although a later study allayed fears of artemisinin 
related birth defects (McGready et al., 2001).  
 
1.4.4 Antibiotics 
Several antibacterial agents also exhibit antimalarial activity. This activity stems from the 
fact that malarial parasites, like other Apicomplexian parasites, possess a plastid-like 
organelle, the apicoplast (Kohler et al., 1997) which fulfills some metabolic functions 
such as the synthesis of isoprenoids, fatty acids and probably heme (Wilson, 2002).  The 
apicoplast contains a residual genome that encodes tRNA’s, rRNA’s, RNA polymerases 
and ribosomal proteins all of which ensure self-replication of this organelle (Wiesner et 
al., 2003). Antibiotics act through inhibition of the prokaryote-like RNA and protein 
synthesis in the apicoplast (Ralph et al., 2001). The tetracyclines may also block 
mitochondrial protein synthesis in the parasite (Ralph et al., 2001). Rifampicin, 
tetracyclines, lincosamides and macrolides are being increasingly used in combination 
with other antimalarials to augment their activity. However, due to their slow effect, 
antibiotics are mostly used for prophylaxis in which case doxycycline is the most popular 
agent. 
 
 
 
 
 12
 
 
 
 
 1.4.5 Hydroxynapthoquinones 
The prototype of this class is atovaquone which blocks mitochondrial electron transport 
through inhibition of the cytochrome bc1 complex (Fry and Pudney, 1992). When used  
 
alone though, resistance emerges rapidly due to a point mutation of cytochrome b gene 
localized in the mitochondrial genome (Srivastava et al., 1999). As a result, atovaquone 
is used as a fixed-dose combination with proguanil which is thought to enhance the 
atovaquone-induced collapse of the mitochondrial membrane potential (Srivastava et al., 
1999). In prophylaxis, atovaquone-proguanil activity against liver stages is advantageous 
as the parasites are killed before an infection of erythrocytes can be established (Berman 
et al., 2001). 
 
1.4.6 Novel antimalarials 
Numerous new antimalarials, some targeting novel molecular entities are under 
development (Rosenthal, 2003). Pyronaridine, a 9-anilinoacridine is generally active 
against chloroquine-resistant parasites while tafenoquine, a derivative of 8-amino 
quinolines primaquine and pamaquine, is active against liver and erythrocytic stages of P. 
vivax and has a better toxicological profile (Wiesner et al., 2003). Fosmidomycin is an 
inhibitor of 1-deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase, a key enzyme in 
the mevalonate-independent pathway of isoprenoid biosynthesis (Wiesner et al., 2000). 
Kinetic studies with E.coli DOXP reductoisomerase revealed that fosmidomycin alters 
the enzyme conformation after binding thus enhancing affinity (Koppisch et al., 2002).  
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 The indoloquinoline alkaloid cryptolepine activity probably depends on the inhibition of 
heme polymerization (Wright et al., 2001). Aspartic proteases (plasmepins), cysteine 
proteases (falcipain-2), metalloproteases (falcilysin) and histoaspartic protease (HAP) 
involved in hemoglobin digestion in the food vacuole are potential antimalarial targets 
and several specific protease inhibitors have been developed (Haque et al., 1999; Moon 
et al., 1997).  
 
Of note, with regards to our work, is that attempts to develop nonpeptide falcipain-2 
inhibitors lead to the identification of chalcones (Li et al., 1996). Type II fatty acid 
synthesis pathway in the parasite’s apicoplast is inhibited by triclosan (Surolia and 
Surolia, 2001) whereas the antifungal imidazoles form complexes with heme (Huy et al., 
2002) and inhibit P. falciparum in vitro (Chong and Sullivan, 2003).  
 
1.5 Antimalarial drug resistance  
Lack of an effective malaria vaccine has resulted in the reliance upon vector control 
measures and chemotherapy as the two main ways of combating the disease. The former 
involves removal of mosquito breeding sites, use of residual insecticides such as DDT to 
kill adult mosquitoes and prevention of human-mosquito contact by use of repellant 
screens and insecticide-treated bed nets while the latter entails administering drugs for 
prophylaxis or cure of malaria (Olliaro, 2001). The effectiveness of drugs in malaria 
control has depreciated considerably over the last few years due the development of drug 
resistant strains of the parasite. This has been attributed to widespread misuse of common  
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 antimalarials together with their extensive deployment (particularly chloroquine (CQ)) to 
the tropical regions of the world. This has provided a tremendous selection pressure for 
the parasites to develop resistance mechanisms (White, 2004).  
 
Globally therefore, malaria control programmes such as the WHO funded Roll Back 
Malaria campaign, which aims to halve malaria mortality cases by the year 2010, are 
under the threat of failing unless measures are put in place to curtail resistance 
progression (Yeung et al., 2004). Resistance to antimalarials is mainly due to point 
mutations and changes in steady-state transcript levels (Arav-Boger and Shapiro, 2005). 
The mutations in, or changes in, the copy number of genes encoding the drug’s parasite 
target e.g. membrane transporters or enzymes affect the intraparasitic drug accumulation 
(White, 2004). 
 
CQ resistance has mainly been attributed to the accumulation of multiple point mutations 
in the gene coding for Plasmodium falciparum chloroquine resistant transporter (PfCRT), 
a putative transporter protein located in the parasite’s digestive vacuole membrane. This 
424 amino acid protein with ten predicted transmembrane domains (Fidock et al., 2000) 
is thought to be involved in drug fluxes and/or pH regulation in the digestive vacuole 
(Wellems and Plowe, 2001). Two mutations, K76T and A220S, have been shown to be 
critical to the evolution of resistance (Fidock et al., 2000; Wellems and Plowe, 2001), a 
fact that lead Hastings et al (2002) to propose that either these two are the 
pharmacologically relevant mutations or that the other mutations serve to compensate for  
 15
 
 
 
 
 impaired protein function after acquisition of the critical mutations.  Sidhu and co-
workers (2002), by swapping the (PfCRT) gene in chloroquine (CQ) sensitive strain with 
the one from CQ-resistant strain, also demonstrated the role of K76T mutation in CQ 
resistance and further proved that up-regulation of PfCRT is not obligatory for resistance 
to occur. Although the actual resistance mechanism remains unclear, several hypotheses 
have been posited and include drug expulsion through an acquired efflux system 
(Sanchez et al., 2003), leaking of the drug out of the digestive vacuole (Bray et al., 2005) 
and variation of vacuolar pH due to altered chloride conductance across the vacuolar 
membrane (Zhang et al., 2002). These fit in with the presumed role of PfCRT. Reversal 
of chloroquine resistance has been observed with several agents among them verapamil, a 
calcium channel blocker and chlopheniramine, a histamine H1 receptor antagonist. These 
agents do not however restore full chloroquine sensitivity (Bray et al., 1996). Verapamil 
has been proposed to act via its hydrophobic binding to the mutated PfCRT protein. By 
so doing, it replaces the lost positive charge and, therefore, repels the access of 4-
aminoquinoline cations to PfCRT (Henry et al., 2006; Warhurst, 2003).    
 
Apart from PfCRT, the multidrug resistance gene Pfmdr1 has also been implicated in 
chloroquine resistance. This gene encodes the ATP-dependent P-glycoprotein homolog 1 
(Pgh-1), a transmembrane protein also found in the parasite digestive vacuole (Cowman 
et al., 1991; Wilson et al., 1989). A widely reported defect in Pgh-1 associated with 
chloroquine resistance is the N86Y mutation (Dorsey et al., 2001). A further four Pgh-1 
mutations (Y184F, S1034C, N1042D and D1246Y) have been shown to play a role in  
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 other quinoline antimalarials resistance in addition to modulating the parasite’s sensitivity 
to chloroquine and artemesinin (Reed et al., 2000).   
 
Resistance to the antifolate antimalarials is conferred by single point mutations of the 
gene encoding for the respective enzyme, resulting in substitutions in the amino acid side 
chains. High-level pyrimethamine resistance results from the accumulation of mutations 
in DHFR, principally at codons 108, 59, 51 and 164, where allelic variation gives rise to 
the mutations S108N, C59R, N51I and I164L. Occasionally, mutations also occur at 
codons 50, 140 and the ‘Bolivian repeat’ of the DHFR gene. Mutations occurring in 
DHPS at codons 436, 437, 540, 581 and 613 correlate with estimated levels of 
sulphadoxine resistance (Ridley, 2002). Highest level of clinical resistance result from 
parasites with four mutations in DHFR and two in DHPS, which may suggest the 
maximum number of mutations that can be tolerated in competition with less affected 
strains (Arav and Shapiro, 2005). Dihydrofolate reductase –thymidylate synthase crystal 
structure provides evidence that the critical mutations mediating clinical drug resistance 
map to the dihydrofolate reductase active site (Yuvaniyama et al., 2003).   
 
Resistance to atovaquone is due to mutations affecting five amino acids clustered in a 
highly conserved fifteen amino acid sequence of cytochrome b from P. yoelii (Arav-
Boger and Shapiro, 2005). Analysis of P. falciparum isolated from patients who failed 
atovaquone monotherapy confirmed predilection for mutations at residue Y268 
(Korsinczky et al., 2000).     
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1.6 Purine metabolism 
Purine nucleotides are essential for the synthesis of nucleic acids and proteins as well as 
for energy-requiring reactions in living organisms (el Kouni, 2003). The metabolic 
pathway for the production of purine nucleotides is conspicuously different between 
protozoan parasites and their mammalian hosts (Allen and Ullman, 1993). Whereas 
mammalian cells obtain purine nucleotides primarily by de novo synthesis and/or the 
purine salvage pathways, parasitic protozoa are auxotrophic for purines and rely on the 
host to provide them with purines or purine ribosides (Shi et al., 1999). The de novo 
synthesis of purine nucleotides requires a minimum of ten enzymes for the production of 
inosine monophosphate (IMP), the major intermediate of purine metabolism and thus the 
salvage pathway provides an energy-saving alternative (You et al., 2003).  
  
P. falciparum proliferation in human erythrocytes requires purine salvage by 
hypoxanthine (-guanine) phosphoribosyltransferase (HPRT) (Shi et al., 1999). It has been 
shown that depletion of hypoxanthine from the parasite cultures by xanthine oxidase 
leads to the death of the organism indicating that IMP formation from this purine, 
catalyzed by HPRT, is not by-passed by an alternate reaction (Berman et al., 1991). 
Furthermore, the relative abundance of adenosine deaminase and purine nucleoside 
phosphorylase, two enzymes that catalyze the conversion of adenine to hypoxanthine, in 
P. falciparum suggests that the salvage of purine bases in this parasite proceeds mainly 
through hypoxanthine (Craig and Eakin, 2000).    
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 Because of the central role played by HPRT in providing the parasite with 
ribonucleotides, it is a promising target in the design of novel anti-malarial 
chemotherapeutics. Such drugs could potentially act by two mechanisms: (i) as inhibitors 
of P. falciparum HPRT and (ii) as substrates which after conversion to their respective 
monophosphate nucleotides by HPRT would inhibit downstream enzymes and/or be 
incorporated into parasite DNA or RNA resulting in eventual cell death (Keough et al., 
1999).  
 
Selective inhibition of the P. falciparum HPRT is however critical since its complete 
deficiency in humans is associated with a debilitating neurological disease known as the 
Lesch-Nyhan syndrome which is clinically characterized by irregular, spastic and 
athetoid movements, mental retardation, hyperuricemia, uric acid nephrolithiasis and a 
unique compulsion for self-mutilation (Musick, 1981). Partial deficiency leads to gouty 
arthritis (Sculley et al., 1992). Inhibition of the human enzyme for the usual duration of 
drug therapy is unlikely to have major deleterious effects.    
 
1.7 The HPRT reaction mechanism 
As shown in scheme 1.0, HPRT catalyzes the Mg2+-dependent reversible transfer of the 
5-phosphoribosyl group from α-D-5-phosphoribosyl-1-pyrophosphate (PRPP) to a 
nitrogen atom of the imidazole ring of the purines hypoxanthine, guanine or xanthine to 
form the corresponding nucleotides and inorganic pyrophosphate (PPi). 
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Scheme 1.0: Schematic diagram of the reaction catalyzed by HPRT (Thomas and Field, 
2002) 
 
The kinetic mechanisms for the HPRT’s from several organisms have been investigated. 
The forward reaction is ordered and sequential, with PRPP binding first followed by the 
purine base. The proposed nucleophilic attack by the purine base at the PRPP ribose C1´, 
which is associated with the inversion of configuration at this anomeric position (Tao et 
al., 1996), is followed first by the release of pyrophosphate and then that of the 
ribonucleotide (IMP, GMP or XMP). Kinetic studies with the human HPRT by Xu et al. 
(1997) have further demonstrated that the binding of substrates is effectively ordered in 
both the forward and the reverse reactions and that product release is the rate-limiting 
step in catalysis for both ribonucleotide formation and pyrophosphorolysis. The same 
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probably applies to P. falciparum HPRT which shares 44% sequence identity and 76% 
similarity with human HPRT (Raman et al., 2005).    
 
The reaction mechanism involves electrostatic re-arrangement during the transition state 
as the PRPP C1´-O1 bond breaks and the C1´-purine N9 bond forms (Focia et al., 1998). 
Two possible mechanisms have been proposed for the reaction. There is a dissociative, 
SN1-like mechanism that first produces PPi and a charged ribooxacarbenium ion and only 
afterward the nucleotide, and there is an associative, SN2-like mechanism in which the 
attack of the purine N9 atom and the departure of the pyrophosphate from ribose C1´ 
occur simultaneously (Scheme 1.1) (Thomas and Field, 2002). Kinetic isotope effect 
analysis of orotate phosphoribosyltransferase (OPRT) demonstrated a ribooxacarbenium 
ion transition state (Tao et al., 1996) similar to that found for purine nucleoside 
phosphorylase (PNP) (Kline and Schramm, 1995). In the human HGPRT with bound 
immucillinG-5′-PO4 and MgPPi, the purine is thought to be anchored throughout the 
reaction, allowing the ribooxacarbenium to migrate between the purine base and the 
pyrophosphate nucleophile (Schramm and Shi, 2001).  
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Scheme 1.1: Two possible mechanisms for the HGPRT reaction (modified from Thomas 
and Field, 2002). 
 
In the case of an SN1-type chemical reaction, the unstable ribooxocarbenium intermediate 
would need to be protected from the bulk solvent. It has been proposed that a large, 
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flexible loop (loop II), which contains an absolutely conserved Ser-Tyr dipeptide, closes 
over the active site to shield the highly reactive ribooxocarbenium from nonproductive 
attack by the bulk solvent water molecules. The deletion of seven residues from active  
 
site loop II of trypanosomal HGPRT does not however prevent either the forward or the 
reverse reaction catalyzed by the enzyme although it lowers the catalytic efficiency 
(Craig and Eakin, 2000). Furthermore, apart from the possible stability provided to the 
positively charged intermediate by the 5′-O of the ribose moiety, X-ray crystal structures 
of the closed active site of the human, malarial and trypanosomal HPRT’s reveal that the 
only residue near enough to provide further stabilization is an invariant tyrosine (human 
Tyr104) (Shi et al., 1999a; Shi et al., 1999b; Focia et al., 1998). These enzymes therefore 
provide only minimal electrostatic stabilization for a ribooxocarbenium ion formed 
during an SN1-type reaction (Craig and Eakin, 2000). The above mentioned observations 
suppose the reaction as being associative (SN2) rather than dissociative (SN1). This is in 
agreement with Fedorov and co-workers (2001) who classify the reaction mechanism of 
phosphoribosyltransferases as nucleophilic displacements by electronic migration, in 
which the DNAN transition state has a partial bond between the purine and sugar and van 
der Waals contact between the pyrophosphate and sugar.    
 
Recent studies (Crehuet et al., 2005) have shown that the preferred reaction chemistry in 
HPRT proceeds via an associative, SN2-type nucleophilic displacement in which rapid 
phosphoribosyl transfer occurs via a ternary complex. Two stepwise mechanisms are 
possible. In one, there is transfer of the phosphoribosyl group followed by a proton 
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transfer from the hypoxanthine to the side chain of Asp148 residue. In the other 
mechanism, proton transfer occurs before the phosphoribosyl transfer. This is illustrated 
in Scheme 1.2. 
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Scheme 1.2: Possible steps for SN2 mechanism in HGPRT (Adapted from Crehuet et al., 
2005). 
 
1.8 Three dimensional structure of HPRT 
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The HPRT’s are members of a larger family of phosphoribosyltransferases (PRT’s) 
which are involved in the biosynthesis of purine, pyrimidine and pyridine nucleotides, as 
well as the aromatic amino acids histidine and tryptophan (Musick, 1981). 
 
Type 1 PRT’s, of which HGPRT belongs, share a common core tertiary structure 
resembling a typical Rossman dinucleotide-binding fold (Figure 1.1). This common core  
 
region consists of four or five parallel β-strands flanked by three or four α-helices. A 
short sequence of 13 amino acids present within this fold, referred to as the PRPP-
binding motif, is located near the C-terminal end of the third β-strand in the core β-sheet 
and is the conserved signature sequence of type 1 PRT’s (Lee et al., 1998). This motif is 
made up of four hydrophobic amino acids, two acidic amino acids and seven variable 
amino acids (Sinha and Smith, 2001). The C-terminal ends of the β-sheets of the core 
domain form the floor of the active site of these enzymes while a poorly conserved hood 
domain contributes residues that complete the active site and participate in binding purine 
substrates. The active site is partly at the interface of the core and hood domains.  
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Figure 1.1: The tetramer of Toxoplasma gondii HGPRT with bound IMP demonstrates the 
interfaces of the tetramer (A). View of the monomer of malarial HGPRT with transition state 
analog imucillinHP bound (B) shows the flexible hood domain (blue) and the core domain 
(orange). The catalytic site is at the interface of the two domains. Images coordinates 
taken from Heroux et al., 1999 and Shi et al., 1999 and rendered with PyMol (DeLano, 2002). 
 
 
1.8.1 The active site 
HPRTs of distantly related organisms share moderate primary sequence homology. The 
aligned sequences of several parasite HPRTs show between 28-49% identities with their 
human counterpart more so in the active site loops (Focia et al., 1998). Analysis of a 
number of high-resolution HPRT crystal structures from humans and parasites reveal that 
several amino acid residues are invariant and play an important role in enzyme function. 
The invariant residues immediately flank or are near the enzyme’s active site which is 
similar in human and parasites’ enzymes (Heroux et al., 1999). This is illustrated in 
Figure 1.2.  
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Figure 1.2: A structural alignment of malarial (1CJB) and human (1HMP) HGPRT with 
bound substrates (immucillinHP and GMP, respectively). The conformation of the base in 
the active site is similar in both the malarial (orange) and human (purple) enzymes (A). The 
extended loop (arrow) in (B) reflects the difference in chain length between the two 
enzymes. The alignment was performed with ALIGN (Cohen et al., with image coordinates 
from Shi et al., 1999 and Eads et al., 1994. 
 
Four segments of the protein polypeptide backbone (loops I, II, III, IV) define a 3D space 
unique to the active site of the enzyme (Freymann et al., 2000). The smallest of these is 
the active-site loop I, which is composed of residues Leu67, Lys68, and Gly69. Gly69 is 
invariant and a G69E mutation inactivates the human HGPRT resulting in Lesch-Nyhan 
syndrome (Sculley et al., 1992). Lys68 participates in an unusual non-proline cis-peptide 
linkage with the preceding leucine residue (Focia et al., 1998; Heroux et al., 1999; 
Heroux et al., 2000). Non-proline cis peptides are infrequently seen in published 
structures (<0.05%) (Stewart et al., 1990).  Where they have been observed in other 
enzymes, structural roles assigned to them have included metal-binding sites (Hohenester 
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et al., 1996; Dominguez et al., 1996). Heroux and co-workers (1999) have hypothesized 
that cis-trans peptide isomerization may assist the catalytic mechanism. The invariant 
glycine may thus be essential for the formation of a tight turn and the unusual non-proline 
cis-peptide (Vos et al., 1997; Shi et al., 1999a; Shi et al., 1999b). The cis-peptide linkage 
geometry allows the main-chain nitrogen atom of Lys68 to form a hydrogen bond with 
the β-phosphate group of bound Mg-PRPP or Mg-PPi while the main-chain carbonyl 
oxygen of Leu67 interacts with Mg-coordinated water molecule (Canyuk et al., 2004). 
This is illustrated in Figure 1.3. The side chain of Lys68 also forms multiple hydrogen 
bonds with residues in the opposing subunit in the dimeric structure of Trypanosoma 
cruzi HPRT (Focia et al., 1998). 
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Figure 1.3: Depiction of the interactions involving the cis-peptide bond observed in loop I 
of the X-ray crystal structure of T. cruzi in ternary complex with substrates. One 
magnesium ion (M1) is associated with two water molecules while the seond (M2) is 
associated with three. Residue numbering is according to structurally analogous residues 
in the human HGPRT. Adapted with permission from Canyuk et al. (2004). 
 
The primary PRT substrate PRPP is cradled between the active site loops I and III. 
Residues in these loops form extensive networks of hydrogen bonds with the phosphate 
and pyrophosphate groups mostly via main chain atoms. One metal ion (usually Mg2+) 
binding site is located on either side of the PRPP pyrophosphate group (M1 and M2). 
Each Mg2+ ion has an octahedral coordination involving two terminal oxygen atoms of 
the pyrophosphate which adopt a cis orientation around the Mg2+. M1 is bonded to four  
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water molecules while M2 is bonded to three water molecules and is also linked to the 
side chain of the conserved Asp193. This is the only direct contact between HGPRT and 
the Mg2+ ions. The eclipsed conformation imposed upon the oxygen atoms of 
pyrophosphate by the Mg2+ ions is a common configuration in structures where 
pyrophosphate is coordinated to either one or two divalent metal ions (Heroux et al., 
1999a). Additionally, Mg2+ ions have a preference for interacting with oxygen over 
nitrogen.  
 
Interaction of Arg199 with Asp193 may help in positioning the substrates for in-line 
nucleophilic attack at the C1 carbon of PRPP or a nucleotide. A D193N mutation which 
drastically alters the kinetic parameters of HGPRT results in Lesch-Nyhan syndrome in 
humans (Sculley et al., 1992). A structural explanation for this is may be revealed by the 
presence of a hydrogen bond linking the side chain carboxyl group of Asp193 to the main 
chain nitrogen of Asp196.  
 
Loop III forms the typical region of conserved sequence in type 1 PRT’s, the PRPP motif 
(129VLIVEDIIDTGKT141). The invariant Glu133 and Asp134 in this loop form hydrogen 
bonds with the 2′- and 3′-hydroxyls of PRPP (Vos et al., 1998). Moreover, Glu133 forms 
a hydrogen bond with a metal-associated (M1) water molecule. The two acidic residues 
are also predicted to participate in stabilizing the transition state of the reaction (Scapin et 
al., 1994). Additionally, they may be involved in networking other water molecules 
bound in the active site to aid further hydration of the pyrophosphate leaving group  
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during or following the reaction (Focia et al., 1998b). Mutagenesis studies have shown 
that Asp137, which is also conserved in the PRPP fingerprint, acts as a catalytic base 
which deprotonates the purine base thus activating it as a nucleophile (Xu and 
Grubmeyer, 1998). It may also contribute to tight binding of nucleotide analog inhibitors 
as evidenced by its interaction with the N7 of the iminoribitols (Li et al., 1999; Shi et al., 
1999). The concluding residues (138TGKT141) of the PRPP motif surround and bind the 
5′-monophosphate group of the ribose ring. Minor differences in sequence are found for 
this part of loop III across type 1 PRT families but usually two threonine residues and a 
glycine are present (Focia et al., 1998b; Sinha and Smith, 2001). This loop participates in 
up to seven hydrogen bonds with the 5′-phosphate group of bound substrate or product 
through main chain nitrogens and threonine side-chain oxygen (Somoza et al., 1996).  
 
Purine bases in the active site are recognized by a convergent array of hydrogen bonds 
and by several van der Waals interactions. N7 of the purine is in van der Waals contact 
with the side chain carboxyl group of Asp137 while O6 is hydrogen bonded to the side 
chain amino group of Lys165 and also main chain nitrogen of Val187. Val187 peptide 
oxygen interacts with N1 atom of both guanine and hypoxanthine and also N2 of guanine 
which is hydrogen bonded to the main chain oxygen atom of Asp193 in loop IV (Eads et 
al., 1994; Shi et al., 1999). Crystal structure of T. gondii HGPRT (Heroux et al., 1999) 
shows that in order to bind xanthine favorably, loop IV shifts such that O2 hydrogen 
bonds to the main chain nitrogen of Asp193. To further stabilize its orientation, the 
purine ring is clamped in place by a π-π stacking interaction with Phe186 above it. Other  
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HGPRT’s contain a similarly located aromatic residue. On the bottom and top, the purine 
ring is held by hydrophobic interactions, sandwiched between the side chain of Val187 
on one side of the planar aromatic ring and the π-π stacking interaction with Phe186 on 
the other side.  
 
With both substrates bound, the active site architecture is completed by the closure of 
active site loop II (catalytic loop) which appears to be highly disordered when only a 
single substrate is bound (Eads et al., 1994; Somoza et al., 1996). This loop, contributed 
by the core domain, generally consists of 11-14 amino acids with only a Ser-Tyr 
dipeptide conserved among them (Munagala et al., 2001). The main chain nitrogen of 
Ser103 forms a hydrogen bond with O1A atom of PRPP whereas the side chain hydroxyl 
interacts with a water molecule which is hydrogen bonded to both Ser109 and the 5′-
phosphate group either PRPP or a nucleotide analog (Focia et al., 1998). The aromatic 
ring of Tyr104 stacks over the PRPP molecule with its main chain nitrogen forming a 
hydrogen bond with PRPP O1A atom while its hydroxyl group is bonded to the 5′-
phosphate O3P. Tyr104 interactions span the PRPP molecule positioning its aromatic 
ring almost perpendicularly to the purine ring. 
 
The extensive interactions of the invariant Ser103 and Tyr104 with PRPP secure the base 
of the closed catalytic loop over the active site and also offer electrostatic stabilization 
during the transition state. Moreover, this loop may indirectly aid in binding of purine  
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substrates through its van der Waals interactions with conserved aromatic residue 
(Phe186) that stack above the purine ring in the active site.      
 
Changes in the interactions involving loops I and II with the active site ligands before and 
after closure of the active site provide a possible mechanism for the liberation of the 
pyrophosphate leaving group after catalysis. 
 
1.9 Plasmodium falciparum HPRT. 
This section aims to analyze the structural features of P. falciparum hypoxanthine 
phosphoribosyltransferase (PfHPRT) mainly, unless otherwise stated, based on the 
crystal structure of PfHPRT in complex with a transition state analog (Shi et al., 1999) 
which is the only PfHPRT atomic structure available.  
 
PfHPRT is a tetrameric enzyme with 231 residues per subunit and a native molecular 
mass of 26 232 Daltons per monomer (Keough et al., 1999). The subunit incorporates a 
core domain consisting of five parallel β-strands surrounded by four α-helices (residues 
46-194) and a hood domain composed of a four stranded anti-parallel β-sheet and two α-
helices (residues 1-45 and 195-231). As seen in the human HGPRT (Eads et al., 1994), a 
mobile loop dissects the core β-sheet into two halves. Three β-strands in the C-terminal 
portion of the core β-sheet extend to form a secondary β-sheet which is located above and 
oriented perpendicularly to the central β-sheet. The active form of the enzyme is a 
tetramer. 
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When compared, the four independent subunits are essentially identical with a root mean 
square (RMS) deviation between all Cα atoms, excluding several loop residues, of less 
than 0.15 Å in pair wise comparison. Superimposing the subunits reveal that the active 
sites are nearly identical with an RMS deviation of less than 0.1 Å between Cα atoms of 
the active site residues. The active site loops of PfHGPRT close more tightly over the 
active site with a distance of 2.8 Å between N7 of the purine base and the side chain 
carboxyl of Asp148 (human Aps137) compared with 3.3 Å in the crystal structure of T. 
cruzi (Focia et al., 1998).  
 
The properties of malarial HGPRT differ significantly from those of other HGPRT’s. 
One difference is in the substrate specificity. While malarial HGPRT can utilize xanthine, 
human HGPRT lacks that ability (Queen et al., 1988). Interestingly however, a chimeric 
HGPRT in which 49 N-terminal residues of the human HGPRT were replaced with the 
corresponding residues from PfHGPRT exhibited specificity for xanthine even though 
none of the switched residues forms part of the purine or PRPP binding region in the 
available crystal structures of HGPRT’s (Subbayya et al., 2000). Another unique feature 
of PfHGPRT lies in its behaviour upon purification. Recombinant PfHGPRT unlike the 
human and T. cruzi enzymes (Xu and Grubmeyer, 1998; Eakin et al., 1997) usually has 
negligible activity on purification and requires incubation with the substrates 
hypoxanthine and PRPP or Mg2+ and PRPP to activate it (Keough et al., 1999; Phehane, 
2002; Mbewe et al., 2006). Although oligomerization into the tetrameric form is a 
requisite for activity, the active form is less stable (Raman et al., 2005). The presence of  
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substrates does not lead to activation when the enzyme is a dimer (Keough et al., 1999). 
Raman et al. (2005) further showed that PfHGPRT activation was actually effected by 
the product, inosine monophosphate.   
 
In spite of its unique properties, binding of substrates in PfHGPRT is similar to that in 
other HGPRT’s and is analyzed subsequently. The purine ring analog binding exhibits a 
low antiglycosidic torsion angle while the imminoribitol ring pucker is 3′-exo 5′O cis to 
N4′. C2′ and C3′ hydroxyl groups of the imminoribitol ring interact with Glu144 and 
Asp145 and also M1 magnesium ion which slots below the plane of the imminoribitol 
ring. The magnesium ions associated with pyrophosphate is also located below the 
imminoribitol ring and its geometry is such that its O2A oxygen is optimally positioned 
for a nucleophilic attack on the carbenium carbon in  case of a ribooxocarbenium ion 
intermediate formation.    
 
Main chain nitrogen atoms of Asp148, Thr149, Gly150 and Thr152 together with the 
hydroxyl groups of Thr149, Thr162 and Tyr116 fix the position of the 5-phosphate group 
of imminoribitol moiety. The aromatic ring of Tyr116 through π-cation, together with the 
5-phosphate group interaction with N4′ of the iminoribitol enhances the stabilization of 
the oxacarbenium ion during catalysis. It should be noted that the backbone nitrogen of 
Tyr116 together with that of Ser115 form favorable hydrogen bonds to O3A of 
pyrophosphate. Lys176 interacts with the exocyclic oxygen of the deazahypoxanthine 
ring while Asp148 acts as the catalytic base by interacting with N7. The peptide carbonyl  
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group of Val198 hydrogen bonds to N1 of deazahypoxanthine whereas Asp204 directly 
interacts with M2 magnesium ion. In addition to orienting the peptide amides of Leu76 
and Lys77 towards the pyrophosphate, the cis bond between these two residues enable 
the side chain amino nitrogen of Lys77 to interact with the main chain carbonyl oxygen 
of Glu108 in the neighboring subunit. 
 
 
 
Figure 1.4: Schematic PfHPRT active site residues involved in non covalent interactions 
with the bound   immucillinHP, Mg2+ and pyrophosphate (adapted with permission from 
Shi et al., 1999).  
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 2.0 Macromolecular x-ray crystallography 
Three-dimensional structures provide important mechanistic insights into the various 
molecular and cellular processes mediated by proteins. These insights are critical for 
practical applications such as structure based drug design and the engineering of proteins 
with improved properties for industrial processes (Saridakis and Chayen, 2003). Over the 
years, X-ray crystallography has become the preferred method for protein structure 
solution as reflected by the number of structures solved by this method in the Protein 
Data Bank (PDB) - the international repository for protein structures (Berman et al., 
2001). 
The complete solution of a three dimensional crystal structure consists of several distinct 
but interlinked (Dauter, 2006) stages which can be summarized as crystallization, data 
collection and processing, model building, refinement and structure validation. The 
availability of high-quality crystals is crucial to the structure determination of proteins by 
X-ray diffraction (Chayen, 2005). 
 
2.1 Structure based drug design 
Innovations in molecular and structural biology techniques have radically transformed the 
opportunities to use protein three-dimensional structures to accelerate drug discovery 
(Blundell et al., 2006; Congreve et al., 2005). By defining the topographies of the 
complementary surfaces of ligands and their protein targets, protein crystal structures 
utility ranges from target validation to lead discovery and optimization (Jhoti, 2001). 
Indeed, several drugs on the market have been developed based on the atomic structures  
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 of their targets. Examples include Agenerase® and Viracept® developed using the crystal 
structure of HIV-1 protease (Hardy and Malikayil, 2003) and the flu drug Relenza® based 
on the crystal structure of neuraminidase (Varghese, 1999). Since the majority of 
successful drugs exert their effects by modifying the activity of proteins (Bourne and 
Weissig, 2003), attempts being made to understand the structure and function of entire 
proteomes are expected to increase validated therapeutic targets by up to 10-fold thus 
paving the way for new opportunities in structure-based drug design (Kuhn et al., 2002). 
A major advantage of X-ray crystallography which is making it increasingly attractive to 
the pharmaceutical industry is that it defines ligand-binding sites with more certainty. It is 
also more sensitive than the bio-assays used in high throughput screening thus it can 
detect lower affinity and therefore lower molecular weight bound ligands (Tickle et al., 
2004). The role of X-ray crystallography in the drug design industry is actually set to 
appreciate with the advent of high throughput crystallography (reviewed in Blundell and 
Patel, 2004). An important caveat the use of crystal structures in drug design, however, is 
the static nature of these structures. Receptor–ligand structures solved by X-ray 
crystallography do not reflect the flexible nature of ligand-binding pockets and as such 
errors may arise in the design of the chemical libraries.  
 
Structure-based drug design (rational drug design) proceeds via several phases which can 
be summarized as follows: target identification, lead identification, structural assessment 
and optimization of the lead, and finally drug candidate validation (Figure 1.6). Structural 
information plays a vital role in target identification and selection, screening of small  
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 molecules and identification of hits, and more importantly in engineering improved 
affinity and selectivity during lead optimization. In the absence of experimental structural 
data of putative targets, homology modeling of the 3D structures also provides insights 
into the ligand binding sites of these targets. 
 
In target identification, macromolecules unique to the organism and possessing altered 
properties from those of the host are good candidates (Subbaya et al., 1997). It is 
however, important to validate the target by proving that modulating its activity affects 
the disease process. This is done in a number of ways which include gene knockouts and 
RNA antisense technology to inactivate the gene (Kurreck, 2003).   
 
Due to its vital role in plasmodium, HGPRT inhibition is detrimental to the survival of 
the parasite and offers an avenue for the design of chemotherapeutic molecules. This is 
the premise for our work. 
 
After target identification, lead compounds are identified. Knowledge of natural ligands, 
high throughput in silico screening and combinatorial chemistry are ways in which leads 
are generated and ultimately a chemical library built. The role of protein structure lies in 
focusing the design and synthesis of leads toward a set of compounds more likely to bind 
to the target’s active site (Salemme et al., 1997; Bourne and Weissig, 2003). Hits-to-leads 
chemistry is required to assess and prioritize initial results and to synthesize close analogs  
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 of active structures while establishing outline structure activity relationship (SAR). All 
this is aimed at improving potency by lowering the K  to the nanomolar range.  i
 
Lead optimization is the longest pre-clinical phase and involves improving the 
biopharmaceutical properties of the chemical lead to enhance its suitability as a drug. In 
this, Lipinski’s rule of five (Lipinski et al., 1997) examines the drug-like properties of a 
small molecule. Once a drug candidate is selected, pre-clinical animal safety studies are 
then carried out after which clinical trials are undertaken. 
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Chemical library 
Crystal structure of target 
Protein active site 
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Lead compound
Lead optimization
Preclinical studies
Clinical trials
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Schematic of the steps involved in structure-based drug design (Modified from 
Jhoti, 2001). 
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2.2 Photoaffinity labeling 
Photoaffinity labeling (PAL) is a biochemical method which utilizes photoactivable 
ligand analogs to identify and characterize the binding sites of target proteins. Discovery 
of this technique is credited to Westheimer, Singh and Thornton (1962) who used 
diazoesters and carbene intermediates to label the active site amino acids of α-
chymotrypsin.  
 
Several functional groups, mostly azido and diazo groups, diazonium ions and diazirines, 
are incorporated into the photoprobes to serve as precursors for the highly reactive 
nitrenes, carbenes and carbocations intermediates upon photolysis (Brunner, 1993). 
Formation of these intermediates which in turn form covalent linkages with the target 
protein is accompanied by chemical changes, for example, extrusion of molecular 
nitrogen in the case of azido compounds. The photolabeling is, however, preceded by the 
formation of a reversible protein-photoprobe complex as indicated by the rate saturation 
effect and competitive inhibition by the natural substrate. Detailed mechanisms are 
elaborated below.  
 
The success of a photolabeling experiment largely depends on the efficiency and 
specificity of the photoprobe employed. This imposes the condition that the photoprobe 
used should give rise to intermediates with a very short half life and no re-arrangement 
into more stable, but nevertheless, reactive compounds as that will lead to indiscriminate 
labeling. Paradoxically, highly reactive reagents tend to self-stabilize through  
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 intramolecular rearrangements to form stable reactive products (Brunner, 1993) and as 
such, design of photoprobes involves a compromise between efficiency and specificity. 
Additional requirements for the photoprobe are: stability in the dark to allow targeting to 
the intended site, small size to avoid steric obstruction in the binding site, photolysis at 
wavelengths that do not damage the protein and formation of easily isolable reaction 
products. The photoprobes must also carry an easily detectable tag bearing radioactivity, 
fluorescent or immunogenic marker (Dorman and Prestwich, 2000).  
 
Although a number of photoprobes have been developed over the years, the aryl azides 
introduced by Bayley and Knowles (1977) are the most popular. This is possibly because 
of their relatively easier synthesis and stability in the dark (Rizk et al., 2006). 
Substituents on the aromatic ring influence the characteristics and reactivity of aryl azides 
as exemplified by the perfluorophenylazides (Keana and Cai, 1989). Young and Platz 
(1991) have shown that fluorinated aryl azides covalently bind to the target sites via the 
singlet fluorinated arylnitrene which, compared to the unsubstituted aryl azides, 
rearranges more slowly to the corresponding didehydroazepine. The slow rearrangement 
allows the intermediate to react with many chemical bonds including C-H bonds by 
insertion. In 3-nitrophenyl azide, shifting of the absorption wavelength beyond the 
protein absorption region by the nitro group permits the selective excitation of this azide 
in protein mixtures (Rizk et al., 2005). Other photoprobes include azidonucleotides, 
aryldiazirines, benzophenones and aryldiazonium salts.  
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2.2.1 General photochemistry of photoprobes 
Arylazides, upon irradiation, are promoted to the singlet excited state which readily loses 
molecular nitrogen to form singlet nitrene. The singlet species generated are powerful 
electrophiles that react with carbon-carbon double bonds, heteroatom-hydrogen bonds 
and can even insert into carbon-hydrogen bonds as is the case in perfluorophenylazides. 
The most common phenomena for the singlet species, however, is the rapid ring 
expansion into cyclic ketenimines (didehydroazepines) via azirine intermediates or 
relaxation to lower energy triplet nitrenes through intersystem crossing (ISC). Both 
didehydroazepines and triplet nitrenes are known to react with the target site amino acid 
residues. The fate of singlet nitrene is schematically illustrated in Figure 1.7 below.   
 
Ar N N N Ar N Ar NH X Protein
N
triplet nitreneazepine
ISC
insertionhv
Ar N .
.
..
singlet nitrene
Protein Ar NH
..
Ar NH Protein
H+ abstraction
coupling
rearrangement
 
                
Figure 1.7: Possible mechanisms for aryl azides binding to proteins 
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Although the notion that the short-lived singlet nitrenes are the general active 
intermediates for the aryl azides has been challenged before (Bayley and Staros, 1984), a 
recent study by Rizk et al. (2006) further proves that the didehydroazepines and 
azepinone intermediates produced are actually responsible for photolabeling. 
 
Radiolabeled azidonucleotides, normally containing an azido group on the C8 position of 
the heterocyclic ring, have been extensively used as photoprobes. The introduction of a 
substituent at the C8 position may, however, cause the compound to adopt a syn 
conformation as opposed to the anti conformation present in the parent nucleotide 
(Scheit, 1980) and this may affect binding onto the target site. The presence of a nitrogen 
atom ortho to the azido group, as in 2-azido nucleotides may also be problematic due to 
isomerization of the azide into tetrazole which is less sensitive to photolysis.  
 
Like in the case of aryl azides, it has been assumed that the photochemistry of this group 
proceeds via formation of short lived nitrenes (Hanna et al., 1989; Hanna et al., 1999). 
This view has, however, been challenged by Polshakov et al. (2005) who, employing 
laser flash photolysis, show that diazaquinodimethane derived from the singlet nitrene 
form covalent linkages with nucleophiles in photolabeling experiments involving 
azidonucleotides. 
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 In this study, we explore the possible use of radiolabeled 2′, 3′-O-(2, 4, 6-trinitrophenyl)-
8-azido-adenosine triphosphate (TNP-8N3-ATP) originally developed by Seebregts and  
 
McIntosh (1988) to probe the active site of sarcoplasmic reticulum Ca2+ -ATPase, in 
photolabeling the active site of PfHPRT. Previous studies in our laboratory have 
indicated that TNP-GMP is a potent inhibitor of PfHPRT (Phehane, 2002) where it was  
 
hypothesized that the TNP moiety occupied the position of Mg2+PPi. In the case of the 8-
azido nucleotides the tendency to adopt the syn orientation of the purine about the 
glycosidic bond would alter the purine binding mode and possibly allow the adenine base 
to bind in spite the fact that adenine is not normally a substrate. Atomic structures of 
HGPRTs with GMP, IMP indicate a rather open active site where loop II has not closed 
down and parts of the phosphate is exposed to the medium suggesting that a triphosphate 
moiety could be accommodated. This compound is an attractive photoprobe because in 
addition to the radioactive tag, it carries the fluorescent trinitrophenyl group making its 
visualization easy. We rationalize that it will bind to the nucleotide binding region in 
PfHPRT. In a further development we have deaminated TNP-8N3-ATP to TNP-8N3-ITP 
and explored its potential as a photoprobe of PfHPRT.  
 
2.2.2 Application of photoaffinity labeling in drug discovery 
PAL provides valuable insights regarding drug-target interactions in structure-based drug 
design (reviewed in Dorman and Prestwich, 2000). At the primary level, photoprobes are  
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 used to identify target proteins of interest. At the next level, information pertaining to the 
ligand binding mode, affinity and specificity can be obtained by competitive 
photolabeling. This is extremely useful when other binding methods are problematic e.g. 
lack of a radiolabeled ligand. The site derivatization may be obtained by sequencing the 
short labeled peptide fragments. Figure 1.8 summarizes these steps schematically.   
 
 
 
 
 
 
  
 
 
 
 
 
Early lead 
Target identification 
Chemical library
High throughput screening 
Photoaffinity labeling 
New lead Photoaffinity labeling Binding mode  
 
 
Fig 1.8: The various stages that PAL can be utilized in a drug discovery process (modified 
from Dorman and Prestwich, 2000). 
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2.3 Structural bioinformatics 
Full understanding of the biological role of proteins requires knowledge of their structure 
which in turn helps to understand their function. Despite the fact that the number of 
experimentally solved structures has increased exponentially over the last few years due 
to advances in X-ray crystallography and NMR methodologies, not many structures are 
known when compared with the number of elucidated sequences. This sequence-structure 
gap is largely attributed to the success of the various genome sequencing projects.  One 
focus now is on decoding structural information from sequences through experimental 
and computational methods. The latter, though prone to inaccuracies (Bonneau et al., 
2002), provides an avenue for narrowing the sequence-structure gap as it saves time and 
human effort.  
 
Computational structure prediction methods can be grouped into two classes: (i) 
homology modeling and (ii) ab initio methods (Baker and Sali, 2001). Homology 
modeling is based on the observation that evolutionarily related sequences tend to have 
similar three-dimensional structures (Chothia and Lesk, 1986). Thus, given a sequence 
(target), a model of its three-dimensional structure can be predicted based on a known 
structure (template) with which it shares considerable sequence identity. Some exceptions 
to this rule of sequence-structure similarity have, however, been reported (Panchenko et 
al., 2005) and in such cases, threading comes into play. Ab initio structure prediction, on 
the other hand, solely relies on the sequence information and is usually employed in cases  
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 where no known structure for the sequence in question exists. Two hypotheses, local and 
global, have been projected to explain how the amino acid sequence of a protein 
determines its fold (Lattman and Rose, 1993). In the local hypothesis it is argued that 
only a few critical residues in a protein sequence determine its fold while the global 
hypothesis proposes that each amino acid position ultimately contributes to protein 
folding. Studies support both hypotheses (Thomas et al., 1995; Bowie et al., 1990) but 
the finding by Russell and co-workers (1997) that very low sequence identities result in 
striking structural variation seem to give weight to the local hypothesis in that critical 
residues are likely to be altered at low sequence identity (Wood and Pearson, 1999). This 
also ties in with the observation that useful protein models can only be built by 
comparative modeling if the sequence identity between the target and template sequence 
is over 40% (Chakrabarti et al., 2003). 
 
2.3.1 Homology modeling 
This knowledge-based strategy can be split into two approaches: comparative modeling 
and threading. In the first approach, three-dimensional model building heavily relies on 
sequence similarity between the target and the template. The basic assumption here is that 
with increasing sequence identity, two proteins are likely to have a similar fold. This is 
nevertheless not an exhaustive approach since most similar structure pairs seem to have 
less than 12% sequence identity (Rost, 1997).  
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 Threading (Jones et al., 1994; Jones, 1999) on the other hand unambiguously includes 
template structural information in the modeling procedure (Fischer and Eisenberg, 2003) 
and as a result can identify distant homologues. Fold assignment, in this case, is by 
mapping the unknown sequence through each structure in a library of experimentally 
solved structures. The ability to recognize distant homologues arises from the fact that 
structure is more conserved than sequence during evolution (Lesk and Chothia, 1980). 
Additionally, threading can identify unrelated proteins which share a common fold. 
Considering the estimation that 75% of homologous enzymes share below 30% sequence 
identity (Todd et al., 2001), threading is commonly employed nowadays in homology 
modeling. The applicability of homology modeling thus depends on finding a suitable 
template i.e. one with at least some detectable similarity with the target sequence.   
 
2.3.2 Homology modeling steps 
2.3.2.1 Searching for homologs 
Comparative modeling is a multi-step process which commences with the identification 
of known structures (templates) related to the target sequence. Computer programs which 
utilise the target sequence as input are used to query sequence and/or structural databases 
such as the National Centre for Biotechnology Information (NCBI), TrEMBL/SWISS-
PROT, the Protein Data Bank (PDB, Berman et al., 2000), DALI (Holm and Sander, 
1998), CATH (Orengo et al., 1997) and the Structural Classification of Proteins (SCOP, 
Murzin et al., 1995). These programs can either be exhaustive, heuristic, threading or the 
Hidden Markov Model (HMM) algorithms. Exhaustive programs compare the unknown  
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 sequence with each entry in a database as opposed to the heuristic programs which scan 
the database for regions of strong homology. While this latter option compromises 
sensitivity i.e. detection of distantly related sequences, it saves on the time taken to 
search a database and also minimizes computational hardware requirements. The obvious 
pitfall to this method, thus, is that by not comparing the target with all the database 
entries, weak similarities are possibly missed. Also, since the final statistics are based on 
a subset of and not the whole database entries, their significance could be doubtful. 
 
The original dynamic programming algorithm (Needleman and Wunsch, 1970) and its 
modification (Smith and Waterman, 1981) are examples of exhaustive algorithms while 
the Basic Local Alignment Search Tool ((BLAST) Altschul et al., 1990; Altschul et al., 
1997), Position-Specific Iterated BLAST (PSI-BLAST) and FAST-All ((FASTA) 
Pearson and Lipman, 1988) represent heuristic methods. The Needleman and Wunsch 
algorithm produces an optimal global alignment of sequences and even allows the 
introduction of gaps. BLAST and FASTA both perform pairwise sequence alignments 
while searching the data base. BLAST has been developed further into specialized forms 
such as BLAST2 and BLASTp which both query a protein database using a given protein 
sequence, PHI-BLAST (pattern hit initiated blast), RPS-BLAST used for searching for 
protein domains in a conserved Domains Database and the Position-Specific Iterated 
BLAST (PSI-BLAST). A PSI-BLAST search progresses via profile-sequence alignment 
in which the weighted multiple sequence alignment generated after the initial search is 
used to construct a position specific matrix that further searches the database for  
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 additional homologs. This iterative procedure makes PSI-BLAST more sensitive. Newer 
programs include SAM-T02 which employs the Hidden Markov Models method, 
SALIGN which employs a profile-profile alignment procedure and several threading 
programs among them GenThreader (Jones, 1999a; McGuffin and Jones, 2003), 3D-
PSSM (now phyre; Kelley et al., 2000) and FUGUE (Shi et al., 2001). A thorough 
template search involves the use of an assortment of these programs.  
 
The output of a given program depends on the scoring matrix used by the program. The 
matrix defines the similarity score, penalties for opening and extending gaps and the 
mismatch penalty. Point Accepted Mutation (PAM; Dayhoff, 1978) and BLOSUM 
(Henikoff and Henikoff, 1992) matrices are employed by most search programs.      
 
2.3.2.2 Choosing the template 
After homologs to the unknown sequence are identified, the next step is choosing the 
most suitable template for alignment. Although high sequence similarity between the 
target and template results in superior models, several other factors are also considered. 
When considering templates solved by X-ray crystallography, the resolution and the 
reliability factor (R-factor) both of which determine the quality of the structure are 
important. In the case of NMR structures, the number of restraints per residue is vital. 
Since protein families can further be grouped into subfamilies, multiple sequence 
alignments together with phylogeny trees aid in selecting template(s) from the same 
subfamily as the target sequence (Retief, 2000). The target-template environment (Marti- 
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 Renom et al., 2000; Fiser, 2006) should also be factored. For example, when modeling a 
protein bound to a ligand, a template complexed with a similar ligand or its analog is 
more appropriate.  
 
The use of multiple templates generally improves the model accuracy (Sanchez and Sali 
1997). In modeling using multiple templates, one can choose to align the templates with 
different domains of the target with little overlap between in which case the entire target 
sequence is modeled, or the templates can be aligned to the same region of the target and 
the model built based on the best local template (Fiser, 2006).  
 
Ultimately, the best template picked depends on the quality of the model arising from the 
target-template alignment. Model quality, determined by energy or scoring functions will 
be elaborated further below.   
 
2.3.2.3 Aligning the target to the template 
The accuracy of the target-template(s) alignment forms the core of homology modeling 
since it describes the correspondence between the target and template residues. 
Considering a misalignment by a single residue results in an estimated error of 4 Å in the 
model (Fiser, 2004), the accuracy of the alignment dictates the quality of the resulting 
model structure. The importance of correctly aligning a given sequence to the chosen 
template has been particularly overemphasized in a number of reviews (Dunbrack, 2006; 
Ginalski, 2006; Sali, 1995).  
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 With high sequence identity (> 40%) between the target and the template, alignment is 
uncomplicated and can be confidently performed using any of the available automatic 
programs (see below) with minimal manual intervention. This range of sequence 
similarity has few gaps and also, the structural differences that exist are confined to the 
loop regions and the sidechains (Sali, 1995). Below 30% sequence identity however, 
alignment errors increase making this a major cause of incorrect models in comparative 
modeling (Fiser et al., 2002). In such cases, threading is employed. It is noteworthy to 
point out though that any given alignment should be manually inspected to ensure that the 
conserved residues, insertions or deletions are within the appropriate secondary structure 
elements.  
 
Several sequence-sequence and sequence-structure (threading) alignment programs have 
been developed. Two most popular ones are ClustalW (Thompson et al., 1994) and T-
Coffee (Notredame et al., 2000). These programs are both based on the progressive 
alignment strategy (Feng and Doolittle, 1987; Taylor 1988) in contrast to earlier rigorous 
programs such as MSA (Lipman et al., 1989) and DCA (Stoye et al., 1997). While 
ClustalW and T-Coffee perform multiple sequence alignments, they differ in the fact that 
ClustalW performs a global optimal alignment of the sequences while T-Coffee does a 
local-global alignment. Since global alignments with ClustalW deteriorate at low 
sequence identity (Sauder et al., 2000), T-Coffee is becoming even more favoured.  
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 Once the sequence alignments have been optimized, the JOY program (Mizuguchi et al., 
1998) can be used to correlate the alignment information with the three-dimensional 
structural features therefore extracting useful information in a given sequence alignment 
which aids in understanding the conservation of amino acids in their specific local 
environments. 
 
Sequence-structure alignment programs include FUGUE (Shi et al., 2001), GenThreader 
(Jones, 1999b) and 3D-PSSM (Kelley et al., 2000). Generally these programs match a 
query sequence (target) with a known structure (template) and assess the compatibility 
using mean force potentials (Sippl, 1995). The way in which each program executes its 
function, however, varies. The flexible hybrid of profile and hidden Markov model 
(HMM) sequence-structural alignment strategy implemented in FUGUE selects the most 
optimal alignment based on the length difference between the sequence and the structure 
to be aligned. The algorithm takes into account the residue environment in the template 
when comparing it with the target sequence equivalent. Thus, the substitution tables are 
environment specific. 
 
GenThreader, on the other hand, approaches the alignment problem in two ways: (i) 
using the target sequence, a sequence profile alignment is undertaken using the global-
local dynamic programming algorithm and scanned through a structural database or (ii) a 
profile of the template sequences is built and then matched against the target sequence.  
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 The program uses both approaches concurrently but takes the highest scoring alignment 
as the preferred one. The alignment is then evaluated using a statistical pairwise potential  
of mean force [(Hendlich et al., 1990; Jones et al., 1992) and a solvation potential (Jones 
et al., 1992). 
 
Lastly, in 3D-PSSM, the multiple sequence profile generated by aligning the target 
sequence with its homologs using the PSI-Blast routine is combined with a novel 
structural alignment of remote template homologues which includes their secondary 
structure information and solvation potentials. The resulting alignment is therefore coded 
for by multiple sequences and structures. 
 
The best possible alignment from either the sequence based method or the fold 
recognition method is then used for modeling the probable structure of the given 
sequence.   
 
2.3.2.4 Model building 
There are three ways in which the actual modeling proceeds. In the first approach, 
superposition of the conserved regions of the templates forms the three dimensional 
outline of the model (Browne et al., 1969; Blundell et al., 1987). Once this assemblage of 
template core regions is in place, loops and side chains are then modeled (Greer, 1990). 
In this case, the use of multiple templates with considerable sequence identity increases  
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 the model accuracy (Srinivasan and Blundell, 1993). This method is implemented in an 
early model building program COMPOSER (Sutcliffe et al., 1987).  
 
The second approach, termed segment matching or co-ordinate reconstruction (Fiser, 
2006), uses a subset of the template(s) atomic positions, usually the Cα atoms of residues 
in the conserved fragments of the target-template alignment, to calculate the co-ordinates 
of the target sequence atoms (Jones and Thirup, 1986; Levitt, 1992). This method is 
attractive in that it can model main chain and side chain atoms, gaps and loops.   
 
The last and most widely used method is modeling by satisfaction of spatial restraints 
(Sali and Blundell, 1993). Here, the target-template alignment is used to derive restraints 
to be imposed on the model structure by assuming that the distances between the aligned 
residues in the target and the template are equal. In addition to these homology based 
restraints, stereochemical restraints from the molecular mechanics force field (Brooks et 
al., 1983) are also applied to the model. Model restraints violation is then minimized by 
real space optimization or distance geometry. 
 
Modeling by satisfaction of spatial restraints is implemented in the popular program 
MODELLER (Sali et al., 1990; Sali and Blundell, 1993; Fiser et al, 2000). As a first step, 
MODELLER derives distance and dihedral angle restraints from the target-template 
alignment and expresses them as probability density functions. These are then converted 
into an objective function which is then optimized in Cartesian space using the variable  
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 target function which uses conjugate gradient and molecular dynamics with simulated 
annealing.     
 
2.3.3 Loop modeling 
Loops connect the regular secondary structure elements (i.e. alpha helices and beta 
sheets) of proteins and frequently constitute the variable regions among similar structures 
(Chothia and Lesk, 1986). Although mostly found on the hydrophilic surface of proteins, 
they form an important part of the protein structure by contributing to the active site and 
thus may determine functional specificity (Todd et al., 2001). Even though not a trivial 
task, the accurate modeling of loop conformation is a critical step in homology modeling 
since this determines the model’s usefulness in deciphering protein-ligand interactions 
and examining active and binding sites (Fernandez-Fuentes et al., 2006). Therefore, like 
in the case of alignment, the modeler’s input is essential at this stage and serious thought 
on which of the seemingly similar choices to pick determines whether one ends up with 
the correct model. 
 
For the modeling of loops, two main methods have been developed. One involves 
searching the databases of solved structures for known loop fragments (canonical loops) 
that fit into the two stem regions cradling the loop (Deanne and Blundell, 2000; Shepherd 
et al., 1999; Krieger et al., 2003; Fiser et al., 2000). Once obtained, the fragments are 
evaluated and then chosen based on geometrical properties and sequence matching to 
both the target and template(s) loop sequences. The chosen fragments are then  
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 superposed and annealed onto the stems and subsequently refined by energy function 
optimization (Fiser et al., 2000). Here, the secondary structure elements bracing the loop 
to be modeled and the spatially close regions influence the fragment choice (Chothia and 
Lesk, 1987; Fernandez-Fuentes et al., 2006).  
 
Although limited by the exponential increase in the number of possible geometrical 
conformations as the loop lengthens, and the considerably small number of solved 
structures, this popular approach has been incorporated in a number of modeling 
programs and servers such as ArchPRED (Fuentes et al., 2006), MODELLER (Sali and 
Blundell, 1993), WHAT IF (Vriend, 1990) and Swiss-Model (Peitsch et al., 2000).  
 
The exponential increase in the number of possible geometrical conformations seen with 
the direct database search method led to the development of a slightly different technique 
which uses the CHARMM non-bonded energy function (Brooks et al., 1983) for 
optimization and ranking of probable loop fragments (van Vlijmen and Karplus, 1997). 
This offers the advantage of slowly increasing the number of fragments to be minimized 
with the CHARMM function as the loop length increases as opposed to the exponential 
increment seen with method one. 
 
The second approach originated with Go and Scheraga (1970) who first proposed a 
method for predicting the conformation of a segment joining two core regions in a solved 
structure. Since then, numerous studies on ab initio loop modeling have been conducted  
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 (Pedersen and Moult, 1995; Fiser et al., 2000; Deanne and Blundell, 2000). This method 
involves a conformational search for the global energy minima. Different energy function 
provisions and optimization algorithms have been employed in the search and include 
genetic algorithms (Ring and Cohen, 1994), Monte Carlo and molecular dynamics (Rapp 
and Friesner, 1999) and self-consistent field optimization (Koehl and Delarue, 1995). An 
attractive feature of the method is its ability to carry out modeling of several loops 
simultaneously (Fiser et al., 2000). 
 
Apart from the two main approaches, some programs implement a combined algorithm. 
An example is CODA (Deanne and Blundell, 2001) which integrates a database search 
program, FREAD, with an ab initio method, PETRA (Deanne and Blundell, 2000). 
 
2.3.4 Side chain modeling 
The importance of correctly modeling side chains in a protein structure arises from the 
central role that side chains play in molecular recognition. For example, they are involved 
in the packing of protein hydrophobic cores, binding of ligands and regulation of protein-
protein interactions (Vasquez, 1996). 
 
Side chain modeling is, however, difficult due to the large number of possible 
combinations of conformations encountered and as a result, methods commonly utilized 
perform limited sampling of side-chain torsion angle space. Generally, two procedures to  
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 tackle this problem have been developed. The popular prediction strategy is to choose a 
set of torsion angles which represent the most frequent orientations i.e. rotamers observed 
in solved structures (Swain and Kemp, 2001; Petrella and Karplus, 2002) and model the 
unknown side chains based on this. The rotamer search may consider main-chain-side-
chain interactions or may just focus on side-chain-side-chain interactions (Tanimura et 
al., 1994). The suitability of the rotamers is then measured using some scoring function 
(Peterson et al., 2004). Several algorithms such as the genetic algorithm (Jones, 1994), 
simulated annealing (Koehl and Levitt, 1999) and the dead-end elimination algorithm 
(Voigt et al., 2000) have been developed for the rotamer search and placement.  
 
Despite being relatively inexpensive in terms of computational speed, this cannot always 
map all model side chains accurately onto a given rotamer library. Such was the case in a 
study conducted by Bower and co-workers (1997) in which approximately 6 % of the 
more than 40,000 side-chains studied exhibited a variance of ~40 ° from any rotamer in 
their library. Furthermore, an analysis of high resolution crystal structures conducted by 
Lovell and co-workers (2000) found out that about 5 % of residues in these structures did 
not match any of the 153 rotamers in their library. These ‘off-rotamer’ (Petrella and 
Karplus, 2002) side chain conformations can be modeled using an alternative strategy 
referred to as ab initio modeling.  
 
 
 
 61
 
 
 
 
 In ab initio side chain modeling, a search for the global minimum energy, is performed 
empirically by optimization of an energy function. This approach, however, is 
computationally intensive and thus not widely applied. 
 
Ultimately the two methods yield comparable results since they both involve energy 
minimization to find the most suitable side chain conformation. They differ from one 
another primarily in two aspects; the selection of an initial conformation and the survival 
criteria used to produce the next generation in an iteration procedure. 
 
The complexity of side chain modeling is exemplified by the fact that only a limited 
number of computer programs are publicly available (Canutescu et al., 2003). The 
program side-chains with a rotamer library ((SCWRL) Bower et al., 1997) is one such 
program that is widely used because of its speed, accuracy, and simplicity. The algorithm 
building of an initial residue placement is strongly backbone dependent. After the initial 
placement, methodical searches are carried out to minimize steric clashes. Overall, the 
program assumes that the local main-chain conformation of each residue largely 
determines the side-chain conformation and that a search strategy to mitigate steric 
clashing is also essential for precise placements.  
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 2.3.5 Model quality assessment and usefulness  
Once a three-dimensional model has been built, the final step of evaluating its accuracy is 
then carried out. During this stage, errors that might have occurred during earlier stages 
are highlighted. Target-template(s) mis-alignments, mistakes in loop modeling and error 
in side chain conformation assignment are frequently encountered causes of improper 
models. Usually, when assessing a model, sequence identity between the target and the 
template(s) is a good indicator of the expected accuracy. With more than 50% identity, 
models with up to 1 Å random mean standard deviation (rmsd) of the backbone carbon 
atoms compared to solved structures can be obtained (Ginalski, 2006).  
 
Evaluating the model stereochemistry is an obvious starting point in quality assessment. 
In doing this, bond lengths, bond angles, torsion angles and hydrogen bonding energies 
are some of the parameters checked for comparability with those normally encountered in 
solved structures. The Ramachandran plot (Ramachandran et al., 1963), a plot of phi 
versus psi main-chain angles, is routinely used to check the stereochemical quality of a 
model. If the quality of the model is good, most of the residues will fall in the favoured 
regions of the plot. Glycines and prolines are, however, exempted from the clustering rule 
due to their unique side chain properties. Software programs based on the Ramachandran 
plot have been written and include the popular PROCHECK (Laskowski et al., 1993), 
WHAT-CHECK (Hooft et al., 1996) in the WHAT-IF suite (Vriend, 1990). 
 
 
 63
 
 
 
 
 An alternative model evaluation protocol involves the use of energy functions such as the 
statistical potential functions implemented in PROSA (Sippl, 1995). This approach is, 
however, not very common and is mostly undertaken when authenticating whether the 
correct template was used for the modeling procedure.  
 
2.4 Research aims 
Several aims were set for this project. One was to purify the malarial enzyme and attempt 
co-crystallizing it with a chalcone synthesized in our laboratory. This chalcone has been 
shown to accelerate the enzyme turnover, activate an inactive to active transition and also 
inhibit the enzyme in the presence of Ca2+ (Mbewe, 2005). We wanted to validate 
whether this chalcone binds to the active site or an effector site on the enzyme. In case of 
the former, successful structure solution of PfHPRT with the chalcone would then 
facilitate development of better binding chalcone inhibitors. 
 
We also set out to model the structure of the malarial enzyme in the open conformation 
based on the structures of other phosphoribosyltransferases in the same state. To our 
knowledge, neither the crystal structure of the unliganded PfHPRT nor its homology 
model has been elucidated. Availabilty of a free PfHPRT model would then facilitate 
docking of ligands onto the enzyme’s active site.  
 
We also aimed to photalabel the active site of PfHPRT using [32P]TNP-8N3-ATP. In 
addition, we set out to synthesize a new azidonucleotide derivative, [32P]TNP-8N3-ITP,  
 64
 
 
 
 
 from [32P]TNP-8N3-ATP and evaluate whether it was useful as a photoprobe of the 
malarial enzyme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65
 
 
 
 
 CHAPTER TWO: MATERIALS AND METHODS 
 
  
2.0 Reagents and Chemicals 
 
Reagent or Chemical                                                         Supplier 
 
Ammonium persulfate                                                          Bio-Rad, USA 
 
Disodium Hydrogen Phosphate                                                    Merck, Germany 
(Na2HPO4. 2H2O) 
 
Sodium dihydrogen phosphate                                             Merck, Germany 
(NaH2PO4. H2O)                                                                      
 
Hepes                                                                                    Sigma, USA 
 
3-Morpholinopropanesulfonic acid                                      Sigma, USA 
(MOPS)  
                                                                                   
Sodium pyrophosphate                                                         Sigma, USA 
 
Polyethylene glycol 4000                                                     Merck, Germany 
 
Tris(hydroxymethyl)aminomethane                                     Merck, Germany 
(H2NC(CH2OH)3) 
 
Sodium chloride (NaCl)                                                        Merck, Germany 
 
Sodium dodecyl sulfate (SDS)                                              Bio-Rad, USA 
 
Acrylamide/Bis solution, 19:1 (5% C)                                  Bio-Rad, USA 
 
Dnase1                                                                                   Roche, Switzerland  
 
Dithiothreitol (DTT)                                                              Sigma, USA 
 
Diethylaminoethyl cellulose (DE-52)                                   Whatman, USA 
 
Reactive Red 120 agarose                                                     Sigma, USA 
 
Tetramethylammonium hydroxide                                        Fluka, USA 
(TMAH) 
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Coomassie Brilliant Blue R-250                                            Sigma, USA 
 
Ethylenediaminetetraacetic acid                                            BDH AnalR, England 
(EDTA)                                                                                      
 
Magnesium chloride hexahydrate                                          Merck, Germany 
(MgCl2. 6H20)                                                                           
 
Yeast Extract                                                                          Merck, Germany 
 
Tryptone                                                                                 Merck, Germany 
 
Chloramphenicol                                                                    Roche, Switzerland 
 
Isopropyl β-D-1-thiogalactopyranoside                                 Sigma, USA 
(IPTG)                                                                                        
 
Ampicillin                                                                               Roche, Switzerland  
 
Crystal screen 1 & 2                                                               Hampton Research, USA 
 
Structural screen 1 & 2                                                           MDL, USA 
 
Silicon oil                                                                               Hampton Research, USA                                   
 
Paraffin oil                                                                             Hampton Research, USA 
 
Ethanol (EtOH) [99.7-100% v/v)                                           BDH AnalR, England 
 
Methanol                                                                                 BDH AnalR, England 
 
Acetic acid, Glacial                                                                 BDH AnalR, England 
                                                                                                                        
Adenosine monophosphate (AMP)                                         Sigma, USA 
 
Guanosine monophosphate (GMP)                                         Sigma, USA 
 
Dimethyl sulfoxide (DMSO)                                                  Merck, Germany 
 
Sodium hydroxide (NaOH)                                                    Merck, Germany 
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 Molecular weight marker kit for gel filtration chromatography (MW-GF-200 Kit) was 
from Sigma-Aldrich, VDX plates, 72 well microbatch plate, seeding tool, cryo-loops, 
glass sitting drop rods, 22 mm thick siliconized circle cover slides and Dow Corning 
vacuum grease were all from Hampton Research.  
 
2.1 Culture media  
2.1.1 Luria Bertani (LB) Broth 
Luria Bertani broth, supplemented with 10 mM sodium phosphate, was prepared as 
follows: 
Constituents, per litre 
Tryptone                                                          10 g 
Yeast extract                                                    5 g 
NaCl                                                                 5 g 
Na2HPO4. 2H2O                                              1.78 g 
NaH2PO4. H2O                                                1.38 g 
 
pH adjusted to 7.3 ± 0.2 with 5 N NaOH at 25 °C before autoclaving. 
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 2.2 Protein expression  
The glycerol stocks of BL21(DE3)pLysS Escherichia coli cells transformed with pET-
17b expression plasmid harboring the malarial HPRT cDNA were prepared by Dr. 
Boniface Mbewe in our laboratory (2005) and stored in the -80 ºC freezer. 
 
1 L of Luria-Bertani medium supplemented with 10 mM sodium phosphate, 100 μg/mL 
ampicillin and 34 μg/mL chloramphenicol was inoculated with ~20 μL of 
BL21(DE3)pLysS E. coli cells. The cells were grown overnight at 37 ºC without shaking 
until an OD600 of 0.4-0.6 was attained. PfHPRT expression was induced by the addition 
of IPTG to a final concentration of 0.4 mM. Expression was allowed to continue for three 
hours at 37 ºC with vigorous shaking at 200 rpm. Cells were then harvested in an Avanti 
J-30I high-speed centrifuge (Beckman Coulter) using a JA-14 rotor rotating at 8 000 rpm 
at 4 ºC for 10 minutes. The supernatant was decanted, pellet rinsed gently with de-ionised 
water and stored -80 ºC.   
 
The bacterial pellets were then re-suspended in an equal volume (~25 mL) of ice-cold 
lysis buffer (50 mM Tris-HCl, pH 8.0, 25 mM NaCl, 2 mM EDTA containing 1 mM 
DTT, 1 mM PMSF) then disrupted gently mechanically using a Potter-Elfeljen glass 
homogeniser. To the pooled homogenate (100 mL), 5 mM MgCI2 was added followed by 
0.05 mg/mL DNAse1 (Sigma) to break down the DNA strands released upon cell lysis. 
The cell homogenate was then incubated for 30 min at 25 ºC while shaking at 160 rpm in 
a C24KC refrigerated incubator shaker (New Brunswick Scientific, NJ, USA). After, it  
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 was divided into four 25 mL fractions and clarified by spinning at 21 000 x g for 30 
minutes at 4 ºC in an Avanti® J-30I centrifuge with a JA-30.50 rotor (Beckman Coulter). 
The supernatant containing the soluble PfHPRT was then subjected to purification 
procedures.  
 
2.3 Protein purification 
Chromatographic steps were routinely performed at 4 ºC unless otherwise stated. Prior to 
use, buffers for HPLC experiments were filtered through 0.22-micron filters (Millipore). 
Protein samples were concentrated by ultrafiltration to a final volume of 1 mL using an 
Amicon 8010 stirred cell fitted with a 25 mm diameter Ultracel YM-10, NMWL, 10 kDa 
membrane (Millipore). Further concentration to microliter volumes was routinely carried 
out using 0.5 mL Amicon centrifugal filter devices fitted with Ultracel YM-10, NMWL, 
10 kDa membrane (Millipore). Buffer exchange between chromatographic steps was 
achieved by dialysis using a 6-8 kDa NMWL dialysis tubing (Merck).       
 
2.3.1 Tandem anionic and dye affinity chromatography 
2.3.1.1 DEAE-cellulose column preparation 
Approximately 10 g of DEAE cellulose resin (DE-52, Whatman) was suspended in ~ 250 
mL of de-ionised water. The fines were decanted and the resin washed with more water, 
each time removing the fines. The slurry was loaded onto a 2.0 x 6.0 cm column which 
was then washed with 10 mL of cell lysis buffer. 
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2.3.1.2 Reactive Red 120 column preparation 
Reactive Red 120-agarose suspension (type 3000-CL) in 0.5 M NaCl, 0.02% thimerosal 
(Sigma) was packed onto a 2 x 5 cm column which was then thoroughly washed with de-
ionised water. 
 
2.3.1.3 Chromatography on DE-52 and Reactive Red 120 columns.  
The two columns were then placed in tandem with the anionic DE-52 column on top of 
the Reactive Red column. The supernatant was applied and allowed to flow through by 
gravity at a flow rate of 30 mL/h. The columns were then washed with 50 mL of 50 mM 
Tris-HCl, pH 8.0, 1 mM DTT, and 1 mM PMSF and detached. The Reactive Red 120 
column was developed with 50 mL of 10 mM sodium phosphate, pH 7.0/ 200 mM NaCl 
and subsequently eluted with 50 mM sodium pyrophosphate in 10 mM sodium 
phosphate, pH 7.0 (PPi), collected in 10 mL fractions. The column was finally washed 
with 50 mL of 1 M NaCl. The purity of PfHPRT obtained from this and subsequent 
preparations were analyzed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE; Coomassie Blue stain, see below). Fractions containing 
PfHPRT were pooled, dialysed overnight in 10 mM sodium phosphate, pH 7.0, 1 mM 
DTT, concentrated to 1 mL using an Amicon 8010 stirred cell (Millipore). Further 
concentration for crystallization was carried out using 0.5 mL Amicon centrifugal 
devices. 
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2.3.1.4 Modifications to the chromatographic procedure  
To further understand the separation behaviour on the two columns, several modifications 
were tested. Firstly, the two columns were run separately. The DE-52 flow through 
followed by the Tris-HCl wash was collected in 10 mL fractions, analysed on SDS-
PAGE and fractions containing PfHPRT loaded onto the Reactive Red 120 column which 
was developed as described in section 2.1.1.3. Fractions containing PfHPRT, determined 
by SDS-PAGE gel, were treated as outlined earlier. In the next preparation, the pH of the 
DE-52 flow through and the wash fractions was monitored at room temperature to 
ascertain the highest pH to which the target enzyme was exposed to. Fractions containing 
PfHPRT in this preparation were again purified further on a Reactive Red 120 column. In 
line with the method of Mbewe et al. (2006) for the purifications described so far, the 
DE-52 column was washed with 10 mL of the lysis buffer before loading of the 
supernatant. For the subsequent experiment, the DE-52 column was equilibrated as 
follows: approximately 6 g of the resin was suspended in 60 mL of 10X 75 mM Tris-
HCl, pH 8.9 and the fines washed off. This was followed by further suspension in 120 
mL 1X 75 mM Tris-HCl, pH 8.9. The slurry was then packed onto the column and the pH 
of the effluent measured. The supernatant pH was adjusted to 8.9 before loading onto the 
column. The flow-through was collected in 10 mL fractions. The column was then 
washed with 50 mL of 50 mM Tris-HCl, pH 8.0, 1 mM DTT, and 1 mM PMSF also 
collected in 10 mL. Fractions containing PfHPRT were purified further on a Reactive 
Red 120 column as described earlier. 
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 Finally, two purifications using a longer DE-52 column (2 x 17.5 cm) were carried out. In 
one purification, the column was only washed with 30 mL lysis buffer prior to applying 
the supernatant. In the other purification, the column was equilibrated with 10 column 
volumes of the lysis buffer. In the two cases, the column was washed with 80 mL of 50 
mM Tris-HCl, pH 8.0, 1 mM PMSF, and 1 mM DTT after collecting the supernatant 
flow-through. The eluate was collected in 10 mL fractions. Other contaminating proteins 
were washed off the column with 100 ml of 1 M NaCl. Fractions containing PfHPRT as 
judged by SDS-PAGE were pooled, purified further on a Reactive Red 120 column as 
described previously.   
 
2.4 Alternative purification strategies 
2.4.1 Ammonium sulphate fractionation and dye affinity chromatography  
Solid ammonium sulphate was added to 100 mL of the supernatant with gentle stirring to 
achieve 40-80% saturation. After the salt was completely dissolved, the solution was 
stirred for an additional 1 h before centrifugation at 10 000 x g for 30 min. The resulting 
pellet was re-suspended in a minimal volume of 50 mM Tris-HCl, pH 8.0, 1 mM DTT, 
and 1 mM PMSF, dialysed overnight against 10 mM MOPS, pH 7.0, 1 mM DTT and 
applied to a Reactive Red column 120 (2 x 5 cm) equilibrated with 10 mM MOPS, pH 
7.0, 1 mM DTT. The column was washed with 20 mL of 10 mM MOPS, pH 7.0 and 
protein eluted with 50 mM sodium pyrophosphate in 10 mM sodium phosphate, pH 7.0. 
Fractions containing PfHPRT were pooled, dialysed against 10 mM sodium phosphate,  
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 pH 7.0, 1 mM DTT, concentrated in an Amicon stirred cell and assayed for activity as 
described below.  
2.4.2 Anion and cation exchange chromatography  
The supernatant was loaded onto a DE-52 column (2 x 15 cm) equilibrated with 50 mM 
Tris-HCl, pH 8.0, 25 mM NaCl, 2 mM EDTA, 1 mM DTT, and 1 mM PMSF. Following 
collection of the flow through, the column was washed with 80 mL of 50 mM Tris-HCl, 
pH 8.0, 1 mM DTT, and 1 mM PMSF collected in 10 ml fractions. A final wash of the 
column was with 100 mL of 1M NaCl. SDS-PAGE gel was then run to determine the 
purity of the fractions containing PfHPRT. Fractions containing PfHPRT were pooled 
and passed through two cationic Sep-Pak cartridges held in tandem. The cartridges were 
then detached and each eluted with 5 mL of 10 mM MOPS, pH 7.0, 400 mM NaCl, and 
0.05% NaN3 collected in 1 mL fractions. SDS-PAGE (15%) gel was then run to 
determine purity attained. Pure fractions were pooled, dialysed against 10 mM sodium 
phosphate, pH 7.0, 1 mM DTT, concentrated by ultrafiltration in an Amicon stirred cell 
and assayed. 
 
2.5 HPLC gel filtration chromatography 
Size exclusion chromatography was used to examine the oligomeric status of PfHPRT 
under various conditions and also for further purification of PfHPRT. Experiments were 
performed at ambient temperature using a Tosohaas TSKgel G 3000 SW column (7.5 mm 
x 30 cm, 10 μm) attached to a Beckman System Gold 126 pump mechanism/168 diode 
array detector HPLC system. Elution was monitored at 280 nm. Molecular mass was  
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 determined from a calibration curve using Alcohol dehydrogenase (Mw 150.0 kDa), 
albumin (Mw 67.0 kDa), ovalbumin (Mw 43.0 kDa), carbonic anhydrase (Mw 29.0 kDa) 
and cytochrome C (Mw 12.4 kDa) (MW-GF-200 Kit, Sigma-Aldrich) as protein markers. 
Blue dextran (2 000 kDa) and tyrosine (185 Da) were used to determine the excluded 
(Vo) and included void (Vi) respectively. Partition coefficient (Km) values for the 
calibration curve were calculated as per Equation 1 and plotted against the logarithm of 
the molecular weight for the markers.  
 
Vr = Vo + KmVi                                                                                                                                                       (Equation 1) 
 
Where Vr = retention volume of protein             
           Vo = excluded volume 
           Km = partition coefficient  
           Vi = included volume 
 
2.5.1 Standards preparation and running buffer evaluation 
Standard stocks (1 mg/mL) were prepared by dissolving the appropriate amount in de-
ionized water.  20 µL of each standard was then taken and mixed to give the final 
standard cocktail from which 20 μL was routinely injected into the column. Three 
running buffer systems, 10 mM MOPS/TMAH, pH 7.0, 0.05% NaN3, 10 mM 
MOPS/TMAH, pH 7.0, 100 mM NaCl, 0.05% NaN3, and 10 mM MOPS/TMAH, pH 7.0, 
400 mM NaCl, 0.05%  
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NaN3 were tested at a flow rate of 1 mL/min. Duplicate runs were performed for each 
buffer system.  
 
2.6 Analytical techniques 
2.6.1 SDS-PAGE gel electrophoresis 
All SDS-PAGE analyses were carried out according to the discontinuous method of 
Laemmli (1970). Resolving gels consisted of a 15% (w/v) polyacrylamide matrix 
(arylamide: bisacrylamide, 29:1) in 375 mM Tris-HCl and 0.1% (w/v) SDS, and were 
overlaid with a 3% (w/v) polyacrylamide stacking gel (acrylamide: bisacrylamide, 29:1) 
in 75 mM Tris-CI and 0.1% (w/v) SDS. After stacking, gels were allowed to polymerize 
for 2 h at room temperature. In some cases gels were prepared a day before 
electrophoresis, tightly wrapped in a clear plastic wrap and stored at 4 ºC. Samples were 
diluted 1:1 with SDS-PAGE sample application buffer (0.5 M Tris-CI, pH 6.8, 10% (w/v) 
SDS, 0.1% (w/v) bromophenol blue, 10% (v/v) glycerol and 2% (v/v) β-mercaptoethanol) 
and vortexed for ~10 sec before loading 10 μL into the wells. Gels were electrophoresed 
at 20 mA per gel for 1 h and 30 min in a Hoefer dual gel caster (Armesharm) 
electrophoresis system. Following electrophoresis, gels were stained with 0.25% (w/v) 
Coomassie Brilliant Blue R-250 (Sigma) stain solution overnight and destained for 1 h in 
10% acetic acid, 30% ethanol followed by 24 h destaining in 7% acetic acid. 
 
 
 76
 
 
 
 
 2.7 Determination of protein concentration  
2.7.1 Bradford Assay 
Protein concentration was determined by the method of Bradford (1976) using bovine 
serum albumin (BSA) as a standard. The assay was carried out as follows: 50 μL of 
sample followed by 750 μL of dH20 were pipetted into 1.5 ml Eppendorf tubes into 
which 200 μl of Bradford reagent (Bio-Rad) was added. The mixture was incubated for 5 
min at ambient temperature before measuring absorbance at 595 nm. A mixture 
containing 800 μl dH2O and 200 μl Bradford reagent was used as a blank. The standard 
calibration curve obtained is shown in the appendix section.  
 
2.7.2 Spectroscopic assay 
During purification HPRT estimation was performed spectrophotometrically on an 
Agilent 8453 UV-visible spectrophotometer (Agilent technologies) by measuring the 
absorbance at 280 nm. The program PROTPARAM on the ExPASy web server 
(http://au.expasy.org/tools/protparam.html) which computes protein molar extinction 
coefficients (EM) based on their amino acid sequence as per the method of Gill and von 
Hippel (1989) was used in calculating HPRT EM. The value returned was 23, 755 M-1 cm-
1. 
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 2.8 PfHPRT activation  
Routinely, prior to setting up activation experiments, the protein was dialysed against 10 
mM sodium phosphate buffer pH 7.0, 1 mM DTT, and 1 mM MgCI2.  Typical protein 
concentration for activation was 1 mg/mL. To aid solubility, base stock solutions were 
prepared in 0.4 M NaOH. PRPP stock solution was prepared in either de-ionised water or 
in 10 mM sodium phosphate, pH 7.0. 50 μL of purified protein was routinely incubated 
overnight at 4 ºC with PRPP and hypoxanthine at concentrations indicated in the table  
below.  
PRPP (mM) Hypoxanthine (mM) 
1 0.06 
0.2 0.06 
 
2.8.1 PfHPRT activity assay 
Enzyme activity for the purine bases guanine and hypoxanthine was determined in a 
continuous spectrophotometric assay on an Agilent Chemstation spectrophotometer at 
room temperature according to the methods of Keough et al. (1999) and Subbayya and 
Balaram (2000). The change in absorbance at 257.5 nm and 245 nm for guanine and 
hypoxanthine respectively was monitored. The 1 mL total assay mixture consisted of 100 
mM Tris-HCI, pH 8.5, 110 mM MgCI2 or 100 mM Tris-CI, pH 7.5, 12 mM MgCI2. To 
the mixture, 1 mM PRPP and 0.06 mM hypoxanthine/guanine were added immediately 
followed by the addition of an appropriate amount protein (10-1000 μg) to initiate the  
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 reaction. The values of the extinction coefficients were measured under assay conditions 
for the guanine and hypoxanthine reactions at pH 8.5 were 5817 and 2283 M−1 cm−1, 
respectively. 
 
2.9 Crystallization experiments  
A number of strategies were explored in an attempt to crystallize free PfHPRT or in 
complex with IMP, GMP or chalcone. 
 
2.9.1 Vapour diffusion screening 
Crystal Screen kits I and II (Hampton Research) based on the sparse matrix sampling 
method (Jancarick and Kim, 1991) were used to test for probable crystallization 
conditions and also to develop cogent strategies for subsequent screens. The hanging 
drop vapour diffusion method was employed. To 200 μL of 10-15 mg/mL PfHPRT in 10 
mM sodium phosphate, pH 7.0, 1 mM DTT, IMP or GMP and MgCl2 were added to a 
final concentration of 1 mM for each. The trials for PfHPRT with the chalcone were set 
up in the presence of CaCl2 also at 1 mM final concentration for both. The mixtures were 
then incubated on ice for 30 min to allow the substrate to bind. For each screen condition, 
2 μL of protein plus substrate was dispensed onto a 22 mm diameter circular siliconized 
cover slide and mixed with an equal amount of precipitant. The cover slide was then 
gently but rapidly inverted and sealed (using Dow Corning® vacuum grease) over 1 mL 
of the precipitant held in the wells of a VDX plate (Hampton Research). The hanging 
drops were observed under the microscope immediately after set up, every day for a week  
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 and once weekly and thereafter until equilibration was assumed complete. For each 
substrate, parallel screens for the 100 individual conditions were set up at 4 ºC and 18 ºC. 
 
2.9.2 pH and precipitant concentration grid search. 
Using the hanging drop vapour diffusion method, a grid search of pH versus precipitant 
concentration was performed for the promising conditions obtained from screening. An 
example of the grid screens set up is shown in Figure 2.0. The range for both pH and 
precipitant concentration was chosen to be on either side of the promising screen 
conditions. Protein and substrate concentrations were not adjusted. The incubation 
temperature was 18 °C 
 
     PEG 
4000 
pH 
 
20% 
 
22% 
 
24% 
 
26% 
 
28% 
 
30% 
7.0       
7.5       
8.0       
8.5       
  
Figure 2.0: An example of pH versus precipitant concentration grid search. 
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 2.9.3 Vapour diffusion rate control  
This method aids in slowing down the rate of nucleation and subsequent crystal growth. 
Hanging drop vapour diffusion method using VDX plates (Hampton Research) was 
employed. Paraffin oil, Silicon oil and Al’s oil (a 1:1 mixture of paraffin and silicon oils) 
were separately tested. Trials were set up as follows: 1 mL of precipitant at the desired 
concentration and pH was dispensed into the wells. To a 1 μL drop of 15-20 mg/mL 
PfHPRT pipetted onto square siliconized cover slides, 0.5 μL of IMP, GMP or chalcone 
(10 mM stock for each) was added followed by 0.5 μL of CaCI2. The drop was gently 
mixed with 2 μl of precipitant from an appropriate well. To the reservoir, 400 μL of oil 
was then gently layered on top. The cover slide was sealed over the well and the 
crystallization plate incubated at 18 ºC. Subsequently, trials were performed with       
200-700 μL of oil layered onto the reservoir. 
 
2.9.4 Modified microbatch screening  
In this modified microbatch method, the drop containing the protein of interest combined 
with the precipitant is dispensed under a layer of oil which acts as sealant by preventing 
evaporation of water from the drop. Protein and precipitant concentrations thus remain 
almost constant. This method was used in an attempt to crystallize PfHPRT with GMP or 
IMP and was performed as follows: 
 
Paraffin oil (6 mL) was pipetted into a 72 well microbatch plate (Hampton Research) so 
that the cone shaped wells on the plate were submerged. 2 μL of PfHPRT (incubated  
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 beforehand with 1 mM of either IMP or GMP plus 1 mM MgCI2 on ice for 30 min) were 
carefully pipetted into the appropriate well followed by 2 μL of the precipitant (Crystal 
Screen I and II conditions; Hampton Research) and incubated at 18 ºC.  
   
3.0 X-ray data collection 
Diffraction data for the crystals tested were collected on the in-house X-ray diffraction 
machine at the University of Western Cape, South Africa. The diffractometer consists of 
a Rigaku RUH3R copper rotating-anode X-ray source operated at 40 kV, 22 mA; a 
Rigaku R-axis IV+ image plate camera (Rigaku MSC, Tokyo, Japan); an X-stream 2000 
low-temperature system (Rigaku MSC, Houston TX, USA); and an AXCO PX50 glass 
capillary optic with a 0.1 mm focus (Australian X-Ray Capillary Optics, Parkville VIC, 
Australia).  
 
Two initial images with an oscillation 0.5° per frame were collected to ascertain whether 
the crystals were protein or salt crystals. The detector-to-crystal distance was set at 120 
mm.  
 
3.1 Comparative modeling 
The first step of the modeling procedure was to align PfHPRT sequence with the 
structures of human HPRT (PDB code 1Z7G (Keough et al., 2005)), Tritichomonas 
foetus HPRT (PDB code 1HGX (Somoza et al., 1996)) and Salmonella typhimurium 
HPRT (PDB code 1J7J (Lee et al., 2001)) using 3D-Coffee (Poirot et al., 2004). The  
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 template structures selected were of the free form of the enzymes. All the templates share 
moderate sequence similarity with PfHPRT. The sequence-structure alignment was 
manually edited to ensure no gaps in the core regions, guided by PSIPRED (McGuffin et 
al., 2000), and that the aligned template sequences matched the corresponding PDB 
entries. Missing residues in the PDB templates were omitted from the alignment. 
Modeling was performed using the external program MODELLER v0.99 (Sali and 
Blundell, 1993) which implements comparative modeling by satisfaction of spatial 
restraints. These template-derived restraints are then combined with CHARMM energy 
terms (Brooks et al., 1983) to obtain a full objective function which is optimized by 
conjugate gradients and molecular dynamics with simulated annealing.  
 
An iterative approach comprising sequence-structure alignment and model building was 
followed. 50 models were generated and one with the fewest restraints’ violation and 
lowest energy was chosen for further evaluation. Side chains for this model were 
optimized using SCWRL (Canutescu et al., 2003). Model quality was evaluated using 
PROCHECK (Laskowski et al., 1993) and MOLPROBITY (Davis et al., 2004). Three-
dimensional images of PfHPRT model structure were generated using PyMOL v0.99 
(DeLano, 2002).    
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 3.2 Synthesis of TNP-8N3-ITP and [γ32P]TNP-8N3-ITP 
A pilot synthesis of TNP-8N3-ITP from TNP-8N3-ATP was first carried out to ascertain 
the time required for the reaction to proceed to completion. To form TNP-8N3-ITP, the 6-
amino group of TNP-8N3-ATP is converted into an oxo-group using sodium nitrite 
(NaNO2) and acetic acid. The reaction was carried out as follows:  To 140 µL of ice-cold 
glacial acetic acid (99.8%), in a 2 mL Eppendorf, 263 µL of ice-cold 2 M NaNO2 (≡0.526 
millimoles) was added. To the mixture, 200 µL of 150 μM TNP-8N3-ATP (≡30 
nanomoles) was added followed by 97 µL of ice-cold distilled water. The reaction mix 
was incubated on ice in the dark. Each aliquot (25 μL, taken after 3 min, 1 h, 2 h, 3 h and 
4 h) was mixed with 50 μL of 10 mM potassium phosphate, pH 6.0, 60% (v/v) 
acetonitrile and analyzed on a Vydac C18 column attached to a Beckman System Gold 
126 pump mechanism/168 diode array detector HPLC system at room temperature. 
Absorption was monitored at 210 nm and 408 nm.  
After 4 h the reaction mix was purified on a C18 Sep-Pak cartridge (Waters) previously 
conditioned with 6 mL methanol followed by 10 mL of distilled water. After sample 
application, the cartridge was washed with 10 mL of 10 mM potassium phosphate, pH 6-
7 to displace the unattached TNP-8N3-ITP 10 mL. The cartridge was then washed with 
0.8 mL of distilled water and sample eluted with 10 mM potassium phosphate, pH 6-
7, 60% (v/v) acetonitrile in two fractions of 0.5 mL and 1.5 mL. The first fraction was 
discarded and the acetonitrile content of the latter fraction reduced by blowing N2 over 
the surface.  
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 Synthesis and purification of [γ32P]TNP-8N3-ITP from [γ32P]TNP-8N3-ATP was carried 
out in a similar manner.  
3.3 [γ32P]TNP-8N3-ATP and [γ32P]TNP-8N3-ITP photoaffinity labeling of PfHPRT  
PfHPRT photolabeling conditions included 25 mM EPPS/TMAH, pH 8.5, 2 mM EDTA 
(or 1 mM MgCl2, or 1 mM CaCl2) , and 20% glycerol. The experiments were performed 
as follows: To 0.01 mg/mL of PfHPRT in 1.5 mL Eppendorf tubes placed on ice, 18.8 µL 
of 4X buffer (100 mM EPPS/TMAH, pH 8.5) and an appropriate volume of distilled 
water were added. This was followed by the addition of 15 μL of glycerol and an 
appropriate volume of [γ32P]TNP-8N3-ATP or [γ32P]TNP-8N3-ITP to give a 
concentration range of 0.01 to 30 μM. The final reaction mix (75 μL) was transferred to a 
1 mL quartz cuvette and placed between two quartz cuvettes with fresh toluene to protect 
the protein from ultraviolet radiation damage (the only transmissible light was above 290 
nm). Samples were then irradiated using a 150 W Xenon lamp (Hi-Tech). Following the 
labeling reaction, samples were transferred into 1.5 mL Eppendorf tubes and placed on 
ice. To the mixtures, 8 μL of solubilization buffer (1.2%, 3.6% β-mercaptoethanol and 
bromophenol blue) was added. After vortexing, 50 μL aliquots were taken and analyzed 
on 12% SDS-PAGE gels, run at 40 mA for 3-4 h, according the method Laemmli (1970). 
Once electrophoresis was complete, the bottom section of the gels (containing the 
majority of the radioactivity) was excised and the remainder dried by heating under 
vacuum. To the dried gels, reference spots, 1 μL of 10 μM [γ32P]TNP-8N3-ATP) were  
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 positioned alongside the gel bands for stoichiometry measurement. Gels were then placed 
on a MS phosphor screen in film cassette (in a lead-lined box which protects the gels 
against cosmic radiation) for ~24 h after which they were scanned for radioactivity on a 
Cyclone Storage Phosphor Screen (Packard Bioscience). Quantitative analysis of the 
visible bands was performed using OptiQuant software which allows calculation of an 
average background value.  By quantitating the counts per band in digital light units 
(dlu), moles of [γ32P]TNP-8N3-ATP (or [γ32P]TNP-8N3-ITP) bound per mole of PfHPRT 
could be calculated using the formula described below.  
3.3.1 Amount of PfHPRT in gel band 
Mw of PfHPRT = 26230 g/mol >> 0.0262 mg/nmol 
Protein on gel = 0.01 mg/mL x 0.05 mL = 0.0005 mg 
Nmol protein on gel = 0.0005/0.0262 = 0.0191 nmol 
3.3.2 Amount of [γ32P]TNP-8N3-ATP in gel band 
 
a = dlu in gel band            b = dlu in mean background 
c = dlu in 1 μL spot of [γ32P]TNP-8N3-ATP (1 μL 1 μM [γ32P]TNP-8N3-ATP ≡ 0.001 
nmol) 
c dlu / 0.001 nmol TNP-8N3-ATP 
therefore c * 1000 dlu / nmol TNP-8N3-ATP 
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 nmol probe in gel band = (a- b) / c * 1000 nmol 
mol probe bound / mol protein = (a-b) / (c * 1000 * 0.0191) mol / mol 
3.3.3 Curve fitting 
Graphs were drawn using SigmaPlot 3.0 (Jandel Scientific Software). TNP-8N3-ATP and 
TNP-8N3-ITP concentration-dependent photolabeling of PfHPRT data were fitted to the 
binding equation 
RC = RCmax[S]/ (K0.5 + [S]) 
Where RC = relative counts, 
           RCmax = relative maximum counts, 
          [S] = photolabel concentration, 
          K0.5 = photolabel concentration at which half-maximal labeling is obtained. 
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CHAPTER THREE: RESULTS 
 
3.0 Protein purification: Ionic exchange and dye-affinity chromatography 
In order to obtain PfHPRT of the highest possible purity for crystallization experiments, 
considerable effort was devoted to improving and optimizing the purification process.  
 
Our starting point was the purification procedure developed by B. Mbewe during his PhD 
programme in this laboratory (Mbewe, 2005; Mbewe et al., 2006). The method involves 
starting with 1 L culture, to produce 100 mL of supernatant in 50 mM Tris-HCl, 25 mM 
NaCl, 2 mM EDTA, 1 mM PMSF and 1 mM DTT (lysis buffer), which was passed by 
gravity through a DE-52 cellulose anionic exchanger column (2 x 6 cm, treated with 10 
mL lysis buffer) placed in tandem with a Reactive Red 120-agarose dye affinity column 
(2 x 5 cm). A further 50 mL of lysis buffer was passed through, the columns separated, 
the second column washed with 50 mM sodium phosphate, pH 7.0, 200 mM NaCl 
followed by PfHPRT elution with 10 mM sodium phosphate, 50 mM sodium 
pyrophosphate, pH 7.0 (RR elution buffer or PPi buffer).  The first 8 mL were discarded 
and the next 15 mL collected, pooled, dialysed against 10 mM sodium phosphate, 1 mM 
DTT, lyophilized, and re-suspended to approximately 3 mL at around 3 mg of protein 
/mL.  Under the conditions used, PfHPRT came through the anion exchange column, but 
bound to the Reactive Red 120 column. The preparation was inactive as isolated, but 
could be activated by incubation overnight at 0 oC with 0.06 mM hypoxanthine plus 1 
mM PRPP. It is well-known that isolated recombinant PfHPRT is inactive and requires  
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 activation with partial substrates or products to produce activity (Keough et al., 1999; 
Phehane, 2002; Mbewe, 2005; Mbewe et al., 2006; Phehane, 2002; Raman et al., 2005). 
 
An attempt to reproduce this procedure is shown in Figures 3.0 and 3.1.  
 
      1          2        3         4         5          6         7       8                    9    10      11     12      13     14      
15     16       17 
       
PfHPRT
116> 
67> 
35> 
25> 
18.4> 
Figure 3.0: SDS–PAGE (15%) analysis of fractions eluting from a short DE-52 column (2 x 6 
cm) placed in tandem with a Reactive Red 120 column (2 x 5 cm). Lane 1, pellet fraction (re-
suspended to 100 mL); lane 2, supernatant fraction (100 mL); lane 3, Reactive Red flow through 
fraction (150 mL); lane 4, 10 mM sodium phosphate, pH 7.0, 200 mM NaCl wash (40 mL); lanes 
5-16, RR elution buffer (10 mM sodium phosphate, 50 mM sodium pyrophosphate, pH 7.0) (2 mL 
each); lane 17, Reactive Red 1 M NaCl wash (50 mL). Equal volume aliquots (10 μL) were 
applied to each well, and the gel was stained with Coomassie Brilliant Blue. Approximate 
positions of molecular weight standards (in kDa) are shown on the left hand side. 
 
In our case, after elution, the RR elution buffer (PPi) fractions were pooled and dialysed 
overnight against two changes of 10 mM sodium phosphate, pH 7.0, 1 mM DTT and 
afterwards concentrated to about 2 mL in an Amicon stirred cell at 4 °C fitted with a YM-
10 membrane (Millipore). The concentrate was afterward re-dialyzed against 10 mM 
sodium phosphate, pH 7.0, 1 mM DTT. For activation, aliquots were incubated with 
substrates (1 mM PRPP + 0.06 mM hypoxanthine) for 16 h, and subsequently assayed for  
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activity. PfHPRT eluted from the Reactive Red column with 1 M NaCl was treated in the 
same manner. The protein content of both concentrates is shown in Figure 3.1. It can be 
seen from a comparison of lanes 1 and 2 in Figure 3.0 that approximately 40% of the 
recombinant PfHPRT was in the supernatant fraction, which is consistent with what 
Mbewe obtained (Mbewe et al., 2006). Presumably the majority of the expressed enzyme 
is in an insoluble form in inclusion bodies. Lane 3 shows that approximately half of the 
protein in the supernatant came through both columns (a comparison of the band in lanes 
2 and 3 needs to take into account the larger volume of the eluate). The 200 mM NaCl 
wash removed a bit of the target protein but effectively removed a contaminant of ~ 35 
kDa (lane 4).  PfHPRT started eluting in the 4th fraction with PPi (lane 8), and continued 
through to the 12th fraction (lane 16). The column was finally washed with 50 mL 1 M 
NaCl, and the contents are shown in lane 17.  Approximately 40% of the protein came off 
with the high salt, and probably consists of PfHPRT that could have eluted with PPi if the 
elution had been continued and some tightly bound PfHPRT, which may be a different 
form (see later). Because there was a significant amount of PfHPRT in this 1 M NaCl 
fraction, it was processed further along with the PPi fraction 
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PfHPRT
Figure 3.1: SDS-PAGE (15%) analysis of PfHPRT fractions after 
dialysis and concentration. Lane 1, PPi concentrate (2 mL); lane 2, 1 
aCl concentrate (2 mL). Gel stained with Coomassie Blue. 
 
Analysis of the protein content of the concentrates in Figure 3.1 reveals that the RR 
elution buffer concentrate was ~80% pure and the 1 M NaCl concentrate ~40%, the first 
figure is consistent with what Mbewe et al., 2006 obtained. 
 
Both the PPi and NaCl concentrates were capable of being activated with substrates  
(specific activity of 1.7 and 0.6 μmols/min/mg, respectively, activated by overnight 
incubation at 0 oC with 1 mM PRPP + 0.06 mM hypoxanthine, and measured with 
guanine as substrate at pH 7.5 with 10 mM MgCl2 at room temperature; the figure of 1.7 
approximately equates to the maximum activity of 5 μmoles/min/mg at pH 8.5 with 100 
mM MgCl2 at room temperature described by Mbewe et al. (2006) and Keough et al. 
(1999). The lower activity of the salt fraction can be attributed to the protein 
contamination. The fact that PfHPRT contained in the fraction eluted with 1 M NaCl had  
high activity was surprising considering that it is an unstable enzyme (Mbewe, 2005; 
Raman et al., 2005) and is inactive in high salt due to a conversion from the active 
tetramer to an inactive dimer (Keough et al., 1999).  This rather impure salt fraction was  
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 used to investigate whether HPLC gel filtration might be used for further purification, 
and the experiments and results will be described in a later section (Section 3.2). The 
purer PPi fraction was used for crystallization trials, which will also be described later 
(Section 3.3). 
 
In conclusion, although significant purification was achieved by the tandem anion 
exchange and affinity chromatography with the procedure described, it could be better 
both in terms of purification and minimization of losses, and improvements were 
explored. Also, the retention of significant amounts of PfHPRT on the Reactive Red 120 
column after the PPi elution was not what Mbewe reported (about 90% eluted with PPi), 
and needed verification.  
 
We first checked whether the entire flow-through and eluate from the DE-52 column 
needed to be passed through the next Reactive Red 120 column (i.e., if both beginning 
and end contained PfHPRT). Fractions from the DE-52 column were collected 
individually (10 mL each), and analysed for their protein content prior to placing on the 
Reactive Red 120 column, and the results are shown in Figure 3.2. 
 
It is evident that PfHPRT begins to elute in fraction 2 (lane 2), continues through the 
entire flow-through period, and into the wash period, but gradually diminishing in 
amount with more volume. The majority elutes during the flow-through, but a significant 
amount is in the first 40 mL of wash.  
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 This substantiates what was done in the previous experiment; the Mbewe method (100 
mL supernatant plus 50 mL wash) captured most of the target protein for the Reactive 
Red 120 column. However, it is also evident that the protein eluting in the flow-through 
was significantly purer than that coming off with the wash.  In the flow-through fractions 
there is virtually no high molecular weight species, only smaller molecular weight 
proteins, and these latter we now know to be mostly proteolytic digestion products of 
PfHPRT (see later). In contrast, the fractions eluting in the wash contained significant 
amounts of high molecular weight species. 
 
        1     2      3       4     5     6      7     8      9      10               11       12       13       14       15       16       
17                                           
            
PfHPRT
Figure 3.2: Elution profile from a poorly equilibrated, short DE-52 column. Lanes 1-10 
represent the 10 fractions (10 mL each) of the 100 mL flow-through while lanes 11-17 are the 
wash of 70 mL of 50 mM Tris-HCI, pH 8.0, 1 mM PMSF, and 1 mM DTT (10  mL each).  SDS-
PAGE analysis with 15% acrylamide and staining with Coomassie Blue. 
 
The flow-through fractions 2-10 and wash fractions 1-4 were pooled and loaded onto a 
Reactive Red 120 column (2 x 5 cm). The column was developed in the usual way with 
40 mL 10 mM sodium phosphate, pH 7.0/ 200 mM NaCl and then eluted with 50 mL 10 
mM sodium phosphate, 50 mM sodium pyrophosphate, pH 7.0 (collected in 10 mL 
fractions), and finally washed with 50 mL 1 M NaCl (Figure 3.3).  
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                               1              2            3                4               5              6                7                 8 
 
PfHPRT
Figure 3.3: Elution profile from a Reactive Red 120 column. Lane 1, flow through fraction (140 
mL); lane 2, sodium phosphate/NaCl wash (40 mL); lanes 3-7, pyrophosphate eluate (10 mL 
ach); lane 8, 1 M NaCl wash (50 mL). e
 
It is evident that all the PfHPRT was retained by the column (the flow-through, lane 1, 
contained no PfHPRT), and the overwhelming majority of the PfHPRT was eluted with 
sodium pyrophosphate (lanes 3-7), and the high salt wash produced rather little protein 
(lane 8).  It is also evident in this gel that the amount of small molecular weight species 
(running with the front in this poorly resolved electrophoresis run) correlates with the 
proportion of PfHPRT, suggesting that the former are proteolytic digestion products of 
the latter. This was confirmed later by HPLC gel filtration in which the primary protein 
and digestion products co-eluted (evidently the nicked protein still retained nearly native 
secondary, tertiary and quaternary structure). The digestion seen here was peculiar to this 
preparation, and the eluate was not processed further, but it did prompt us to explore the 
use of additional protease inhibitors.    
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The other aspect of the purification that concerned us was the significant elution of 
contaminant proteins during the DE-52 wash period (Figure 3.2), which led us to 
investigate the pH of the individual fractions.  It seemed that the presence of the extra 
proteins could possibly be caused by the pH drifting from 8 down to acid pH values. 
 
To examine this, a new preparation was made, incorporating a protease inhibitor cocktail 
of PMSF, AEBSF, aprotinin, bestatin hydrochloride, E-64, EDTA and leupeptin and the 
expression and purification are shown in Fig 3.4. Again, the supernatant contained less 
PfHPRT than the pellet fraction (not shown). Lane 1 shows the pooled flow-through 
fractions and lanes 2-6 the wash fractions, which corresponds very nicely to the results 
obtained for the previous preparation. Again it is clear that many contaminating proteins 
emerge with the extra 50 mL wash. A 1 M NaCl wash of the DE-52 column is shown for 
nd (lane 7).  the first time, and it is evident that none of the PfHPRT remains bou
                                            1               2           3            4           5            6           7               
   
PfHPRT 
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Figure 3.4: Elution profile from a poorly equilibrated DE-52 column.  Lane 1, DE-52 flow-
through fraction (100 mL); lanes 2-6, wash fractions (10 mL each); lane 7, 1 M NaCl wash (100 
mL).  
 
 
The pH measurements, shown in Figure 3.5, of each fraction coming through the DE-52 
column were very revealing. The first fractions were approximately pH 11, until about 80 
mL of supernatant had passed through the column, at which stage the pH began to drop, 
reaching approximately 6.5 at the time the wash was applied, and slowly returning to 8 
after about 50 mL. In the original procedure of Mbewe, and in all the above purifications,  
the DE-52 column was pre-treated with 10 mL of lysis buffer (50 mM Tris-HCl, pH 8.0, 
2 mM EDTA, 25 mM NaCl, 1 mM DTT, and 1 mM PMSF) which obviously failed to 
equilibrate the column. The other interesting thing is that the pH went down below that of 
the Tris-HCl buffer.  
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Fraction
pH
 
50 mM Tris-
Supernata
nt fraction 
Figure 3.5: pH profile of fractions eluting from the poorly equilibrated, short DE-52 column. 
Supernatant (100 mL) was applied to the column pretreated with 10 mL lysis buffer (50 mM Tris-
HCL, pH 8.0, 25 mM NaCl, 2 mM EDTA, 1 mM DTT, and 1 mM PMSF) followed by 60 mL of 
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wash (50 mM Tris-HCl, pH 8.0, 1 mM DTT, and 1 mM PMSF). Fractions (10 mL each) were 
ollected and the pH of each determined. The protein content is shown in Figure 3.4. c
 
 
 
 
 
The DE-52 flow-through and the first 3 wash fractions were combined and loaded onto a 
Reactive Red 120 column.  As usual, the column was then washed with 10 mM sodium 
phosphate, pH 7.0, 200 mM NaCl, and then developed with the PPi elution buffer, and 
the results are shown in Fig 3.6.  The 200 mM salt wash again removed high molecular 
weight contaminants, and PPi eluted a relatively pure form of PfHPRT. Unfortunately, 
some proteolysis of PfHPRT is evident, perhaps to the extent of more than 50% after 
concentrating (Figure 3.6, gel B), and the enzyme failed to gain activity after activation 
with substrates.  
             
                            1           2              3             4              5              6                         1                    2 
                           
A B 
PfHPRT
PfHPRT 
Figure 3.6: Elution profile from a Reactive Red 120 column. In the experiment shown in Gel 
A, the flow-through and 3 wash elutions from DE-52 chromatography (Figure 3.4) were loaded 
onto a Reactive Red 120 column. The column flow-through is shown in lane 1; the 10 mM sodium 
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phosphate/200 mM NaCl wash (30 mL) is in lane 2; 10 mM sodium phosphate/50 mM sodium 
pyrophosphate, pH 7.0 eluate (10 mL each) is in lanes  3-5 and 1 M NaCl wash (30 mL) is in lane 
6. Gel B shows the 3 pooled PPi fractions (30 mL) after dialysis (lane 1) and concentration (8 mL) 
(lane 2). 
 
 
 
 
In the next preparation, we used a properly equilibrated DE-52 column and a stronger 
buffer in an attempt to achieve better separation and also to ascertain whether the pH 
variation seen before could be controlled and subsequently the effect on PfHPRT activity. 
The column was well equilibrated with 10x strength 75 mM Tris-HCl, pH 8.9 (i.e. 750 
mM), and finally with 1x buffer, as directed by the manufacturer. Prior to loading the 
supernatant onto the column, its pH was also adjusted to 8.9. The flow-through followed 
by 50 mL of 50 mM Tris-HCl, pH 8.0, 1 mM DTT, and 1 mM PMSF, were all collected 
in 10 mL fractions and the pH measured. After that, the column was washed with 80 mL 
1 M NaCl to bring off all other bound contaminants. Figure 3.7 shows the results 
obtained.  
 
Protein expression levels for this preparation were relatively low compared with previous 
preparations. Like in the preceding preparations, most of the target protein was in the 
insoluble inclusion bodies (lane 2). The first two fractions of the flow-through (lanes 4 
and 5) contained no PfHPRT consistent with earlier results. PfHPRT starts eluting in the 
third fraction (lane 6) and continues till all the supernatant has passed through although 
the last two fractions contain very little protein (results not shown). At the start of Tris-
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HCl wash (lane 12), a significant amount of the high molecular weight contaminants start 
coming off with more PfHPRT. Again this is consistent with earlier results.  
 
 
 
 
               1        2        3        4      5        6       7        8        9     10                   11        12      13     
14      15 
Mw marker 
                   
116.0 k 
66.2 k 
45.0 k 
35.0 k 
25.0 k 
PfHPRT
18.4 k 
Figure 3.7: Elution profile from a short DE-52 column well equilibrated with 75 mM Tris-
HCl, pH 8.9. Lane 1, molecular weight marker; lane 2, pellet fraction (re-suspended to 100 mL); 
lane 3, supernatant fraction (100 mL); lanes 4-11, DE-52 flow-through fractions (10 mL each); 
anes 12-15, wash fractions (10 mL each of 50 mM Tris-HCl, pH 8.0, 1 mM PMSF, 1 mM DTT).  l
 
The 1 M NaCl wash brought off other bound contaminants without much PfHPRT as is 
shown in Figure 3.8 (lane 1). Despite doubling the concentration of the protease inhibitor 
cocktail, PfHPRT proteolysis was evident as some low molecular weight species in this 
preparation. 
 
The flow-through fractions containing PfHPRT were pooled, an aliquot taken and 
concentrated and the rest loaded onto a Reactive Red 120 column. The column was then 
washed in the usual manner with 10 mM sodium phosphate, pH 7.0, 200 mM NaCl and 
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developed with the PPi elution buffer. The results are shown in Fig 3.8 A. The 
concentrate of the pooled DE-52 flow-through fractions (lane 2) shows that a lot of 
impurities come off in these fractions and thus the need for further purification. Most 
high molecular weight contaminants flow straight through the Reactive Red 120 column 
(lane 3) and in the 10 mM sodium phosphate, pH 7.0/200 mM NaCl wash (lane 4). The  
 
 
PPi eluate (lanes 5-9) is significantly purer with the major impurity apparently being low 
molecular weight proteolytic products. Satisfyingly, very little target protein was brought 
off by the 1 M NaCl wash, probably due to well-controlled pH (see below). The PPi 
fractions were then pooled, dialysed overnight in 10 mM sodium phosphate, pH 7.0, 1 
mM DTT, concentrated (shown in Figure 3.8 C) and activated with PRPP and 
hypoxanthine as previously described. Unfortunately, on assay, the specific activity was 
very low (0.2 μmole/min/mg). This is most likely due to PfHPRT proteolysis.  
 
The Tris-HCl eluted fractions were also pooled, taken through a Reactive Red 120 
column and eluted in the usual manner. The results, though less visible due to the low 
protein content, are shown in Figure 3.8B and are similar to the flow-through results 
shown on the left hand side.                                                                                                                                       
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     1         2       3      4       5        6        7        8        9    10            1        2      3       4         5      6         
7         8 
          
PfHPRT
Figure 3.8:  Elution profile from a Reactive Red 120 column. In Gel A, lane 1 shows the 
bound contaminants coming off the DE-52 column with the 1 M NaCl wash (continued from Fig 
3.7); lane 2 shows the concentrated DE-52 fraction (0.2 mL); lane 3 shows Reactive Red 120 
column flow-through (70 mL); The 10 mM sodium phosphate, 200 mM NaCl wash is shown in 
lane 4 (40 mL); 10 mL aliquots of 10 mM sodium phosphate, 50 mM sodium pyrophosphate, pH 
7.0 are in lanes  5-9 while the final 1 M NaCl wash in shown in lane 10 (40 mL). Gel B shows the 
elution profile of the pooled DE-52 Tris-HCl wash fractions from a Reactive Red 120 column. The 
flow-through fraction (50 mL) in lane 1 is followed in lane 2 by the 10 mM sodium phosphate, 200 
mM NaCl wash (40 mL). Lanes 3-7 show the PPi eluate (10 mL each) while lane 8 shows the 1 M 
aCl wash (40 mL). Gel C shows a concentrate of pooled PPi fractions (continued from gel A).  N
 
 
The pH measurements for the eluted DE-52 fractions, shown in Figure 3.9, indicate that 
the pH was reasonably well controlled, and the pH of the pooled flow-through fractions 
was 8.9. 
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Figure 3.9: pH of fractions eluting from a short DE-52 column, well equilibrated at pH 8.9. 
 
In conclusion, the results in terms of elution characteristics and purification were very 
similar for both the poorly and well-equilibrated short DE-52 columns, even the elution 
profiles of the Reactive Red 120 column were the same, except that the well-equilibrated 
column failed to yield active enzyme, which may be due to proteolysis.  It, therefore, 
seems that exposure to pH 11 is not harmful to PfHPRT. 
 
We then decided to employ a longer DE-52 cellulose column (2.0 x 17.5 cm) in an 
attempt to effect better separation by increasing the number of theoretical plates.  
 
In the first attempt the column was equilibrated with 30 mL of the lysis buffer before 
loading the supernatant, knowing that this would not control the pH, but influenced by 
the fact that the purity of the DE-52 eluate of the poorly equilibrated column (Figure 3.2) 
was somehow better than that of the well-equilibrated one (Figure 3.7), and the 
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knowledge that the former produced active PfHPRT. The results are shown in Figure 
3.10.  
 
Passage of the supernatant through the DE-52 column resulted in all the proteins being 
retained (lane 1). The column was developed with an extra 100 mL of 50 mM Tris-HCI, 
pH 8.0, 1 mM DTT, and 1 mM PMSF collected in 10 mL fractions. The first 4 fractions 
did not contain any protein (not shown), but the next 3 did (lanes 5-7) and with reduced 
amounts in the following fractions (not shown), and the 1 M salt wash showed that rather 
little was retained (lane 8). In terms of purification and yield the results were quite 
remarkable – in lanes 5 and 6 there is a very strong band associated with PfHPRT and 
little else. Pooling the fractions from which the lanes 5, 6, and 7 were derived produced 
30 mL of 0.2 mg protein/mL, i.e. 6 mg total. 
 
The sample was dialysed overnight against two changes of 10 mM MOPS, 1 mM DTT, 
pH 7.0, and tested for activity after overnight activation with substrates. Unfortunately, 
the enzyme was inactive. This was perhaps not surprising as the pH of the sample prior to 
dialysis was approximately 13! It still, however, remains a puzzle that PfHPRT behaved 
so differently from all the other proteins. 
 
 
Out of interest, the protein was further processed through a Reactive Red 120 column, 
and the results are shown in Figure 3.11. Before loading the protein, the column was 
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equilibrated with 10 mM MOPS, pH 7.0, 1 mM DTT, whereas before it was simply 
washed with water.  
 
                            1              2                3               4               5              6              7               8 
 
Figure 3.10: Elution profile from a poorly equilibrated, long DE-52 column (2.0 x 17.5 cm). 
Lane 1, flow-through fraction (100 mL); lane 2, crude lysate (100 mL); lane 3, pellet fraction (re-
suspended to 100 mL); lane 4, supernatant fraction (100 mL); lanes 5-7, 50 mM Tris-HCl, pH 8.0 
fractions (10 mL each); lane 8, 1 M NaCl wash (100 mL).  
 
                              1                  2                 3                 4                 5                6                   7 
 
 
 
PfHPR
PfHPR
Figure 3.11: Elution profile from a Reactive Red 120 column. Lane 1, flow- through fraction (30 
mL); lane 2, 10 mM MOPS, pH 7.0, 1 mM DTT wash (10 mL); lanes 3-5, PPi eluate (10 mL each); 
lanes 6-7, 1 M NaCl wash (10 mL each).   
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All protein bound to the affinity column as is evident from the lack of protein bands in 
lane 1. The prominent high molecular weight impurity and also some PfHPRT came off 
with 10 mM MOPS, pH 7.0, 1 mM DTT (lane 2). Very little protein eluted with the PPi 
eluate, (lanes 3-5), and the majority appeared in the 1 M NaCl wash (lanes 6-7). It is clear 
that most of the protein is behaving very differently from before, binding extremely 
tightly to Reactive Red 120, which is consistent with it being in a different conformation 
or state and incapable of being activated with substrates. 
 
Finally, a long DE-52 column (2 x 17.5 cm) well-equilibrated with the lysis buffer was 
run and the results analysed (Figure 3.12). Although the pellet fraction still had a 
considerable amount (lane 1) of the target protein, this preparation contained more 
soluble PfHPRT (lane 2) in comparison with previous ones. Starting in the third fraction, 
PfHPRT came off the column almost entirely in the flow-through (lanes 5-12) and only 
required a 30 mL rinse with 50 mM Tris-HCl, pH 8.0, 1 mM DTT, and 1 mM PMSF to 
bring off most of the remainder (lanes 13-15). A further 20 mL wash (lanes 16-17) 
brought off a negligible amount of PfHPRT. 
 
If the small molecular weight species are ignored (probably proteolytic digestion product 
of PfHPRT), the purification achieved with this long DE-52 column seems rather similar 
to that of the short column (compare with Figure 3.7), although the wash fractions seem 
worse with the shorter column and the latter contain more PfHPRT. 
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    1       2       3       4       5       6     7       8        9     10         11         12          13           14        15          
16           17 
    
PfHPRT
Figure 3.12: Elution profile from a well equilibrated, long DE-52 column (2 x 17.5 cm). Lane 
1, pellet fraction (re-suspended to 100 mL); lane 2, supernatant fraction (100 mL); lanes 3-12, 
flow-through fractions (10 mL each); lanes 13-17, wash fractions (10 mL each). Equal volume 
aliquots (10 μL) were applied to each well. Approximate position of PfHPRT is shown. 
 
The flow-through fractions together with the first three wash fractions were pooled and 
further purified on a Reactive Red 120 column as described earlier. Although this step 
eliminated some contaminating proteins, two high molecular weight bands plus the 
proteolysis band were visible on SDS-PAGE after concentrating the PPi fractions (lane 
10). This preparation exhibited a very low specific activity (0.7 μmole/min/mg protein).  
                                          1        2         3         4         5         6         7          8         9                10 
                                 
PfHPRT
Figure 3.13: Elution profile from a Reactive Red 120 column followed by concentration. 
Lane 1, pooled fractions from DE-52 (110 mL); lane 2, flow-through fraction (110 mL); lane 3, 10 
mM sodium phosphate, 200 mM NaCl wash (40 mL); lanes 4-8, 10 mM sodium phosphate, 50 
mM sodium pyrophosphate, pH 7.0 eluate (10 mL each); lane 9, 1 M NaCl (40 mL); lane 10, 
concentrated PPi fractions (2 mL).  
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3.1 HPLC gel filtration: PfHPRT oligomeric state analysis and further purification  
The oligomeric state of PfHPRT during and after purification, and also on activation with 
substrates was analysed by analytical gel filtration on a Tosohaas TSKgel G 3000 SW 
column (7.5 mm x 30 cm, 10 μm). A major motivation for performing these experiments 
was to determine whether the “pure” PfHPRT was a single species or not. For 
crystallization, it is desirable that the protein exists as a single oligomeric species in 
solution.  
 
The column characteristics were determined by running standards at different salt 
concentrations as shown in Figure 3.14. The exclusion and inclusion marker compounds 
were Dextran Blue (2 000 000 Daltons) and tyrosine (185 Daltons), respectively. The 
resolution of the column was better with increasing concentration of salt. At 0 mM NaCl, 
three proteins co-eluted and cytochrome c remained bound to the column. 
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Figure 3.14: Calibration of the Tosohaas TSKgel G SW 3000 HPLC column (7.5 mm x 30 cm, 10 μm). A mixture of 
standards containing Dextran Blue (MW 2 000 000 Daltons), Alcohol dehydrogenase (150 000 Daltons), Albumin (67 
000 Daltons), ovalbumin (44 000 Daltons), carbonic anhydrase ( 29 000 Daltons), cytochrome c (11 700 Daltons) and 
tyrosine (185 Daltons) was injected (20 μL) at time zero, and the mobile buffer was 10 mM MOPS/TMAH, pH 7.0, 0.05% 
NaN3 with 0 (top panel), 100 (middle panel), or 400 mM NaCl (bottom panel). The flow rate was 1 mL/min. 
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Figure 3.15: Calibration curves for protein standards at 100 mM NaCl (top) and 400 mM 
NaCl (bottom). The chromatography of the standards is shown in Figure 3.14. The equation 
used in the plot is provided in Chapter Two: Materials and Methods. Mw refers to the molecular 
eight and Km the Partition Coefficient.   w
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The quaternary structure of PfHPRT is known to be dependent on salt concentration, and 
has been identified as tetrameric at 10 mM phosphate, pH 6.9, in the presence of 60 μM 
hypoxanthine, 0.2 mM PRPP, and 5 mM DTT (active preparation), and dimeric if 1.2 M 
KCl is included (inactive) by sedimentation equilibrium (Keough et al., 1999). We tested 
the quaternary structure of PfHPRT by gel filtration HPLC using the first preparation 
described above following elution from Reactive Red 120 column with 1 M NaCl, 
dialysis, and concentration, to have a final preparation of Figure 3.1. The preparation was 
inactive, but capable of being activated with substrates to approximately 3 μmole/min/mg 
of protein. The results at several concentrations of NaCl are shown in Figure 3.16.  It is 
simplest to start with the profile obtained at 100 mM NaCl.  Here major peaks are found 
at approximately 8 (labeled A), 9 (labeled B), 11 (labeled X), and 13 min.  Peaks A and B 
were identified as PfHPRT by collecting the peaks and analyzing by SDS-PAGE, and 
those at 11 and 13 min were not identified, but did not appear to be protein.  Peaks A and 
B correspond to molecular weights of 63 000 and 40 000 Daltons, respectively, according 
to the calibration curve at 100 mM NaCl (Figure 3.15), and 57 000 and 36 000 Daltons at 
400 mM NaCl, and have tentatively been assigned as tetramer (should be 104 000 
Daltons) and dimer (52 000 Daltons), respectively. As can be seen in the other frames, 
the proportion of tetramer increases at low salt and decreases at high salt. Quantification 
of the PfHPRT peaks is shown in Figure 3.17. It is evident that the proportion of tetramer 
at low salt is approximately 70%, and this could have profound implications for obtaining 
crystals. 
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Figure 3.16: Effect of NaCl concentration on PfHPRT quaternary structure. Aliquots of protein (50 μL; the preparation 
had been dialysed against 10 mM sodium phosphate for ~24 h, and concentrated to ~1 mg/mL; it could be activated by 
substrates to yield an activity of ~3 μmol/min/mg of protein) were injected onto HPLC Tosohaas TSKgel G 3000 SW 
column (7.5 mm x 30 cm, 10 μm) at time zero with running buffer of 10 mM MOPS/TMAH, pH 7.0, 0.05% NaN3, and the 
concentrations of NaCI shown. A and B identify two putative quaternary forms of PfHPRT, and X denotes an unidentified 
peak that shifts position with salt concentration. 
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Figure 3.17: Effect of NaCI concentration on the proportion of A and B quaternary forms of 
PfHPRT. Details of conditions and HPLC elution profiles are shown in Figure 3.16. Quantification of 
peaks A and B was by gravimetric analysis of peak cut-outs. Profiles at 0 and 10 mM NaCI were not 
 
We investigated whether HPLC gel filtration could be used to further purify PfHPRT.  
For this purpose the preparation that was capable of being activated and obtained from 
the 1 M NaCl elution from Reactive Red 120 column detailed in Figures 3.0 and 3.1 was 
used. The gel filtration was carried out at 10 mM MOPS, pH 7.0, 20 mM NaCl without 
NaN3 in order to maximize the proportion of tetramer and a representative elution profile 
is shown in Figure 3.18. Peaks 1, 2, and 3 were collected from 4 injections of 200 μL 
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each, concentrated, and re-analyzed by HPLC gel filtration (Figure 3.19) and by SDS-
PAGE (Figure 3.20). 
 
                 
1 2 3
 
 
 
 
Figure 3.18: Preparative isolation of peaks 1, 2, and 3 by HPLC gel filtration. The HPLC trace shows an 
example of preparative scale purification by HPLC gel filtration on a Tosohaas TSKgel G3000 SW column (7.5 
mm x 30cm, 10 μm) with 10 mM MOPS/TMAH, pH 7.0, and 20 mM NaCl (flow rate 1 mL/min), where 200 μl of 
PfHPRT, purified by ion exchange and Reactive Red 120 chromatography, dialyzed and concentrated to ~0.3 
mg/ml, was injected and peaks 1, 2 and 3 collected.  Similar HPLC chromatography was performed 4 times and 
 
The gel filtration in 20 mM NaCl revealed that peak 1 was almost entirely tetrameric 
PfHPRT with one or two very minor peaks of smaller molecular weight species (the peak 
at ~13 min is not protein), and SDS-PAGE confirmed that the major species was PfHPRT 
plus a protein of approximately 30 000 Daltons (lanes 3 and 4). The contaminant species 
is likely a trimer or tetramer, to account for its elution with tetrameric PfHPRT during gel 
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filtration. Peak 2 contained tetrameric and dimeric PfHPRT in roughly equal amounts by 
gel filtration as expected, and the presence of PfHPRT was verified in the gel (lanes 5  
 
 
and 6; there are also faint higher molecular weight bands because of the high 
concentrating effect). Peak 3 showed the presence of the species eluting at 10 min as 
expected, but what was difficult to understand was that the gel (lanes 7 and 8) showed the 
presence of a small amount of PfHPRT and little else.  We tentatively explain this by the 
peak eluting at 10 min not to be protein, and a small amount of contamination by 
PfHPRT, although where it came from is not clear. Another possibility is that it is 
monomeric PfHPRT. 
 Peak 1  Peak 2 Peak 3 
 
 
 
 
Figure 3.19: Rechromatography of Peaks 1, 2, 3 by HPLC gel filtration. Aliquots (50 μl, peak 1 with 
volume of 1.4 ml from approximately 10 mL, ~7x concentration; 30 μl for peaks 2 and 3 with volumes of 0.2 ml 
from 6 mL each, ~30x concentration) from the above experiment were analysed as in Figure 5.0 after 
concentrating. The peak eluting at 10-12 min (included volume) is a small molecular species that was not 
 114
 
 
 
 
                                        1            2          3            4             5            6               7                8 
 
Figure 3.20: Analysis of PfHPRT purification using HPLC gel filtration. Lane 1, I M NaCl fraction from the Reactive 
Red 120 column; Lane 2, 1 M NaCl eluate of Reactive Red 120 filtered through a 0.22 μm filter; lanes 3-8 represent peaks 
collected from HPLC and concentrated as indicated in Figures 3.19 and 3.20. Two lanes were loaded for each peak to 
avoid cross-lane contamination and are as follows: Lanes 3-4, peak 1; Lanes 5-6, peak 2; Lanes 7- 8, peak 3. 
 
It was of interest to determine whether Peak 1, the tetrameric species purified by HPLC 
gel filtration was active and exhibited the same salt-dependent tetramer-dimer 
equilibrium. The protein was activated with substrates and found to have an activity of 
0.7 μmole/min/mg of protein, i.e. partially active. The salt-dependence of the quaternary 
equilibrium is shown in Figures 3.21 and 3.22, and can be seen to be similar to that in 
Figure 3.16, except that there is no dimer at low salt concentrations. 
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Figure 3.21: Effect of NaCl concentration on quaternary structure of HPLC gel filtration-purified HPRT. 
Aliquots of HPRT protein (50 μl, ~0.3 mg/ml; purified by HPLC gel filtration in 10 mM MOPS/TMAH, pH 7.0, 20 mM 
NaCl, dialysed against 10 mM MOPS, pH 7.0 overnight, and concentrated ~5x) were injected onto HPLC Tosohaas 
TSKgel G 3000 SW column (7.5 mm x 30 cm, 10  μm) at time zero with running buffer of 10 mM MOPS/TMAH, pH 
7.0, without (at 20 mM NaCl) or with (at other NaCl conentrations) 0.05% NaN3, and the concentrations of NaCl 
shown. A and B identify two putative quaternary forms of malarial HPRT. 
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Figure 3.22: Effect of NaCl concentration on the proportion of quaternary forms of PfHPRT. 
The peaks shown in Figure 3.21 were quantified by gravimetric analysis of cut-outs. 
 
Overall, gel filtration seems a very effective means of providing substantial final 
purification. 
 
3.2 Comparative Modeling 
In contrast to the human HPRT and HPRT’s from other common disease-causing 
parasitic protozoa for which several crystal structures have been elucidated, the only 
available atomic structure for the malarial HPRT is that in complex with a transition-state 
analog inhibitor (PDB code 1CJB (Shi et al., 1999)). The crystal structures reveal 
substantial differences between the holoenzyme, the substrate complexes, and product  
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complexes, as well as the transition-state structures. Thus, in addition to the 
crystallization experiments carried out, the structure of the free malarial HPRT was 
modeled using several solved structures of the phosphoribosyltransferase family of 
proteins as templates. 
 
3.2.1 The open PfHPRT model structure 
The model of the open PfHPRT was fashioned on the 1.90 Å structure of free human 
HPRT (PDB code 1Z7G (Keough et al., 2005)), the 1.90 Å structure of Tritichomonas 
foetus HPRT (PDB code 1HGX (Somoza et al., 1996)) and the 2.30 Å structure of 
Salmonella typhimurium HPRT (PDB code 1J7J (Lee et al., 2001)). Sequence identity 
between the malarial enzyme and the human, Tritrichomonas foetus and Salmonella 
typhimurium enzymes is 49%, 31% and 38%, respectively, indicating that the three 
solved structures could be useful templates. The first step in the modeling procedure was 
the generation of a multiple sequence –structure alignment using the advanced option of 
the 3DCoffee server (Poirot et al., 2004). The alignment obtained was then manually 
refined to ensure no gaps in the core regions and that the aligned template sequences 
matched the corresponding PDB entries. Missing residues in the PDB templates were 
omitted from the alignment. A comparison of this alignment to the one obtained using the 
MALIGN3D routine of the MODELLER program (Sali and Blundell, 1993; Fiser et al., 
2000) confirmed it to be better and was, therefore, used for subsequent modeling. For 
modeling, an iterative approach comprising sequence-structure alignment and model 
building was followed. Models containing non-hydrogen atoms were then generated from  
 
 118
 
 
 
 
the best alignment using MODELLER which implements comparative modeling by 
satisfying spatial restraints extracted from the target-template(s) alignment. Out of the 50 
models generated, only the one with fewest restraints violation and lowest energy was 
evaluated further.  
 
Side chains for this model were optimized using SCWRL (Canutescu et al., 2003). To 
evaluate the model quality, stereochemical analysis using PROCHECK (Laskowski et al., 
1993) and MOLPROBITY (Davis et al., 2004) was carried out. Three-dimensional 
images of PfHPRT model structure were generated using PyMOL (DeLano, 2002). The 
sequence-structure alignment is shown in Figure 3.23.  
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Figure 3.23: A structural-sequence alignment profile obtained using 3D-Coffee (http://igs-
server.cnrs-mrs.fr/Tcoffee). Seven structures were aligned with the human HGPRT sequence. The 
relative reliability of the various regions is indicated by codes (blue, unreliable; green, low reliability; 
yellow, moderately reliable; orange, reliable; red, highly reliable portion of the alignment). Conserved 
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Three-dimensional models of PfHPRT dimer and monomer were generated with 
MODELLER (Sali and Blundell, 1993). The overall fold of the models is similar to that 
of previously determined phoshophoribosyltransferase structures (reviewed in Sinha and 
Smith, 2001) which consists of the core and hood domains as shown in Figure 3.24.  
 
Cor
Hoo
 
Catalytic 
 
 
 
Figure 3.24: Cartoon representation of PfHPRT dimer and monomer. Top panel shows dimer with β-
strands and α-helices coloured magenta and orange respectively. The tetramer can be generated by applying 
crystallographic symmetry to the dimer. The monomer with the catalytic loop in the open conformation is 
shown in the bottom panel with β-strands and α-helices coded blue and orange, respectively. Loops are 
l d i b th di Th i d d i P MOL 0 99 (D L 2002)
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3.2.2 Subunit structure 
Figure 3.24 (bottom panel) shows the three dimensional arrangement for the PfHPRT 
monomer. The secondary structure of the model organization consists of eight β-strands 
and seven α-helices linked together by loops and coils. The β-strands are formed by 
residues β1 (Leu40-Val45), β2 (Phe70-Leu75), β3 (Leu105-Lys113), β4 (His139-Ile146), 
β5 (Thr167-Lys176), β6 (Phe188-Ile193), β7 (Val198-Val199) and β8 (Cys215-Val218) 
while the α-helices are formed by residues α1 (Asp27-Ser29), α2 (Ala34-Tyr36), α3 
(Val47-Tyr65), α4 (Arg81-Asn95), α5 (Leu132-Leu135), α6 (Lys151-Lys162) and α7 
(Asp220-Tyr226). The sequence of secondary structure elements is represented in a 
simplified form using TOPS (Westhead et al., 1998) in Figure 3.25. The β-strands are 
organized into β-sheets with the major parallel sheet, made up of four strands (β5, β4, β2 
and β3), forming part of the core region of the subunit. β4 and β5 of this sheet extends 
into a small parallel sheet almost perpendicular to the core sheet. The core β-sheet is 
braced by α-helices (α3, α4 one side and α5 on the other side). The smaller anti-parallel 
sheet (β1, β8) is found in the variable hood region. The arrangement seen in the model 
differed slightly from that predicted by PSIPRED (Jones, 1999a) using sequence 
information only. The secondary structure architecture predicted by PSIPRED consists of 
ten β-strands and seven α-helices and is schematically shown in Figure 3.26. 
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Figure 3.25: TOPS (Westhead et al., 1998) cartoon representation of the secondary structural 
elements of PfHPRT. The green triangles represent β-strands and orange circles helices. The N- and C-
 123
 
 
 
 
 
 
 
 
 
Figure 3.26: PfHPRT secondary structure prediction based on the amino acid sequence 
performed with PSIPRED (Jones, 1999). The top panel shows the probable secondary structure 
location along the sequence while the bottom panel represents the various symbolic keys used.  
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 Pair-wise alignment of PfHPRT model structure with the solved crystal structure in 
complex with a transition state analog inhibitor (1CJB; Shi et al., 1999) using ALIGN 
(Cohen, 1997) revealed that the secondary structural elements were fairly similar, but 
there was significant structural variability in the loop regions, particularly in the large 
flexible loop region as shown in Figure 3.27. This loop closes over the active site, thus, 
protecting the reactive transition-state from bulk solvent during catalysis in 
phosphoribosyltransferases (Focia et al., 1998; Heroux et al., 1998a; Shi et al., 1999b). It 
acts catalytically (holds a key tyrosine) as well. In closing over the active site, the loop 
becomes ordered and forms an antiparallel β-sheet. Overall, however, structures of free 
PfHPRT and 1CJB are rather similar as they superpose with a root-mean-square deviation 
(RMSD) of 1.29 Å for 189 Cα atoms The mobility of the catalytic loop in the unliganded 
enzyme could be one contributing factor as to why crystallization of free PfHPRT has 
been elusive thus far.  
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Catalytic 
loop 
movement
Figure 3.27: Superposition of the free PfHPRT (orange) with the solved crystal structure (PDB 
code 1CJB; green (Shi et al., 1999)). The movement of the flexible loop which sequesters the active 
site from the bulk solvent is shown. The structures were superposed using ALIGN (Cohen et al., 1997) 
 
3.2.3 Active site characterization  
Identification and characterization of surface pockets and internal cavities in the 
monomer structure was performed by the CASTp server (http://cast.engr.uic.edu). The 
program permits identification and calculation of Connolly's molecular surface and  
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 volume (Connolly, 1983) for all pockets and cavities in a protein structure. The 
cavities/pockets are then graded according to their sizes with the largest in most cases 
being the active site. It was found, using a probe radius of 1.4 Å, that PfHPRT monomer 
has a total of 38 pockets and cavities. A representation of the largest cavity/pocket, 
rendered in JMol is shown in Figure 3.28. This cavity has an area of 1137.8 Å2 and a 
volume of 2913.8 Å3 and is lined by 44 residues, mostly conserved residues involved in 
substrate binding. The large volume of this major cavity/pocket suggests that the enzyme 
can accommodate sizeable ligands. Possibly, therefore, both 2’,3’-O-(2,4,6-
trinitrophenyl)-guanosine monophosphate (TNP-GMP) and 4-iodo chalcone both of 
which have been shown to inhibit PfHPRT in this laboratory (Mbewe, 2005; Mbewe et 
al., 2007) bind to this site. 
 
Several conserved residues involved in ligand binding adopt different conformations in 
the free and liganded PfHPRT. As shown in Figure 3.29, Leu76-Lys77 in catalytic loop I 
and Ser114-Tyr115 in loop II swivel by about 180 ° to be in the proper orientation for 
substrate binding. The effect of this translocation in the case of Leu76-Lys77 is the 
formation of the cis-peptide bond which is essential for the enzymes interaction with the 
pyrophosphate moiety. A similar rotation by Lys176, postulated to play a role in substrate 
recognition (Shi et al., 1999b), aids in orienting the terminal amino group towards the 
purine ring exocyclic oxygen (Figure 3.30, top panel). Phe197 which forms a 
hydrophobic interaction with the purine ring adopts a similar conformation in both the 
free and the liganded structures (Figure 3.30, bottom panel). 
 
 127
 
 
 
 
  
Figure 3.28: Wireframe representation of PfHPRT monomer showing the major pocket/cavity 
identified using a probe radius of 1.4 Å. The green spheres show the residues lining the cavity. 
he image was generated using CASTp (Liang et al., 1998) and rendered in JMol.  T
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Tyr11
Lys77
Ser11
Ser11
Tyr11
Figure 3.29: Orientations of the various conserved residues in the free (modeled) and 
ligand bound (1CJB) PfHPRT monomers. The free enzyme structure is coloured magenta 
while the liganded structure is colored orange. Top panel shows the orientations of the conserved 
cis dipeptide (Leu76-Lys77) represented as sticks and coloured blue for the liganded structure 
and red for the free structure. Bottom panel shows the orientation of Ser114-Tyr115 (sticks) in the 
wo structures.  t
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Lys17
 
 
Phe19
Figure 3.30: Positioning of Lys176 and Phe197. Top panel shows Lys176 in the free (magenta) 
and liganded PfHPRT (orange) structures. The residue, shown in stick representation is coloured 
blue and red in the free and ligand bound structures respectively. Bottom panel shows the 
orientation of Phe197 in both structures. Color coding is as for the top panel.   
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Superposition of the coordinates of the model with those of chain A of the human 
enzyme (1Z7G; Keough et al., 2005) using ALIGN (Cohen et al., 1997) showed that the 
two enzymes are significantly similar. The two superposed with a RMSD of only 0.67833 
Å with major differences confined to the loop regions. Again the major difference was in 
the flexible loop region which was not built in the solved human structure because of 
unseen electron density due to disorder of the region.  
 
 
Flexible 
loop
Figure 3.31: A structural superimposition of PfHPRT model (blue) and human HPRT 
(orange; PDB code 1Z7G; Keough et al., 2005). The random mean of standard deviation 
(RMSD) between the two is 0.67833 Å. Structurally variable regions occur in the loops especially 
the flexible loop and the C-terminal end. Superposing was performed using ALIGN while the ray 
traced image was generated with PyMol v0.99 (DeLano, 2002).  
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In addition to the assessment of model quality performed by means of graphical display 
and Cα RMSD calculations, evaluation of the stereochemical parameters was also carried 
out and is shown in Figures 3.32 and 3.33. 
 
The distribution of the phi and psi angles of apo-PfHPRT is excellent with most residues 
within the ‘allowed’ regions and only one residue (Tyr201) in the ‘disallowed’ region. 
This residue is localized in a loop where the modeling process is knowingly more 
difficult. The only outlier according to MolProbity was Lys77 which forms part of the 
unusual cis peptide bond in PfHPRT. 
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 Figure 3.32: Ramachandran plot for the PfHPRT model. The percentage of residues in the 
favoured, additionally allowed, generously allowed and disallowed regions was 88.8% (182), 
9.7% (20), 1.0% (2) and 0.5% (1) respectively. The number of residues in each category is in 
brackets. The plot was generated using PROCHECK.  
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 Figure 3.33: MolProbity Ramachandran plot of PfHPRT model. 
. 
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 3.3 Preliminary crystallization trials 
The ultimate objective of this work was to obtain the crystal structure of PfHPRT in 
complex with a chalcone, which has been shown to act as accelerator of activity (in 
presence of Mg2+ and substrates), an activator of the inactive to active transition (divalent 
cations and substrates not necessary), and a potent inhibitor of activity (when Ca2+ 
replaces Mg2+) (Phehane, 2002; Mbewe, 2005).    
 
Numerous co-crystallization trials of PfHPRT were conducted, mostly in complex with 
IMP, GMP or chalcone. For the trials with IMP or GMP, an excess of the other product, 
Mg2+-pyrophosphate, was usually included in the crystallization drops while for the 
chalcone trials, Mg2+-pyrophosphate was usually substituted for calcium. PfHPRT 
concentration was kept at 15-20 mg/mL (as determined by the method of Bradford). The 
protein was routinely filtered through a 0.22 μm filter prior to setting up trials.  
 
Initial screening for probable conditions was performed using Hampton screens 1 and 2 
(Hampton Research) which comprises a total of 100 individual conditions. These screens 
are based on the sparse matrix approach (Jancarik and Kim, 1991) in which a wide range 
of conditions in the crystallization space are sampled. Hanging drop vapour diffusion 
method (McPherson, 1982), using 24-well VDX plates (Hampton Research), was 
employed. The 2 μL (1 μL protein plus ligand and 1 μL precipitant) hanging drops, 
mounted on 22 mm round siliconized cover slips, were inverted over 1 mL reservoir  
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 solutions in the plates. Parallel screens at both 18 ºC and 4 ºC were set-up in an air-
conditioned room free from vibrations and noise. The drops were observed immediately  
after set up and afterward daily for two weeks. Thereafter, observations were made once 
weekly for up to three months. Most drops, at both temperatures, were clear on set-up. 
After one day, however, majority of drops at 18 ºC had precipitated, while most at 4 oC 
remained clear.  
 
Crystalline precipitate and phase separation, shown in Figure 3.34, generally point at 
potential crystallization conditions. Both occur in the supersaturation region of the phase 
diagram through different obscure mechanisms (Asherie, 2004). Phase separation is 
probably caused by the partitioning of precipitating agents present in the mother liquor as 
a result of immiscibility (McPherson, 1999) while precipitation is mainly a result of 
excessively fast nucleation due to very high supersaturation of either the protein or the 
precipitating agent. In phase separation, the protein sometimes concentrates and forms 
crystals in one phase (Kuznestov et al., 2001). 
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 A B
        
Figure 3.34: Initial crystallization results obtained using Hampton screens 1 and 2 
conditions after 5 days of set-up at 18 °C. Panel A shows a crystalline precipitate of PfHPRT-
IMP obtained using 30% PEG 4000, 0.1 M Tris-HCI, pH 8.5, 0.2 M MgCI2. Panel B shows phase 
separation of PfHPRT-GMP obtained with 30% PEG 4000, 0.2 M (NH4)2SO4.   
 
Results obtained for some drops during the screening trials, as shown Figure 3.34 above, 
were encouraging. Crystalline precipitate and phase separation (hundreds of small round 
droplets) give an indication that the protein may crystallize with careful fine tuning of the 
conditions. This was explored as elaborated in section 3.3.1.  
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 3.3.1 Refinement of initial conditions 
The two conditions in Figure 3.34 were refined further using a fine systematic grid screen 
around some conditions as shown in Figures 3.35 and 3.36. No positive results were, 
however, obtained.  
     PEG 
4000 
pH 
 
20% 
 
22% 
 
24% 
 
26% 
 
28% 
 
30% 
7.0       
7.5       
8.0       
8.5       
 
Figure 3.35: A grid of pH vs. PEG concentration optimization of crystallization for PfHPRT-
IMP. 
 
  
           PEG 
4000 
 
(NH4)2SO4
 
20% 
 
22% 
 
24% 
 
26% 
 
28% 
 
30% 
0.15 M       
0.20 M       
0.25 M       
0.30 M       
 
Figure 3.36: A grid of (NH4)2SO4 concentration vs. PEG concentration optimization of 
crystallization for PfHPRT-GMP. 
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It was then decided to set up trials around the condition in which crystals of PfHPRT in 
complex with immucillinHP grew which was 20% PEG, 100 mM, pH 7.5 Hepes (the 
conditions also included 1.5 uM ImmucillinHP and an excess of Mg2+ pyrophosphate). 
We systematically varied PEG concentration and the pH and held Hepes concentration 
constant. Three screens for IMP, GMP and chalcone were set-up as shown in Figure 3.37. 
 
      
           PEG 
4000 
        
      pH 
 
20% 
 
22% 
 
24% 
 
26% 
 
28% 
 
30% 
7.0       
7.3       
7.5       
7.8       
 
Figure 3.37: A grid screen set-up of PEG concentration vs. pH for PfHPRT co-
crystallization with IMP, GMP or chalcone (each at 1 mM; with 5 mM MgCl2 for IMP/GMP, 
and 5 mM CaCl2 for the chalcone).  
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This screen yielded a number of crystals with GMP and IMP but not with the chalcone, 
as shown in Figure 3.38. 
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Figure 3.38: Crystals obtained from the grid screen in Figure 3.3.7. Top panel shows 
showers of microcrystals with PfHPRT, 1 mM GMP, 5 mM MgCl2, 30% PEG, 100 mM Hepes, pH 
7.5. Middle panel, microcrystals with PfHPRT, 1 mM IMP, 5 mM MgCl2, 20% PEG, 100 mM 
Hepes, 7.3. Bottom panel shows microcrystals with PfHPRT 1 mM IMP, mm 5 MgCl2, 20% PEG, 
100 mM Hepes, 7.5.  
 
Refinement of the conditions was carried out in two ways: for the GMP-mix 
microcrystalline precipitate, PEG concentration lowered to 25%. After mixing the 
protein-ligand solution with the precipitant on a siliconized glass cover slide, the drop 
was seeded with material from the 30% PEG drop using the Hampton Research seeding 
tool. In the second approach, conditions were set up as previously (Figure 3.37) but the 
rate of nucleation was slowed down using oils. Three different types of oil (Al’s, Paraffin 
and Silicon) were tested separately. After mixing the precipitant with protein on the cover 
slide, 400 μL of oil was layered on top of the reservoir solution and the cover slide 
inverted over it for equilibration.  
 
The seeding approach resulted in microcrystals (not shown) while elegant crystals, shown 
in Figure 3.39, were obtained with oils. On diffraction, these crystals however turned out 
to be salt crystals. The salt diffraction pattern is shown in Figure 3.40.  
A B
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Figure 3.39: Salt crystals. Crystals in panel A were obtained with 20% PEG, 100 mM Hepes, 7.3 
as precipitant but layered with 400 μL Al’s oil. Crystals obtained with 26% PEG, 100 mM Hepes, 
pH 7.5 and 400 μL Al’s oil are shown in panel B.   
 
 
 
Figure 3.40: Diffraction pattern of a salt crystal. The crystal arose from a solution of 20% PEG, 
00 mM Hepes, 7.3 as precipitant layered with 400 μL Al’s oil to slow down the rate of nucleation. 1
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Formation of salt crystals is a common phenomenon in macromolecular crystallization. 
Like protein crystals, salt crystals come in different forms and shape. Though it’s not 
easy to differentiate between a protein crystal and a salt crystal by direct observation the 
latter are highly birefrigent. Use of methylene blue dye, which permeates (through) the 
solvent channels in protein crystals thus colouring the crystals blue, or poking with a fine 
glass rod are fast, rough ways of establishing what type of crystals one has. Protein 
crystals, unlike salt crystals, also crumble easily on the slightest application of pressure. 
Ultimately though, crystal type is confirmed by a diffraction pattern.  
 
 
 
The diffraction pattern of salt crystals differs from that of protein crystals. Since small 
molecules, like salt, have shorter Bragg distances compared to protein molecules, they 
tend give fewer reflections with widely separated spots. Because of the longer Bragg 
distances, at the same crystal to detector distance, protein crystals produce more 
reflections and spots much closer to each other.  
 
The fact that most of the optimized drops resulted in salt crystal formation suggested that 
the sodium phosphate used as the final dialysis buffer before setting up trials was 
possibly unfavourable. Thus, this buffer was changed to MOPS and further trials 
performed. Numerous salt crystals, some shown in Figure 3.41, were again obtained with 
this strategy.  
 A B
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Figure 3.41: Salt crystals obtained when PfHPRT was dialysed against 10 mM MOPS, pH 
7.0, 1 mM DTT prior to setting up trials. Panel A shows small salt crystals obtained with 20% 
PEG 4000, 100 mM Hepes, pH 7.3 as precipitant. The 1 mL reservoir solution was layered with 
300 μL Al’s oil. Panel B shows a sizeable salt crystal growing from precipitate and exhibiting 
twinning. This crystal was obtained with 26% PEG 4000, 100 mM Hepes, pH 7.5.  
 144
 
 
 
 
 3.4 TNP-8N3-ITP synthesis 
2’,3’-O-trinitrophenyl nucleotides have been widely used as fluorescent probes for 
nucleotide binding sites in enzymes (Hiratsuka, 1982). The 8-azido derivatives were 
introduced by our laboratory as photoaffinity labels of sarcoplasmic reticulum Ca2+-
ATPase (Seebregts and McIntosh, 1989). TNP-GMP has been found to be a potent 
inhibitor of PfHPRT (Phehane, 2002), and we, therefore, considered that the 8-azido 
derivative of TNP-GMP, and possibly TNP-IMP, could be useful photoaffinity probes of 
this enzyme. However, the synthesis of these compounds in a radiolabelled form presents 
considerable difficulties. The synthesis of 6-oxo-3’,5’-cyclic phosphates from cAMP has 
been described (Meyer et al., 1972), and as the reaction conditions seemed fairly mild, 
and oxidizing (the 8-azido group is very susceptible to reduction), we considered that it 
may be possible to convert TNP-8N3-ATP into TNP-8N3-ITP directly, and possibly [γ-
32P]TNP-8N3-ATP into [γ-32P]TNP-8N3-ITP. The synthesis of [γ-32P]TNP-8N3-ATP is 
routinely performed in our laboratory every two months for photolabelling mutants of 
Ca-2+-ATPase (Clausen et al., 2006; McIntosh et al., 1999). 
 
PfHPRT is specific for the monophosphate species, and it may be considered futile to try 
to use the triphosphate species as a photolabel. However, examination of the open 
structures (unliganded) of several HPRTs led us to believe that the extra two phosphates 
could easily be accommodated by extending out of the active site (see Discussion). 
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Figure 3.42: Scheme for synthesis of TNP-8N3-ITP from TNP-8N3-ATP. 
 
The reaction, according to Meyer et al. (1972), was tested first for ATP, then TNP-ATP, 
and finally TNP-8N3-ATP, and in each case was found to convert these species into the 
inosine derivative with very good yields. The separation of TNP-8N3-ATP and TNP-8N3-
ITP was achieved by reverse phase HPLC. Repeated injections provided a means to 
isolate a fairly large amount of pure TNP-8N3-ITP. The spectrum of TNP-8N3-ITP, as 
well as that following 1 min irradiation, is shown in Figure 3.43. It is evident that there is 
a peak at 273 nm associated with the purine ring, and another at 408 nm and a shoulder at 
468 nm characteristic of the TNP Meisenheimer species. Irradiation resulted in 
disappearance of the 273 nm peak, demonstrating the presence of the azido group in the 
parent compound. 
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Figure 3.43: The absorption spectrum of TNP-8N3-ITP before and after irradiation with UV 
light. The abolishment of the 273 nm peak upon irradiation is indicative of the presence of an 
azido group. The 408 nm peak with a shoulder at 468 nm is characteristic of a TNP 
Meisenheimer complex.  
 
More challenging was defining conditions for conversion of [γ-32P]TNP-8N3-ATP to [γ-
32P]TNP-8N3-ITP as the former species is at low concentration and very hot (typically 2 x 
107 cpm/nmol). We could realistically only use 30 nmol [γ-32P]TNP-8N3-ATP total, and 
the isolation/purification needed to be performed on a C-18 Sep-Pak cartridge.    
 
The time dependence of synthesis of a trial of cold TNP-8N3-ITP from 30 nmol TNP-
8N3-ATP as judged by reverse-phase HPLC is shown in Figure 3.44. After 4 h reaction,  
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the mixture was processed through a Sep-Pak cartridge exactly as if it had been very hot, 
and the resulting HPLC elution at both 210 nm and 408 nm is shown in Figure 3.45.   
Looking at the former trace (blue), if the first peak at 2.5 min is ignored (probably acetic 
acid), TNP-8-N3-ITP is the predominant peak and possibly about 50% pure. In the case of 
the 408 nm trace (red), it could be 95% pure.  The species remaining after 3-4 h at the 
position of TNP-8N3-ATP was, according to the 210/408 nm ratio, not actually TNP-8N3-
ATP, and must represent a minor contaminant of the “pure” TNP-8N3-ATP,  which is not 
surprising as it was purified by the same HPLC system. Taking the latter into 
consideration, it appears that the conversion of TNP-8N3-ATP into TNP-8N3-ITP was 
close to 100%.  
 
Time (min)
0 10 20 30
Ab
so
rb
an
ce
40
8
0.00
0.01
0.02
0.03
0.04
0.05
0.06
Time (min)
0 10 20 30
Ab
so
rb
an
ce
40
8
0.00
0.02
0.04
0.06
Time (min)
0 10 20 30
A
bs
or
ba
nc
e 4
08
0.00
0.01
0.02
0.03
0.04
0.05
0.06
Time (min)
0 10 20 30
A
bs
or
ba
nc
e 4
08
0.00
0.02
0.04
0.06
A 
A 
A 
A
B B
B
B 
1 h3 
2 3 
 
 
 
 
 
 
 
 
 
 
 148
 
 
 
 
Figure 3.44: HPLC traces for reaction mix for the synthesis of TNP-8N3-ITP from 30 nmol 
TNP-8N3-ATP.  Reaction times are as shown. A and B show the position of TNP-8N3-ITP and 
TNP-8N3-ATP respectively. The mobile phase was 10 mM KPi, pH 6, 60% (v/v) acetonitrile. 
Detection was at 408 nm. 
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Figure 3.45: HPLC trace of the Sep-Pak purified TNP-8N3-ITP after 4 h reaction on ice. The 
mobile phase was 10 mM KPi, pH 6, 60% (v/v) acetonitrile. The red and blue spectra represent 
absorption at 408 nm and 210 nm respectively.  
 
Synthesis of [γ-32P]TNP-8N3-ITP was performed under identical conditions as described 
above using 30 nmol [γ-32P]TNP-8N3-ATP with a specific activity of 5.6 x 106 
cpm/nmol. The concentrated sample after Sep-Pak purification was 130 μM, assuming 
the extinction is the same as that for TNP-8N3-ATP.  The volume and yield will be 
determined in the future after the radioactivity has declined to safer levels. 
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3.5 Photoaffinity labeling  
Azidonucleotides, particularly the 8-azido adenine compound, have been used to probe 
nucleotide binding sites of proteins (McIntosh et al., 1992; Seebregts and McIntosh, 
1989). Upon light irradiation, the azido group is converted into the highly reactive nitrene 
species that attacks nearby residues, particularly good nucleophiles, like tyrosine, and 
lysine, forming a covalent bond between the nucleotide and the protein. 
 
Photolabeling of PfHPRT with [γ-32P]TNP-8N3-ATP under the standard conditions 
shown to be optimal for sarcoplasmic reticulum Ca2+-ATPase (pH 8.5, 20% glycerol, 1 
min irradiation) is shown in Figure 3.46, and the quantification shown in graphical form 
in Figure 3.47. The gels show that there is one major component of the preparation that is 
photolabelled that is in a position where PfHPRT is expected, and the overall banding 
pattern at higher concentrations of nucleotide is rather similar to that obtained with 
Coomassie Blue staining. In the absence of divalent cations the concentration dependence 
was complex, exhibiting a hyperbolic rise in labelling in the 0-5 μM range and, 
thereafter, a linear component, the former typifying specific binding and labelling and the 
latter typical of a nonspecific reaction. Fitting the curve yielded a K0.5 of 2.06 μM and 
maximal derivatization of 0.018 mol/mol PfHPRT. Thus, the binding affinity was fairly 
tight and the efficiency rather low. In the presence of either 1 mM Mg2+ or Ca2+, the 
labelling was much poorer and close to linear, suggestive of a nonspecific reaction. Either 
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the TNP-nucleotide does not bind specifically in the presence of divalent cations or the 
photolabelling reaction of bound nucleotide has very poor efficiency. 
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Figure 3.46: Radioactivity imaging of SDS-PAGE (12%) analysis of [γ32P]TNP-8N3-ATP 
photolabeling of PfHPRT. Top, middle, and bottom panels shows photolabeling in the presence 
of 1 mM Mg2+, 1 mM Ca2+, and 2 mM EDTA, respectively, in a standard medium of 25 mM 
EPPS/TMAH, pH 8.5, 20% glycerol, 0.01 mg PfHPRT/ ml, and 0.01-30 mM [γ-32P]TNP-8N3-ATP. 
The concentrations of [γ32P]TNP-8N3-ATP and position of PfHPRT are shown. The spots to the 
right of each PAGE gel represent 1 μL of 1 μM [γ-32P]TNP-8N3-ATP (1 pmol) applied as square 
millimeter filter paper patchs after electrophoresis, and are used to quantify the extent of labelling 
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in the bands.  Note that the relative banding intensity of the gels cannot be directly compared as it 
depends on the specific activity of the probe and the length of exposure to the screens. The 
particular preparation used was inactive, but could be activated to 1 μmol/min/mg of protein on 
incubation with substrates. 
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Figure 3.47: Photolabelling curves of PfHPRT with [γ-32P]TNP-8N3-ATP. The original gels 
from which the data is derived and experimental conditions are in Figure 3.46. Quantification was 
by exposure to radioactivity-sensitive screens for about 2 days, and analysis using a Cyclone 
Imager and associated software. The curves show the best fit to the data using a Hill equation 
ith a linear component (McIntosh et al., 1996). w
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Figure 3.48: Radioactivity imaging of SDS-PAGE (12%) analysis of [γ32P]TNP-8N3-ITP 
photolabeling of PfHPRT. Top, middle, and bottom panels show photolabeling in the presence 
of 1 mM EDTA, 1 mM Mg2+, and 2 mM Ca2+, respectively, in a standard medium of 25 mM 
EPPS/TMAH, pH 8.5, 20% glycerol, 0.01 mg PfHPRT/ ml, and 0.01-30 mM [γ-32P]TNP-8N3-ITP. 
The concentrations of [γ32P]TNP-8N3-ITP (on top of each gel) and position of PfHPRT are shown. 
The spots to the right of each PAGE gel represent 1 μL of 1 μM [γ-32P]TNP-8N3-ATP (1 pmol) 
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applied as square millimeter filter paper patchs after electrophoresis, and are used to quantify the 
extent of labelling in the bands.  Note that the relative banding intensity of the gels cannot be 
directly compared as it depends on the specific activity of the probe and the length of exposure to 
the screens. The particular preparation used was inactive, but could be activated to 1 
μmol/min/mg of protein on overnight incubation with substrates.  
 
 
 
Similar experiments using [γ32P]TNP-8N3-ITP as a photolabel are shown in Figures 3.48 
and 3.49. In the absence of divalent cations (2 mM EDTA), the concentration dependence 
of photolabeling was similar to that obtained with the adenine nucleotide, but the amount 
of specific component was somewhat less (K0.5 = 2.43 μM, and labeling maximum = 
0.010 mol/mol). However, in the presence of Mg2+ and Ca2+ the inosine nucleotide 
exhibited specific components (K0.5 = 4.61 and 2.85 μM respectively, and labeling 
maxima of 0.008 and 0.016 mol/mol, respectively), which contrasts with what was found 
for the adenine nucleotide. The affinity was somewhat higher and the derivatization more 
efficient in the presence of Ca2+.  
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Figure 3.49: Photolabelling of PfHPRT with [γ-32P]TNP-8N3-ITP. The original gels from which 
the data is derived and experimental conditions are in Figure 3.48. Quantification was by 
exposure to radioactivity-sensitive screens for about 2 days, and analysis using a Cyclone Imager 
and OptiQuant software. The curves show the best fit to the data using a Hill equation with a 
linear component (McIntosh et al., 1996). 
 
CHAPTER FOUR: DISCUSSION AND CONCLUSIONS 
 
4.0 Introduction 
The ultimate aim of this work was to obtain a crystal structure of PfHPRT in complex 
with a chalcone. To achieve this, we needed to over-express the enzyme in E.coli and 
purify as far as possible.  Many crystallization trials were undertaken with partially pure 
enzyme.  Alongside, we developed a model of the unliganded malarial enzyme based on 
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atomic structures of human, Salmonella typhimurium, and Trypanosoma cruzi enzymes. 
Methodology was also developed to determine the oligomeric status of our preparations 
of PfHPRT. Another aim was to develop photoaffinity labels of the active site, based on 
2’, 3’ trinitrophenyl nucleotides, in order to determine whether the chalcone binds to the 
active site or not through competitive inhibition of the photolabeling. 
 
4.1 Protein expression 
Recombinant protein expression was achieved in E.coli BL21(DE3)pLysS cells 
transformed with pET-17b vector containing the PfHRPT insert. The cells were grown 
overnight at 37 °C to an optical density of OD600 of 0.4 – 0.6 at 600 nm and protein 
induction initiated by adding IPTG. Expression was examined by SDS-PAGE. Although 
PfHPRT is a soluble protein and supposed to be in the supernatant fraction after cell lysis 
and centrifugation, significant amounts were always present in the pellet fraction most 
likely as inclusion bodies. This was in spite of the rich growth media used, which slows 
inclusion body formation (Moore et al., 1993).  
 
We tried to ameliorate this problem by lowering the temperature of the culture medium 
(34oC) during the 3 h of induction with IPTG, but without noticeable effect. Inclusion of 
10% glycerol during the entire growth period has also been found to be beneficial, but we 
did not obtain an improvement.  It seems that primary instability of the protein, and an 
adverse folded/unfolded equilibrium, may be a major contributor to its deposition in 
inclusion bodies, rather than overproduction per se. The amount of soluble PfHPRT in 
the supernatant was however adequate for further processing.  
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 4.2 Protein purification 
Several methods exist for PfHPRT purification. For example, Shi et al. (1999) used a 
two-step procedure involving an anionic Q-Sepharose column followed by a Superdex G-
75 gel filtration column to obtain a 95% pure enzyme which was subsequently 
crystallized and used in X-ray diffraction studies. Raman et al. (2005) started with 
ammonium sulphate precipitation of the clarified cell lysate followed sequentially by 
HPLC anionic-exchange chromatography on a Q-Sepharose column and 
cationic-exchange chromatography on a Resource S column. Keough et al. (1999) 
employed an anionic DEAE cellulose column (43 x 2.2 cm) followed by an Hg-
Sepharose column (4.3 x 1.7 cm).  
 
 
 
 
 
Our laboratory has developed a method based on a one-procedure two-step protocol of a 
DE-52 column (1.5 x 6 cm) placed in tandem with an agarose-linked Reactive Red 120 
column (2 x 5 cm) (Mbewe et al., 2006). The protein comes straight through the anion 
exchange column, but binds to the Reactive Red 120 column, and can be eluted with 50 
mM pyrophosphate.  PfHPRT has a calculated pI of 7.2 (taking the amino acids cysteine, 
aspartate, glutamate, histidine, lysine, arginine and tyrosine, and the amino- and carboxy-
termini of the protein into account) (www.embl-heidelberg.de/cgi/pi-wrapper.pl), which 
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means that around this pH the protein will not bind to an anion exchange resin.  Most 
proteins have a pKa of between 5 and 6 and would bind well at neutral pH and higher. 
Experimentally, PfHPRT appears not to bind to a resin well- equilibrated at pH 8.0 
(Figure 3.4) as well as at pH 8.9 (Figure 3.7), suggesting either that the actual pKa is 
higher than 7.2 (surface residues are what count), or competing anions, like nucleotides 
(mainly derived from DNAse treatment of DNA), are loosening the interaction with the 
resin.  Whatever the explanation, under the conditions used, PfHPRT binds very poorly to 
the anion exchange resin, which distinguishes it from most other proteins in the 
supernatant, and a significant purification is obtained. This behaviour is in agreement 
with Keough et al., 1999, but seems to disagree with Shi et al., 1999 and Raman et al., 
2005, who needed salt to elute it from anion exchange resins. Reactive Red 120 is a large 
polysulphonated aromatic triazine dye (Figure 4.0) that mimics biological heterocyclic 
substrates such as nucleotides (Dean and Watson, 1979; Kaminska et al., 1999). It is 
ligated to agarose via a reactive chloro group. The polysulphonyl groups mean that it can 
also be considered a cation exchange resin.  
 
However, Mbewe et al., 2006 considered that it behaved in the classical manner of an 
affinity column, due to the aromatic and sulphonated groupings mimicking GMP or IMP, 
PPi, or PRPP, mainly because PfHPRT was so effectively eluted with pyrophosphate, a 
product of the enzyme.     
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 Figure 4.0: Structure of Reactive Red 120. The linkage to agarose is through the two chloro 
groups (coloured green). Sulpur atoms of the sulphonate groups are coloured orange while the 
xygen atoms are coloured red.  o
 
In our attempt to reproduce this method, we found that some of the PfHPRT (~50%) 
seemed to bind tighter than usual and failed to elute with the pyrophosphate, but came off 
with the 1 M NaCl wash. The significance of a very tight binding fraction of PfHPRT 
will be addressed a bit later. 
 
The behaviour of PfHPRT on the anion exchange resin was investigated in more detail by 
running the two columns separately and analysing multiple fractions for protein and pH. 
The majority of PfHPRT came straight through the short DE-52 column (2 x 6 cm) while 
the remainder was brought off by the 50 mM Tris-HCl, pH 8.0, 1 mM DDT, and 1 mM 
PMSF wash of the column. Compared with the flow-through fraction, the Tris-HCl wash  
 
had more contaminants co-eluting with the malarial enzyme perhaps due to lowering of 
the column pH to the acidic range as the lysis buffer passed through.  
 
The pH of the column in this case went up to 11, clearly indicating that the 10 mL of lysis 
buffer used for equilibration did not equilibrate the column. Proper equilibration of the 
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column at pH 8.9 (to induce PfHPRT binding) did not, however, result in any noticeable 
change in the behaviour of PfHPRT on this column.  
 
On a longer DE-52 column (2 x 17.5 cm), washed with 30 mL of lysis buffer prior to 
loading of the supernatant (i.e. poorly equilibrated), PfHPRT was retarded on the column 
and was eluted in a very pure form by 50 mM Tris-HCl, pH 8.0, 1 mM DTT, and 1 mM 
PMSF. The pH of the column effluent for this preparation was extremely alkaline (up to 
13) which could have aided PfHPRT interaction with the resin. While excellent purity 
was obtained with this approach, the resulting enzyme was incapable of being activated, 
most likely due to exposure to the extremely alkaline pH. When the column was well- 
equilibrated (pH 8.0) with the lysis buffer prior to applying the supernatant, PfHPRT did 
not bind or bound poorly and most came straight through the column. The purity was not 
as good as the poorly equilibrated long column, but nevertheless was quite pure.   
 
It seems that the long DE-52 columns produced purer HPRT than the short columns. If 
one compares the concentrates (compare Figure 3.13 with those in Figure 3.1 and Figure 
3.8), and bearing in mind that some of the small molecular weight species could be  
 
proteolytic digestion products of HPRT, there appear to be relatively fewer high 
molecular weight contaminants with the long column.  However, in our two attempts 
with the long column, we were not able to activate the enzyme with substrates, and the 
protein in both cases displayed negligible activity on assay. The reason for this lack of 
 160
 
 
 
 
activity (with the well equilibrated column) is not clear, but could be related to 
proteolysis.  
 
The efficacy of the Reactive Red 120 column was not explored in detail, but its value in 
eliminating high molecular weight contaminants is clearly evident in Figure 3.8, where 
most came straight through the column, and PfHPRT was eluted in a much purer form 
compared with the material placed on the column. It has been shown before that PPi 
selectively elutes PfHPRT, whereas a salt gradient exhibits no selectivity (Mbewe et al., 
2006), suggesting the protein interacts specifically with the resin (affinity mechanism 
rather than cation binding mechanism).   
 
In some experiments, there appeared to be two populations of PfHPRT in relation to 
Reactive Red 120 chromatography, one that eluted with PPi and another that remained 
tightly bound and was eluted with 1 M NaCl. This was especially noticeable in the 
experiment using a poorly equilibrated, long DE-52 column, where the majority of the 
protein appeared in the tight binding fraction (Figure 3.11). Since this preparation had 
been exposed to extremely high pH, it suggests that the tight binding protein is a poorly 
folded form, and not desirable from the point of view of producing a homogeneous  
 
preparation for crystallization. Thus, the Reactive Red 120 column appears to have two 
advantages, one in getting rid of contaminating proteins and second in eliminating an 
alternative structural state of PfHPRT.  
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One problem that was encountered during some of the purification attempts was the 
proteolytic degradation of PfHPRT. This could be seen in small molecular weight species 
in the SDS-PAGE analysis, and was proven by the co-elution of the proteolytic products 
with tetrameric PfHPRT on HPLC gel filtration (fraction collected and subjected to SDS-
PAGE analysis).  
 
It was apparent that the tetrameric complex consisted of full-length protein as well as 
nicked protein, and could explain, in some cases, why the enzyme could not be activated.  
Proteolysis was evident in the supernatant fraction and persisted throughout in the 
purification (see Figures 3.12 and 3.13). The first steps (lysis, DNAse digestion, and 
centrifugation) are rather lengthy and it is likely that the proteolysis is happening during 
this period.  New, freshly prepared PMSF (which covalently modifies the active site of 
many serine proteases irreversibly) as well as a cocktail of other inhibitors in the lysis 
buffer did not help (Figure 3.12). In one experiment, the DNAse digestion was performed 
at 0 oC rather than the usual 25 oC, but it did not help either (results not shown). Other 
protease inhibitors could be explored to get around this problem.   
 
 
 
Overall, from exploration of the elution properties of the DE-52 column, we found that a 
long, well-equilibrated column results in the majority of the PfHPRT coming straight 
through the column with better purity than with the short columns, well-equilibrated or 
not.  This procedure seemed to eliminate the need for a large wash volume, which 
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generally contained several high molecular weight contaminants. We find the Reactive 
Red column to be very effective – likely eliminating both contaminants and poorly folded 
PfHPRT.  HPLC gel filtration will be discussed in detail below, but it seems to offer 
promise to provide substantial further and final purification.  Interestingly, recombinant 
PfHPRT used for obtaining crystals complexed with a transition-state inhibitor was 
purified by just ion exchange and gel filtration (Li et al., 1999; Shi et al., 1999).  
 
4.3 Activity assay  
We had difficulty in routinely obtaining active PfHPRT, even after incubation with 
partial substrates. It is known that PfHPRT is purified in an inactive form and requires 
activation by incubation with partial substrates, i.e. conditions under which there is no 
enzyme turnover (Keough et al., 1998: Keough et al., 1999; Sujay Subbayya et al., 2000; 
Mbewe, 2005; Mbewe et al., 2006). Thus the enzyme exists in at least two 
interconvertable forms.  However, as mentioned, some preparations failed to activate, and 
there are evidently other species that cannot reach the activated state. 
 
The failure of some of the protein to activate could arise from proteolytic degradation of 
PfHPRT, the presence of dimers, or poorly folded forms. Proteolytic cleavage is expected  
 
to be mainly at the flexible loops, and may have affected the enzyme’s ability to bind 
substrates. Dimer protein present in preparations after dialysis at low salt concentration 
appears unable to revert to tetramers. Exposure to extremely high pH results in poorly 
folded protein that cannot be activated. 
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 4.4 HPLC gel filtration: PfHPRT oligomeric state analysis and further 
purification 
Previous work has shown that that PfHPRT exists in its native, active state as a tetramer, 
and that high salt concentrations converts it into an inactive dimer (Keough et al, 1999). 
The possible existence of more than one oligomeric form of the enzyme could have a 
serious detrimental effect on crystallization. It was also of interest to find out the 
relationship between inactivity/activity and quaternary structure in our preparations. It 
was, therefore, desirable to have a method to measure the quaternary state of the enzyme. 
Keough et al. (1999) employed ultracentrifugation, but this is a lengthy procedure and 
unable to provide an accurate measure of the proportion of each species. We opted to try 
HPLC gel filtration instead. It has the advantage of speed and easy quantification.   
 
However, we encountered difficulties in doing the analysis under low salt conditions, 
exactly the conditions we wanted to know the oligomeric status and the proportion of 
each species. Analysis of the behaviour of standard proteins on the particular HPLC gel 
filtration column we used, revealed that proteins migrated anomalously in low salt 
concentrations, probably mostly through inhibition of resin penetration through ionic  
 
effects (i.e. most eluted earlier and together; cytochrome c was the exception and bound 
tightly to the resin). 
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Accordingly, we tested our preparations over a range of NaCl concentrations in the 
HPLC running buffer. There was a clear transition from a larger quaternary form to a 
smaller with an increase in salt concentration, with a midpoint at approximately 300 mM 
NaCl.  The larger was attributed to the tetramer and the smaller to the dimer, even 
though, according to the standards, the molecular weight was about 35% lower, which 
suggests PfHPRT interacts with the resin in some way, rather similar to the behaviour of 
cytochrome c. The latter is strongly cationic, and PfHPRT exhibits similar properties in 
that it fails to bind to an anion exchange resin but does to a cation exchange resin (we 
found it bound to a cation exchange Sep-Pak), even though the overall pI is 7.2. On the 
other hand, the elution position of the two quaternary forms was quite insensitive to the 
salt concentration, the tetramer, for example, eluting at 8 min at 20 and 700 mM NaCl, 
with a fairly good separation of the two forms at these extremes.   
 
Even though the analysis could not be accurately performed at concentrations below 20 
mM salt, it was evident from the extrapolated curve (Figure 3.17) that the particular 
preparation that we analyzed consisted of 70 and 30% tetramer and dimer, respectively at 
zero salt concentration. This preparation had been exposed to 1 M NaCl during the 
purification process and then exhaustively dialyzed, and evidently had gone from being 
dimeric to these proportions during dialysis. The proportion is unlikely to change further  
 
with time, as the dialysis time is already lengthy. The presence of a high proportion of the 
two species could inhibit crystallization. 
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We noticed that preparations that had been exposed to high pH through using a long, 
poorly equilibrated column consisted of mainly dimer, and that prolonged dialysis against 
10 mM MOPS, pH 7.0, resulted in a slow, partial conversion to a tetrameric species. It 
was these preparations that had a high proportion of PfHPRT that bound tightly to the 
Reactive Red 120 column (Figure 3.11). Accordingly, our hypothesis is that the tight 
binding protein is the dimer, and that it is unable to be activated with substrates.   
 
The dissociation of the tetramer into dimer as the ionic strength increases also indicates 
that the interacting forces between the dimers that form the tetramer are weaker than 
those between monomers forming the dimers, and that the former is dominated by salt-
sensitive interactions (ionic), while the latter is held together by salt-independent 
interactions, likely hydrophobic interaction. The crystal structure indicates that the 
monomers interact to produce dimers via burial of a total surface area of 2812 Å2, with 
hydrogen bonds between Lys38, Glu108, and Asp 211 in chain A and Glu100, Lys77, 
Arg80, and Asn95 from chain B respectively, and the involvement of many hydrophobic 
residues (Shi et al., 1999). The interaction of the dimers to form the tetramer involves a 
total surface area of 2070 Å2, and must consist of ionic interactions, although this is not 
readily apparent from the PDB structure, as the interactions are not provided (dimers 
separated).  
 
Our HPLC gel filtration experiments of a preparation eluted from Reactive Red 120 
column with 1 M NaCl and concentrated showed that this procedure could effectively be 
used to purify PfHPRT as a tetramer from contaminants and other quaternary forms. In 
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the particular experiment shown, gel filtration failed to separate tetrameric PfHPRT from 
another protein of approximately 30 000 daltons (as judged by SDS-PAGE, Figure 3.20, 
and presumed to be trimer or tetramer in the absence of SDS). Normally PfHPRT would 
be eluted with PPi from the Reactive Red 120 column and this protein is eliminated in the 
200 mM NaCl wash (Figure 3.6).  
  
We show that it is possible to obtain reasonable amount of protein by repeated 200 μL 
injections of a concentrate of 0.3 mg/mL. The limitation is the volume rather than the 
concentration of protein.  Preparations from DE-52 and Reactive Red 120 purification 
routinely produced approximately 5 mg.  Thus, by concentrating such preparations to 2 
mg/mL or so, it would be possible to purify the entire preparation in 4 h. Overall, one 
could complete an entire purification, from cells to pure protein in 24 h. 
 
It is interesting that the preparations analyzed at low salt concentrations consist of 
predominantly the tetrameric species, and yet are not active, i.e. the preparation still 
needs to be activated by incubation with partial substrates.  This means that the activation 
process is not the conversion from dimer to tetramer, but rather a conformational change 
of the tetramer, which may involve rearrangement of the flexible loops in each monomer  
 
 
around the substrates. In fact, in one experiment, activation (incubation overnight with 
PRPP + hypoxanthine) resulted in a small, partial conversion to dimer. This agrees with 
the finding of Raman et al. (2005) that substrates actually destabilize the protein.    
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 4.5 Crystallization 
For the numerous crystallization trials performed, a myriad of results, including 
precipitates, phase separations, and salt crystals, were obtained but no protein crystals, as 
judged by the prick test, dye binding, and diffraction patterns. Several factors could have 
contributed to the failure to obtain PfHPRT crystals. Among these, the presence of a few 
contaminants in the enzyme preparation, particularly persistent high molecular 
impurities, could have played a major role. While the purity of a protein is a critical 
factor which influences the outcome of macromolecular crystallization experiments, our 
rationale for proceeding with crystallization attempts while the enzyme still contained 
contaminants was that crystallization is often used as a purification step to recover 
proteins from impure mixtures due to the ability of the crystal surfaces’ to recognise 
cognate molecules for adsorption (Bergfors, 2003). 
 
Another factor that may have disfavoured crystallization was the heterogenous 
oligomeric state of PfHPRT. Like purity, the existence of the protein to be crystallized in 
a singular structural species is an important factor. HPLC gel filtration experiments 
pointed to the existence of significant dimer among the tetramer species of PfHPRT at 
low salt concentration, which mitigates against formation of ordered crystals.  
 
The apparent presence of proteolytic degradation products in several of our preparations 
would also hamper crystal formation. The most likely sites for attack by proteolytic 
enzymes are at the flexible loops that close over the substates, and nicks here could 
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prevent ligand binding and closure of the loops. A compact shape may be needed for 
crystallization.   
 
Due to the instability of PfHPRT, it is also possible that the protein aggregated over time.  
 
One of the main problems encountered during crystallization trials was the precipitation 
of chalcone, which was usually added to a final concentration of 1 mM (concentrate in 
DMSO) in order to saturate the ligand binding site (active site concentration 0.4-0.6 mM 
at 10-15 mg/ml). It may be possible to increase the DMSO concentration in the 
crystallization medium to lessen precipitation. Alternatively, it may be advantageous to 
dry the chalcone onto the cover slip and let the chalcone dissolve with time into the 
crystallization droplet.  
 
4.6 Homology modeling  
PfHPRT holoenzyme was modeled based on the structures of the human, T. cruzi and S. 
typhimurium HGPRTs using MODELLER (Sali and Blundell, 1993). Superposition of 
this open, unliganded structure of PfHPRT with the solved closed crystal structure of 
PfHPRT (PDB code 1CJB; Shi et al., 1999) revealed a good overall agreement of  
 
 
secondary structural features as reflected by the low RMSD values. A major difference 
was the less extensive core β-sheet attributed to the opening and flexibility of the 
catalytic loop. The terminal β-strand was thus separated from the sheet and the 
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penultimate β-strand shortened by four residues.  The other significant difference was the 
opening of all the loops that close over the substrates (Figure 4.1). The side chain 
conformations of most residues lining the active site remained unaltered. However, the 
opening of the loops caused several side chains to be displaced.   
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 Figure 4.1: A semitransparent surface representation showing a comparison of the closed 
atomic structure of PfHPRT with bound ImmHP, PPi and two Mg2+ ions at the active site 
with a model of the open unliganded form of PfHPRT.  Blue and red indicate basic and 
acidic charges, respectively.  
 
The homology model emphasized the large size of the open active site cavity. This 
cavity, 2913.8 Å3 in size, is large enough to accommodate sizeable ligands, even larger 
than the substrates. Note the loop movements in the open structure (Figure 4.2). 
 
 
 
 171
 
 
 
 
  
 
Figure 4.2: Comparison of closed and open PfHPRT (model). This top view shows some key 
substrate binding residues in stick form.  
 
The value in having an open PfHPRT structure, albeit a model, is being able to dock 
ligands in an appropriate structure, i.e. one that is likely to bind a competitive inhibitor. 
 
 
 
4.7 Photoaffinity labeling 
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TNP nucleotides have been widely used as probes of nucleotide binding sites because of 
their fluorescent properties and also on account of their generally higher affinity toward 
these sites (Ward and Cavieres, 1998). The 8-azido derivatives were introduced by our 
laboratory as photoaffinity probes. Photoaffinity probes are useful because they can 
identify residues at the active site and be used to investigate whether a ligand of interest 
binds to this site. 
 
In this study, we developed a method for synthesizing [γ-32P]TNP-8N3-ITP (2',3'-O-
(2,4,6-trinitrophenyl)-8-azidoinosine triphosphate) and explored its efficacy as a 
photolabel of the IMP site of PfHPRT. We compared its properties to that of [γ-32P]TNP-
8N3-ATP (2',3'-O-(2,4,6-trinitrophenyl)-8-azidoadenosine triphosphate).  
 
The synthesis entailed directly converting the exocyclic amino group TNP-8N3-ATP to 
an oxo group. The reaction in nitrous acid was mild and quantitative enough to consider 
modification of highly radiolabeled [γ-32P]TNP-8N3-ATP and use the product directly 
following simple purification through a C18 Sep-Pak cartridge.   
 
Labeling PfHPRT with [γ-32P]TNP-8N3-ITP and [γ-32P]TNP-8N3-ATP was rather 
inefficient – derivatization was only to the extent of 0.005 to 0.01 mol probe/mol protein. 
This should be compared with [γ-32P]TNP-8N3-ATP photolabeling of Ca2+-ATPase, 
which proceeds to close to 1 mol probe/mol protein, because of the derivatization of a  
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lysine (K492) – a powerful nucleophile (McIntosh et al., 1992). Presumably there is no 
nucleophile in the vicinity of the azido group in PfHPRT.   
 
The two probes had rather different properties in their interaction with PfHPRT. [γ-
32P]TNP-8N3-ATP bound and photolabeled with high affinity in the absence of divalent 
cations, whereas no specific labeling could be detected in the presence of Mg2+ or Ca2+. 
In contrast, [32P]TNP-8N3-ITP bound and photolabeled with high affinity in the absence 
and in the presence of divalent cations. The poor photolabeling efficiency meant that 
there was a rather high background labeling relative to the specific derivatization. 
 
It is difficult to understand the different effects of divalent cations with the two 
nucleotides, but somehow the Mg- or Ca-complex with the inosine nucleotide makes for 
better interaction with the protein than does the adenine species. One rather remote 
possibility is that it is known that a large substituent at the 8-position of adenine 
nucleotides, such as a bromo or azido group causes the nucleotide to adopt a syn 
configuration rather than the more usual anti configuration about the glycosidic bond, 
and this might not be the case for the inosine nucleotide, and interaction of divalent 
cations with the phosphates could cause other perturbations which alter the syn/anti 
equilibrium. 
 
It may be argued that the triphospho-nucleotides are not good analogues of IMP.  
However, the structures indicate that in the closed structure and with the flexible catalytic  
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loop II pulled back, there should be nothing preventing the extra phosphates from 
sticking out into the medium or making favorable interactions with residues in the 
vicinity (Figure 4.3, top). In the open model structure, the phosphates are even more free 
to extend into the medium (Figure 4.3, bottom). 
 
Figure 4.3: Docking of TNP-ImmHP into closed PfHPRT structure with flexible loop II 
removed (top frame) and of TNP-ATP into open PfHPRT (model, bottom frame). Some 
favorable interactions are shown with green lines. 
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4.8 Future directions 
This study has suggested that a good future purification strategy will be to use a long, 
properly equilibrated DE-52 column (2 x 17.5 cm) as the first step of the purification. 
Most of the enzyme will come off the column in the flow-through fraction. This will 
avoid contaminants that are dislodged from the column by the Tris-HCl wash. Reactive 
Red 120 column chromatography will be retained as the second step, which will 
eliminate most high molecular weight contaminants co-eluting with PfHPRT from the 
DE-52 column and a tight binding PfHPRT fraction, which cannot be activated. HPLC 
gel filtration will be employed as the final step to ensure a homogeneous tetrameric 
preparation and to remove remaining contaminants. We are hopeful that such a 
preparation will lead to protein crystals. 
 
A His-tagged PfHPRT has been expressed previously in this laboratory, and it purifies to 
homogeneity using nickel-affinity chromatography (Phehane, 2002). The histidine tag 
can be cleaved off with the retention of 3 extra amino acid residues. We would like to 
perform crystallization trials on such a protein as well. 
 
The chalcones which we have been identified as activators, accelerators, and inhibitors of 
PfHPRT activity under various conditions are unique and only crystal structures of the  
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 chalcone-PfHPRT complexes, under the different conditions, will provide an explanation 
for how these ligands perform such a diversity of functions in a single protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 177
 
 
 
 
 BIBLIOGRAPHY 
 
Allen, T.E., Ullman, B. (1993) Cloning and expression of the hypoxanthine‐guanine 
hosphoribosyltransferase gene  from Trypanosoma brucei. Nucleic Acids Res. 21: p
5431‐8. 
 
ltschul,  S.F.,  Gish,  W.,  Miller,  W.,  Myers,  E.W.,  Lipman,  D.J.  (1990)  Basic  local A
alignment search tool. J.  Mol. Biol. 215: 403‐10. 
 
Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W., Lipman, D.J. 
1997) Gapped BLAST and PSI‐BLAST: a new generation of protein database search 
: 0
(
programs. Nucleic Acids Res. 25  3389‐4 2. 
 
Arav‐Boger,  R.,  Shapiro,  T.A.  (2005)  Molecular  mechanisms  of  resistance  in 
ntimalarial  chemotherapy:  the  unmet  challenge.  Annu. Rev.  Pharmacol.  Toxicol. a
45: 565‐85. 
 
Asherie, N. (2004) Protein crystallization and phase diagrams. Methods 34: 266‐72. 
 
aker,  D.,  Sali,  A.  (2001)  Protein  structure  prediction  and  structural  genomics. B
Science 294: 93‐6. 
otoaffinity labeling. Methods Enzymol. 46
 
Bayley, H., Knowles, J.R. (1977) Ph : 69‐114. 
 
ayley, H.; Staros, J. V. (1984). In Azides and Nitrenes ­ Reactivity and Utility; Scriven, B
E. F. V. Ed., Academic Press Inc.(New York), Chapter 9. 
 
Berendt,  A.R.,  Simmons,  D.L.,  Tansey,  J.,  Newbold,  C.I.,  Marsh,  K.  (1989) 
ntercellular  adhesion  molecule‐1  is  an  endothelial  cell  adhesion  receptor  for 
t e
I
Plasmodium    falciparum. Na ur  341: 57‐9. 
 
Berman,  H.M.,  Westbrook,  J.,  Feng,  Z.,  Gilliland,  G.,  Bhat,  T.N.,  Weissig,  H., 
hindyalov, I.N., Bourne, P.E. (2001) The Protein Data Bank. Nucleic Acids Res. 28: 
35‐42. 
S
2
 
 
 
 
Berman, J.D., Nielsen, R., Chulay, J.D., Dowler, M., Kain, K.C., Kester, K.E., Williams, J., 
Whelen, A.C., Shmuklarsky, M.J. (2001) Causal prophylactic efficacy of atovaquone‐
roguanil  (Malarone)  in a human challenge model. Trans. R. Soc. Trop. Med. Hyg. 
5: 429‐32.    
p
9
 
 178
 
 
 
 
Blundell,  T.L.,  Patel,  S.  (2004)  High‐throughput  x‐ray  crystallography  for  drug 
design. Curr. Opin. Pharmacol. 4: 490‐6. 
 
Blundell, T.L., Sibanda, B.L., Sternberg, M.J., Thornton, J.M. (1987) Knowledge‐based 
rediction of protein structures and the design of novel molecules. Nature 326: 347‐p
52.  
 
Bonneau,  R.,  Strauss,  C.E.,  Rohl,  C.A.,  Chivian,  D.,  Bradley,  P.,  Malmstrom,  L., 
obertson, T., Baker, D. (2002) De novo prediction of three‐dimensional structures R
for major protein families. J Mol.  Biol. 322: 65‐78. 
 
ourne, P.E., Weissig, H. (2003) Structural Bioinformatics. Wiley‐Liss, Inc., Hoboken, B
New Jersey. 
 
Bower,  M.J.,  Cohen,  F.E.,  Dunbrack,  R.L.  (1997)  Prediction  of  protein  side‐chain 
otamers  from a backbone‐dependent rotamer  library: a new homology modelling r
tool. J. Mol. Biol. 267: 1268‐82.  
 
Bowie, J.U., Clarke, N.D., Pabo, C.O., Sauer, R.T. (1990) Identification of protein folds: 
atching  hydrophobicity  patterns  of  sequence  sets  with  solvent  accessibility 
 
m
patterns of known structures. Proteins 7: 257‐64. 
 
Bray,  P.G.,  Deed,  S.,  Fox,  E.,  Kalkanidis,  M.,  Mungthin,  M.,  Deady,  L.W.,  Tilley,  L. 
2005)  Primaquine  synergises  the  activity  of  chloroquine  against  chloroquine‐
fa
(
resistant P.  lciparum. Biochem. Pharmacol. 70: 1158‐66.  
 
Bray,  P.G.,  Hawley,  S.R.,  Ward,  S.A.  (1996)  4‐Aminoquinoline  resistance  of 
lasmodium  falciparum:  insights  from  the  study  of  amodiaquine  uptake.  Mol. P
Pharmacol. 50: 1551‐8. 
 
reman,  J.G.  (2001) The ears of  the hippopotamus: manifestations, determinants 
nd estimates of the malaria burden. Am. J. Trop. Med. Hyg. 64: 1‐11. 
B
a
 
 
reman,  J.G.,  Alilio,  M.S.,  Mills,  A.  (2004)  Conquering  the  intolerable  burden  of      B
malaria: what’s new, what’s needed: a summary.  Am. J. Trop. Med. Hyg. 71: 1‐15. 
 
Brooks, B.R., Bruccoleri, R.E., Olafson, B.D., States, D.J., Swaminathan, S., Karplus, M. 
1983)  CHARMM:  A  program  for  macromolecular  energy,  minimization,  and (
dynamics calculations. J. Comput. Chem. 4: 187. 
 
Browne, W.J., North, A.C., Phillips, D.C., Brew, K., Vanaman, T.C., Hill, R.L.  (1969) A 
ossible  three‐dimensional  structure of bovine alpha‐lactalbumin based on  that of 
en's egg‐white lysozyme. J. Mol. Biol. 42: 65‐86.  
p
h
 
 179
 
 
 
 
Brunger,  A.T.,  Adams,  P.D.,  Clore,  G.M.,  DeLano,  W.L.,  Gros,  P.,  Grosse‐Kunstleve, 
R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., Read, R.J., Rice, L.M., Simonson, 
., Warren,  G.L.  (1998)  Crystallography & NMR  system:  A  new  software  suite  for T
macromolecular structure determination. Acta  Cryst. D. 54: 905‐21. 
 
runner,  J.  (1993).  New  photolabeling  and  crosslinking  methods.  Annu.  Rev. B
Biochem. 62:483‐514. 
 
anutescu, A.A., Shelenkov, A.A., Dunbrack, R.L. (2003) A graph‐theory algorithm for C
rapid protein side‐chain prediction. Protein Sci. 12: 2001‐14. 
 
Canyuk,  B.,  Medrano,  F.J.,  Wenck,  M.A.,  Focia,  P.J.,  Eakin,  A.E.,  Craig,  S.P.  (2004) 
Interactions  at  the  dimer  interface  influence  the  relative  efficiencies  for  purine 
ucleotide  synthesis  and  pyrophosphorolysis  in  a  phosphoribosyltransferase. 
0  
n
J.Mol.Biol. 335: 9 5‐21.
 
Chakrabarti,  S.,  John,  J.,  Sowdhamini,  R.  (2003)  Improvement  of  comparative 
odeling by the application of conserved motifs amongst distantly related proteins m
as additional restraints. J. Mol. Model. 10: 69‐75.  
 
Chong, C.R., Sullivan, D.J. (2003) Inhibition of heme crystal growth by antimalarials 
nd  other  compounds:  implications  for  drug discovery. Biochem. Pharmacol. 66: a
2201‐12. 
 
hothia, C., Lesk, A.M. (1986) The relation between the divergence of sequence and C
structure in proteins. EMBO J. 5: 823‐6. 
 
hothia, C., Lesk, A.M. (1987) Canonical structures for the hypervariable regions of C
immunoglobulins. J. Mol. Biol. 196: 901‐17.  
 
lark,  I.A.,  Alleva,  L.M., Mills,  A.C.,  Cowden, W.B.  (2004)  Pathogenesis  of malaria 
.  i
C
and clinically similar conditions Clin. Microb ol. Rev. 17: 509‐39. 
 
Clausen,  J.D.,  McIntosh,  D.B.,  Vilsen,  B.,  Woolley,  D.G.,  Andersen,  J.P.  (2006) 
Importance of conserved N‐domain residues Thr441, Glu442, Lys515, Arg560, and 
eu562 of sarcoplasmic reticulum Ca2+‐ATPase for MgATP binding and subsequent 
d
L
catalytic steps. Plasticity of the nucleotide‐bin ing site. J. Biol. Chem. 278: 20245‐58. 
 
ongreve,  M.,  Murray,  C.W.,  Blundell,  T.L.  (2005)  Structural  biology  and  drug 
Discov
C
discovery. Drug  . Today. 10: 895‐907.  
 
onnolly,  M.  L.  (1983)  Solvent‐accessible  surfaces  of  proteins  and  nucleic  acids. C
 180
Science 221: 709‐13.  
 
Cowman, A.F.  (1991) The P‐glycoprotein homologues of Plasmodium falciparum: 
Are they involved in chloroquine resistance? Parasitol. Today. 7: 70‐6. 
 
 
 
 
 
raig,  S.P.,  Eakin,  A.E.  (2000)  Purine  phosphoribosyltransferases.  J.  Biol  Chem. C
275: 20231‐4. 
 
Crehuet, R., Thomas, A., Field, M.J. (2005) An implementation of the nudged elastic 
and  algorithm  and  application  to  the  reaction mechanism  of  HGXPRTase  from b
Plasmodium falciparum. J. Mol. Graph. Model. 24: 102‐10.  
 
Dayhoff, M. O., Schwartz, R.M., Orcutt, B.C. (1978) A model of evolutionary change in 
roteins. Atlas of Protein Sequence and Structure 5,  (National Biomedical Research 
, D.C) Dayhoff, M.O., ed. pp. 345–352. 
p
Foundation, Washington
 
ean,  P.  D.,  Watson,  D.  H.  (1979)  Protein  purification  using  immobilised  triazine D
dyes. J. Chromatogr. 165: 301‐319. 
 
Deanne,  C.M.,  Blundell,  T.L.  (2000)  A  novel  exhaustive  search  algorithm  for 
redicting the conformation of polypeptide segments in proteins. Proteins 40: 135‐p
44. 
 
eanne, C.M., Blundell, T.L.  (2001) CODA: a combined algorithm  for predicting  the D
structurally variable regions of protein models. Protein Sci. 10: 599‐612. 
 
DeTitta,  G.T.,  Luft,  J.R.  (1995)  Rate  of  water  equilibration  in  vapor‐diffusion 
rystallization:  dependence  on  the  residual  pressure  of  air  in  the  vapor  space. c
Acta Crysta. D. 51: 786‐91. 
 
De  Wet,  H.,  McIntosh,  D.B.,  Conseil,  G.,  Baubichon‐Cortay,  H.,  Krell,  J.,  Jault,  J.M., 
Daskiewicz, J.B., Barron, D., DiPietro, A. (2001) Sequence requirements of the ATP‐
binding  site  within  the  C‐terminal  nucleotide‐binding  domain  of  mouse  P‐
lycoprotein: structure‐activity relationships for flavonoid binding. Biochemistry 40: g
10382‐91. 
 
orman, G., Prestwich, G.D. (2000) Using photolabile ligands in drug discovery and 
  : 64‐77. 
D
development. Trends Biotechnol. 18
 
Dorsey,  G,  Kamya,  M.R.,  Singh,  A.,  Rosenthal,  P.J.  (2001)  Polymorphisms  in  the 
lasmodium  falciparum  pfcrt  and  pfmdr‐1  genes  and  clinical  response  to P
chloroquine in Kampala, Uganda. J. Infect. Dis. 183: 1417‐20. 
 
unbrack, J.R. (2006) Sequence comparison and protein structure prediction. Curr. 
 
D
Opin. Struct. Biol. 16: 374‐84. 
 
Eads,  J.C.,  Scapin,  G.,  Xu,  Y.,  Grubmeyer,  C.,  Sacchettini,  J.C.  (1996)  The  crystal 
tructure of human hypoxanthine‐guanine phosphoribosyltransferase with bound 
MP. Cell 78: 325‐34. 
 181
s
G
 
 
 
 
 
Eckstein‐Ludwig, U., Webb, R,J., Van Goethem, I.D., East, J.M., Lee, A.G., Kimura, M., 
’Neill,  P.M.,  Bray,  P.G.,  Ward,  S.A.,  Krishna,  S.  (2003)  Artemisinins  target  the O
SERCA of Plasmodium falciparum. Nature 424: 957‐61. 
 
l  Kouni,  M.H.  (2003)  Potential  chemotherapeutic  targets  in  the  purine E
metabolism of parasites. Pharmacol. Ther. 99: 283‐309. 
uinoline‐  
 
   Famin, O., and Ginsbu  Differential effects  f 4
   containing emoglobin digestion ium   
rg, H. (2002) o ‐aminoq
 antimalarial drugs on h  in Plasmod
   falciparum‐infected erythrocytes. Biochem. Pharmacol. 63: 393‐8. 
 
 
 
Famin, O., Krugliak, M., Ginsburg, H.  (1999) Kinetics of  inhibition of  glutathione‐
ediated  degradation  of  ferriprotoporphyrin  IX  by  antimalarial  drugs. Biochem. m
Pharmacol. 58: 59‐68. 
 
Fedorov  A,  Shi  W,  Kicska  G,  Fedorov  E,  Tyler  PC,  Furneaux  RH,  Hanson  JC, 
Gainsford GJ, Larese JZ, Schramm VL, Almo SC. (2001) Transition  state structure 
f purine nucleoside phosphorylase and principles of atomic motion in enzymatic o
catalysis. Biochemistry 40: 853‐60. 
 
eng, D.F., Doolittle, R.F. (1987) Progressive sequence alignment as a prerequisite to F
correct phylogenetic trees. J. Mol. Evol. 25: 351‐60. 
 
ernandez‐Fuentes,  N.,  Zhai,  J.,  Fiser,  A.  (2006)  ArchPRED:  a  template  based  loop F
structure prediction server. Nucleic Acids Res. 34: 173‐6. 
 
Fidock,  D.A.,  Nomura,  T.,  Talley,  A.K.,  Cooper,  R.A.,  Dzekunov,  S.M.,  Ferdig,  M.T., 
Ursos, L.M., Sidhu, A.B., Naude, B., Deitsch, K.W., Su, X.Z., Wootton, J.C., Roepe, P.D., 
Wellems,  T.E.  (2000)  Mutations  in  the  P.  falciparum  digestive  vacuole 
ransmembrane  protein  PfCRT  and  evidence  for  their  role  in  chloroquine t
resistance. Mol. Cell 6: 861‐71.  
 
ischer,  D.,  Eisenberg,  D.  (2003)  Predicting  structures  for  genome  proteins.  Curr. 
9
F
Opin. Struct. Biol.  : 208‐11. 
 
iser,  A.  (2006)  Protein  structure  modeling  in  the  proteomics  era.  Expert  Rev. F
Proteomics 1: 97‐110. 
 
iser, A., Feig, M., Brooks, C.L., Sali, A. (2002) Evolution and physics in comparative F
protein structure modeling. Acc. Chem. Res. 35: 413‐21. 
 
ocia,  P.J.,  Craig,  S.P.,  Eakin,  A.E.  (1998)  Approaching  the  transition  state  in  the 
rystal structure of a phosphoribosyltransferase. Biochemistry 37: 17120‐7. 
 182
F
c
 
 
 
 
 
Focia, P.J.,  Craig,  S.P., Nieves‐Alicea, R.,  Fletterick, R.J.,  Eakin, A.E.  (1998) A 1.4 Å 
rystal structure for the hypoxanthine phosphoribosyltransferase of Trypanosoma 
ruzi. Biochemistry 37: 15066‐75.   
c
c
 
 
 
 
Freymann, D.M., Wenck, M.A., Engel, J.C., Feng, J., Focia, P.J., Eakin, A.E., Craig, S.P. 
2000)  Efficient  identification  of  inhibitors  targeting  the  closed  active  site 
r ion PRT from  an a . Biol. 7
(
confo mat  of the H Tryp osom  cruzi. Chem : 957‐68. 
 
Fry,  M.,  Pudney,  M.  (1992)  Site  of  action  of  the  antimalarial 
ydroxynaphthoquinone, 2‐[trans‐4‐(4'‐chlorophenyl) cyclohexyl]‐3‐hydroxy‐1,4‐h
naphthoquinone (566C80). Biochem. Pharmacol. 43: 1545‐53. 
 
allup,  J.L.,  Sachs,  J.D.  (2001) The economic burden of malaria. Am.  J. Trop. Med. G
Hyg. 64: 85‐96. 
 
Garg, R.K. (2000) Cerebral malaria. J. Assoc. Physicians India 48: 1004‐13. 
 
Gaur, D., Mayer, D.C., Miller, L.H. (2004) Parasite ligand‐host receptor interactions 
uring  invasion  of  erythrocytes  by  Plasmodium  merozoites.  Int.  J.  Parasitol.  34: d
1413‐29. 
 
inalski,  K.  (2006)  Comparative  modeling  for  protein  structure  prediction.  Curr. G
Opin. Struct. Biol. 16: 172‐7.  
 
insburg,  H.,  Krugliak,  M.  (1999)  Chloroquine  –  some  open  questions  on  its     G
antimalarial mode of action and resistance. Drug Resist. Updat. 2: 180‐7. 
 
Go, M., Go, N., Scheraga, H.A. (1970) Molecular theory of the helix‐coli transition in 
polyamino acids. II. Numerical evaluation of s and sigma for polyglycine and poly‐L‐
laine in the absence (for s and sigma) and presence (for sigma) of solvent. J. Chem. a
Phys. 52: 2060‐79. 
 
Greenwood, B., Mutabingwa, T. (2002) Malaria in 2002. Nature 415: 670‐72. 
 
reer,  J.  (1990)  Comparative  modeling  methods:  application  to  the  family  of  the G
mammalian serine proteases. Proteins 7: 317‐34.  
 
regson, A., Plowe, C.V.  (2005) Mechanisms of  resistance of malaria parasites  to 
.  v
G
antifolates Pharmacol. Re . 57: 117‐45. 
 
uex,  N.,  Peitsch,  M.C.  (2000)  SWISS‐MODEL  and  the  Swiss‐PdbViewer:  an 
nvironment for comparative protein modeling. Electrophoresis 18: 2714‐23. 
 183
G
e
 
 
 
 
 
 
anna, M. M., Bentsen, L., Lucido, M., and Sapre, A. (1999) RNA‐protein cross‐linking 
e l   l
H
with photoreactive nucleotid  ana og. Methods Mol. Bio . 118: 21‐33. 
 
Haque,  T.S.,  Skillman,  A.G.,  Lee,  C.E.,  Habashita,  H.,  Gluzman,  I.Y.,  Ewing,  T.J., 
Goldberg, D.E., Kuntz,  I.D., Ellman,  J.A.  (1999) Potent,  low‐molecular‐weight non‐
eptide  inhibitors  of malarial  aspartyl  protease  plasmepsin  II.  J. Med. Chem. 42: p
1428‐40.  
 
ardy,  L.W.,  Malikayil,  A.  (2003)  The  impact  of  structure‐guided  drug  design  on 
Discov
H
clinical agents. Curr. Drug  . 4: 15–20. 
 
astings,  I.M.,  Bray,  P.G.,  Ward,  S.A.  (2002)  A  requiem  for  chloroquine.  Science H
298: 74‐5. 
 
Hendlich, M., Lackner, P., Weitckus, S., Floeckner, H., Froschauer, R., Gottsbacher, K., 
Casari,  G.,  Sippl, M.J.  (1990)  Identification  of  native  protein  folds  amongst  a  large 
umber  of  incorrect  models.  The  calculation  of  low  energy  conformations  from n
potentials of mean force. J. Mol. Biol. 216: 167‐80. 
 
enikoff, S., Henikoff, J.G. (1993) Performance evaluation of amino acid substitution H
matrices. Proteins 17: 49‐61.  
 
Henry, M., Alibert., S., Orlandi‐Pradines, E., Bogreau, H., Fusai, T., Rogier, C., Barbe, 
.,  Pradines,  B.  (2006)  Chloroquine  resistance  reversal  agents  as  promising J
antimalarial drugs. Curr. Drug Targets 7: 935‐48.  
 
Heroux, A., White, E.L., Ross, L.J., Davis, R.L., Borhani, D.W. (1999) Crystal structure 
of Toxoplasma gondii hypoxanthine‐guanine phosphoribosyltransferase with XMP, 
yrophosphate,  and  two  Mg(2+)  ions  bound:  insights  into  the  catalytic p
mechanism. Biochemistry 38: 14495‐506.   
 
Heroux,  A., White,  E.L.,  Ross,  L.J.,  Borhani,  D.W.  (1999)  Crystal  structures  of  the 
Toxoplasma  gondii  hypoxanthine‐guanine  phosphoribosyltransferase‐GMP  and  ‐
MP complexes: comparison of purine binding interactions with the XMP complex. I
Biochemistry 38: 14485‐94. 
 
Hohenester, E., Maurer, P., Hohenadl, C., Timpl, R.,  Jansonius, J.N., Engel,  J. (1996) 
tructure  of  a  novel  extracellular  Ca(2+)‐binding  module  in  BM‐40. Nat.  Struct. S
Biol. 3: 67‐73. 
 
olm,  L.,  Sander,  C.  (1998) Dictionary of  recurrent domains  in  protein  structures. 
roteins 33: 88‐96.  
H
P
 
 184
 
 
 
 
Huy, N.T., Kamei, K., Kondo, Y., Serada, S., Kanaori, K., Takano, R., Tajima, K., Hara, 
. (2002) Effect of antifungal azoles on the heme detoxification system of malarial 
 
S
parasite. J. Biochem. 131: 437‐44.  
 
Ismaili,  J.,  Van  der  Sande, M.,  Holland, M.J.,  Sambou,  I.,  Keita,  S.,  Allsopp,  C.,  Ota, 
.O., McAdam, K.P.W.J., Pinder, M. (2003) Plasmodium falciparum  infection of the 
 
M
placenta affects newborn immune responses. Clin. Exp. Immunol. 133: 414‐21. 
 
ones, D.T.  (1994) De novo protein design using pairwise potentials  and a  genetic J
algorithm. Protein Sci. 3: 567‐74. 
 
ones, D.T. (1999) GenTHREADER: An efficient and reliable protein fold recognition J
method for genomic sequences. J. Mol. Biol. 287: 797‐815. 
 
ones, D.T. (1999) Protein secondary structure prediction based on position‐specific J
scoring matrices. J. Mol. Biol. 292: 195‐202.   
 
ones,  D.T.,  Taylor,  W.R.,  Thornton,  J.M.  (1992)  A  new  approach  to  protein  fold J
recognition. Nature 358: 86‐9. 
 
ones, T.A., Thirup, S. (1986) Using known substructures in protein model building 
   
J
and crystallography. EMBO J. 5: 819‐22.
 
han,  S.M.,  and  Walters,  A.P.  (2004)  Malaria  parasite  transmission  stages:  an       K
update. Trends Parasitol. 20: 575‐80. 
 
Keana, J.F.W., Cai, S.X. (1990) New reagents for photoaffinity labeling: synthesis and 
 photolysis of functionalized perfluorophenyl azides. J. Org. Chem. 55: 3640‐47. 
 
elley,  L.A., MacCallum, R.M.,  Sternberg, M.J.  (2003) Enhanced  genome annotation 
sing structural profiles in the program 3D‐PSSM. J. Mol. Biol. 299: 499‐520. 
K
u
 
 
 
Keough, D.T., Ng, A.L., Winzor, D.J., Emmerson, B.T., de Jersey, J. (1999) Purification 
and  characterization  of  Plasmodium  falciparum  hypoxanthine‐guanine‐xanthine 
hosphoribosyltransferase  and  comparison  with  the  human  enzyme.  Mol. p
Biochem. Parasitol. 98: 29‐41. 
 
irk K. (2004) Channels and transporters as drug targets in the Plasmodium‐K
infected erythrocyte. Acta Trop. 89: 285‐98. 
 
Kline, P.C., Schramm, V.L.  (1995) Pre‐steady‐state  transition‐state analysis of  the 
ydrolytic  reaction  catalyzed  by  purine  nucleoside  phosphorylase.  Biochemistry 
4: 1153‐62.  
 185
h
3
 
 
 
 
 
Koehl, P., Delarue, M. (1995) A self consistent mean field approach to simultaneous 
ap  closure and side‐chain positioning  in homology modelling. Nat. Struct. Biol. 2: g
163‐70.    
 
oehl,  P.,  Levitt,  M.  (1999)  Structure‐based  conformational  preferences  of  amino K
acids. PNAS 96: 12524‐9. 
 
Kohler, S., Delwiche, C.F., Denny, P.W., Tilney, L.G., Webster, P., Wilson, R.J., Palmer, 
J.D.,  Roos,  D.S.  (1997)  A  plastid  of  probable  green  algal  origin  in  Apicomplexan 
Sparasites.  cience 275: 1485‐9. 
 
oppisch,  A.T.,  Fox,  D.T.,  Blagg,  B.S.,  Poulter,  C.D.  (2002)  E.  coli  MEP  synthase: 
 kin a
K
steady‐state etic an lysis and substrate binding.  Biochemistry 41: 236‐43.  
 
Korsinczky,  M.,  Chen,  N.,  Kotecka,  B.,  Saul,  A.,  Rieckmann,  K.,  Cheng,  Q.  (2000) 
Mutations  in  Plasmodium  falciparum  cytochrome  b  that  are  associated  with 
atovaquone  resistance  are  located  at  a  putative  drug‐binding  site.  Antimicrob. 
Agents Chemother. 44: 2100‐8. 
 
Kuhn, P., Wilson, K., Patch, M.G., Stevens, R.C. (2002) The genesis of high‐throughput 
structure‐based  drug  discovery  using  protein  crystallography.    Curr.  Opin.  Chem. 
Biol. 6: 704‐10. 
 
Kurreck,  J.  (2003)  Antisense  technologies:  Improvement  through  novel  chemical 
odifications. Eur. J. Biochem.  m 270: 1628–44. 
 
 
 
uznestov, Y.G., Larson, S.B., Day, J., Greenwood, A., McPherson, A. (2001) Structural K
transitions of satellite tobacco mosaic virus particles. Virology 284: 223‐34. 
 
Laskowski,  R.A., MacArthur, M.W., Moss,  D.S.,  Thornton,  J.M.  (1993)  PROCHECK:  a 
rogram to check the stereochemical quality of protein structures. J. Appl. Cryst. 26: p
283‐91. 
 
attman,  E.E.,  Rose,  G.D.  (1993)  Protein  folding‐what's  the  question? L
PNAS 90: 439‐41. 
 
eavitt,  S.,  Freire,  E.  (2001) Direct measurement  of  protein  binding  energetics  by 
 
L
isothermal titration calorimetry. Curr. Opin. Struct. Biol. 11: 560‐66. 
 
Lee,  C.C.,  Craig,  S.P.,  Eakin,  A.E.  (1998)  A  single  amino  acid  substitution  in  the 
uman  and  a  bacterial  hypoxanthine  phosphoribosyltransferase  modulates 
pecificity for the binding of guanine. Biochemistry 37: 3491‐8. 
h
s
 
 186
 
 
 
 
Lesk, A.M., Chothia, C. (1980) How different amino acid sequences determine similar 
rotein  structures:  the  structure  and  evolutionary dynamics  of  the  globins.  J. Mol. p
Biol. 136: 225‐70.  
 
evitt, M. (1992) Accurate modeling of protein conformation by automatic segment L
matching.  J. Mol. Biol. 226: 507‐33.   
 
Li, R., Chen, X., Gong, B.,  Selzer, P.M., Li, Z., Davidson, E., Kurzban, G., Miller, R.E., 
Nuzum,  E.O.,  McKerrow,  J.H.,  Fletterick,  R.J.,  Gillmor,  S.A.,  Craik,  C.S.,  Kuntz,  I.D., 
ohen,  F.E.,  Kenyon,  G.L.  (1996)  Structure‐based  design  of  parasitic  protease 
ib .   M C
C
inh itors Bioorg. ed.  hem.4: 1421‐7. 
 
Li,  Y.Z.,  Kirby,  J.P.,  George,  M.W.,  Poliakoff,  M.,  Schuster,  G.B.  (1988) 
1,2‐Didehydroazepines  from  the  photolysis  of  substituted  aryl  azides:  analysis  of 
heir  chemical  and  physical  properties  by  time‐resolved  spectroscopic methods.  J. t
Am. Chem. Soc. 110: 8092‐8. 
 
Lipinski,  C.A.,  Lombardo,  F.,  Dominy,  B.W.,  Feeney,  P.J.  (1997)  Experimental  and 
omputational approaches to estimate solubility and permeability in drug discovery 
nd development settings. Advanced Drug Delivery Reviews. 23: 3‐25. 
c
a
 
 
ipman,  D.J.,  Altschul,  S.F.,  Kececioglu,  J.D.  (1989)  A  tool  for  multiple  sequence 
.
L
alignment  PNAS 86: 4412‐5. 
 
Loria,  P.,  Miller,  S.,  Foley,  M.,  Tilley,  L.  (1999)  Inhibition  of  the  peroxidative 
egradation  of  haem  as  the  basis  of  action  of  chloroquine  and  other  quinoline d
antimalarials. Biochem. J. 339: 363‐370. 
 
Lovell,  S.C.,  Word,  J.M.,  Richardson,  J.S.,  Richardson,  D.C.  (2000)  The  penultimate 
   :rotamer library. Proteins 40  389‐408. 
 
aitland,  K.,  Makanga,  M.,  Williams,  T.N.  (2004)  Falciparum  malaria:  current M
therapeutic challenges. Curr. Opin. Infect. Dis. 17: 405‐12. 
 
aitland, K., Marsh, K. (2004) Pathophysiology of severe malaria in children. Acta M
Trop. 90: 131‐40. 
 
Marti‐Renom,  M.A.,  Stuart,  A.C.,  Fiser,  A.,  Sanchez,  R.,  Melo,  F.,  Sali,  A.  (2000) 
omparative protein structure modeling of genes and genomes. Annu. Rev. Biophys 
S
C
.Biomol.  truct. 29: 291‐325. 
 
Mbewe,  B.  (2005)  Cloning,  expression,  purification  and  drug  targeting  of 
lasmodium falciparum hypoxanthine guanine xanthine phosphoribosyltransferase, 
h.D. Thesis, University of Cape Town, South Africa.   
 187
P
P
 
 
 
 
 
Mbewe, B., Chibale, K., McIntosh, D.B. (2007) Purification of human malaria parasite 
hypoxanthine guanine xanthine phosphoribosyltransferase (HGXPRT) using 
immobilized Reactive Red 120. Protein Expr. Purif. 52: 153-58.   
 
cIntosh, D.B., Parrish, J.C., Wallace, C.J. (1996) Definition of a nucleotide binding 
1: 18379‐86. 
M
site on cytochrome c by photoaffinity labeling. J. Biol. Chem. 27
 
 in   
McGready, R., Cho, T., Villegas, L., Brockman, A., van Vugt, M.,  
en, F. (2001) A tem imalarials
t study of 539 pi ltidrug‐ 
Looareesuwan, S., White, N.J., Nost r isinin ant
regnancy: a prospective treatmen  e sodes of mup
resistant Plasmodium falciparum. Clin. Infect. Dis. 33: 2009‐16. 
 
cGuffin,  L.J.,  Jones,  D.T.  (2003)  Improvement  of  the  GenTHREADER  method  for M
genomic fold recognition. Bioinformatics 19: 874‐81. 
 
cPherson,  A.  (1999)  Crystallization  of  biological  macromolecules.  Cold  Spring M
Harbour Laboratory Press, New York, USA. 
 
Meshnick,  S.R., Taylor, T.E., Kamchonwongpaisan,  S.,  (1996) Artemisinin  and  the 
ntimalarial  endoperoxides:  from  herbal  remedy  to  targeted  chemotherapy. a
Microbiol. Rev. 60: 301‐15. 
 
iller, H.L., Baruch, D.I., Marsh, K., Doumbo, O.K.  (2002) The pathogenic basis of M
Malaria. Nature 415: 673‐79. 
 
Mizuguchi, K., Deane, C.M., Blundell, T.L., Johnson, M.S., Overington, J.P. (1998) JOY: 
is.protein sequence‐structure representation and analys  Bioinformatics 14: 617‐23. 
Moore,  J.  T.,  Uppal,  A.,  Maley,  F.,  Maley,  G.  F.  (1993)  Overcoming  Inclusion  Body 
Formation in a High‐Level Expression System. Protein Expression and Purification 4: 
160‐168. 
ota,  M.M.,  Hafalla,  J.C.,  Rodriguez,  A.  (2002)  Migration  through  host  cells M
activates Plasmodium sporozoites for infection. Nat. Med. 8: 1318‐22. 
 
Mota, M.M., Pradel, G., Vanderberg, J.P., Hafalla, J.C., Frevert, U., Nussenzweig, R.S., 
ussenzweig,  V.,  Rodriguez,  A.  (2001)  Migration  of  Plasmodium  sporozoites 
nce
N
through cells before infection. Scie  291: 24‐5. 
 
ota, M.M.,  Rodriguez, A.  (2001) Migration  through host  cells  by  apicomplexian 
1  
M
parasites. Microbes Infect. 3:  123‐8.
 
Munagala,  N.,  Basus,  V.J.,  Wang,  C.C.  (2001)  Role  of  the  flexible  loop  of 
ypoxanthine‐guanine‐xanthine  phosphoribosyltransferase  from  Tritrichomonas 
oetus in enzyme catalysis. Biochemistry 14: 4303‐11. 
 188
h
f
 
 
 
 
 
Murzin,  A.G.,  Brenner,  S.E.,  Hubbard,  T.,  Chothia,  C.  (1995)  SCOP:  a  structural 
lassification of proteins database for the investigation of sequences and structures. c
J. Mol. Biol. 247: 536‐40. 
 
Musick,  W.D.  (1981)  Structural  features  of  the  phosphoribosyltransferases  and 
heir  relationship  to  the  human  deficiency  disorders  of  purine  and  pyrimidine t
metabolism. CRC Crit. Rev. Biochem. 11: 1‐34. 
 
eedleman, S.B., Wunsch, C.D. (1970) A general method applicable to the search for N
similarities in the amino acid sequence of two proteins. J. Mol. Biol. 48: 443‐53. 
 
issani,  E.,  Ginsburg  H.  (1989)  Protonophoric  effects  of  antimalarial  drugs  and N
alkylamines in Escherichia coli membranes. Biochim. Biophys. Acta 978: 293‐8. 
 
otredame, C., Higgins, D.G., Heringa, J. (2000) T‐Coffee: A novel method for fast and N
accurate multiple sequence alignment. J. Mol. Biol. 302: 205‐17. 
 
Ockenhouse, C.F., Tegoshi, T., Maeno, Y., Benjamin, C., Ho, M., Kan, K.E., Thway, Y., 
Win, K., Aikawa, M.,  Lobb, R.R.  (1992) Human vascular endothelial  cell  adhesion 
receptors  for Plasmodium  falciparum‐infected  erythrocytes:  roles  for  endothelial 
eukocyte adhesion molecule 1 and vascular cell adhesion molecule 1. J. Exp. Med. 
8
l
176: 11 3‐9. 
 
lliaro,  P.  (2001) Mode  of  action  and mechanisms  of  resistance  for  antimalarial O
drugs. Pharmacol.Ther. 89: 207‐19. 
 
Orengo, C.A., Michie, A.D., Jones, S., Jones, D.T., Swindells, M.B., Thornton, J.M. (1997) 
ATH‐a  hierarchic  classification  of  protein  domain  structures.  Structure  5:  1093‐C
108. 
 
Panchenko, A.R., Wolf, Y.I., Panchenko, L.A., Madej, T. (2005) Evolutionary plasticity 
f protein families: coupling between sequence and structure variation. Proteins 61: o
535‐44.  
 
asvol  G.  (2003)  How many  pathways  for  invasion  of  the  red  blood  cell  by  the P
malaria parasite? Trends Parasitol. 19: 430‐2. 
 
earson,  W.R.,  Lipman,  D.J.  (1988)  Improved  tools  for  biological  sequence P
comparison. PNAS 85: 2444‐8. 
 
edersen, J.T., Moult, J. (1995) Ab initio structure prediction for small polypeptides P
 189
and protein fragments using genetic algorithms. Proteins 23: 454‐60. 
 
Peterson,  R.W.,  Dutton,  P.L.,  Wand,  A.J.  (2004)  Improved  side‐chain  prediction 
accuracy  using  an  ab  initio  potential  energy  function  and  a  very  large  rotamer 
library. Protein Sci. 13: 735‐51. 
 
 
 
 
 
 
etrella,  R.J.,  Karplus,  M.  (2001)  The  energetics  of  off‐rotamer  protein  side‐chain 
1  
P
conformations. J. Mol. Biol. 312: 116 ‐75.
 
Phehane,  V.  N.  (2002)  Expression  and  drug  targeting  of  parasite  hypoxanthine‐
uanine  phosphoribosyltransferase  (HGXPRT),  Ph.D.  Thesis,  University  of  Cape g
Town, South Africa. 
 
Polshakov, D., Rai, S., Wilson, R.M., Mack, E.T., Vogel, M., Krause, J.A., Burdzinski, G., 
Platz, M.S. (2005) Photoaffinity  labeling with 8‐azidoadenosine and its derivatives: 
hemistry of closed and opened adenosine diazaquinodimethanes. Biochemistry 44: c
11241‐53. 
 
Queen, S.A., Vander‐Jagt, D., Reyes, P. (1988) Properties and substrate specificity of 
 purine phosphoribosyltransferase from the human malaria parasite, Plasmodium a
falciparum. Mol. Biochem. Parasitol. 30: 123‐33. 
C., McFadden, G.I. (2001) The apicoplast as an   
 
alph, S.A., D’Ombrain, M.R
 antimalarial drug target. Drug Resist. Updat. 4: 145‐51.  
 
amachandran, G.N., Ramakrishnan, C., Sasisekharan, V. (1963) Stereochemistry of 
J
R
polypeptide chain configurations.  . Mol. Biol. 7: 95‐9.  
 
Raman,  J.,  Ashok,  C.S.,  Subbayya,  S.I.,  Anand,  R.P.,  Selvi,  S.T.,  Balaram,  H.  (2005) 
lasmodium  falciparum  hypoxanthine  guanine  phosphoribosyltransferase. P
Stability studies on the product‐activated enzyme. FEBS J. 272: 1900‐11. 
 
app, C.S.,  Friesner, R.A.  (1999) Prediction of  loop geometries using a generalized R
born model of solvation effects. Proteins 35: 173‐83. 
 
Reed, M.B., Saliba, K.J., Caruana, S.R., Kirk, K., Cowman, A.F. (2000) Pgh1 modulates 
ensitivity  and  resistance  to  multiple  antimalarials  in  Plasmodium  falciparum. s
Nature 403: 906‐9. 
 
Reeder, J.C., Cowman, A.F., Davern, K.M., Beeson, J.G., Thompson, J.K., Rogerson, S.J., 
Brown, G.V. (1999) The adhesion of Plasmodium falciparum‐infected erythrocytes 
o  chondroitin  sulfate  A  is  mediated  by  P.  falciparum  erythrocyte  membrane 
rotein 1. PNAS 96: 5198‐202. 
t
p
 
 
 
etief, J.D. (2000) Phylogenetic analysis using PHYLIP. Methods Mol. Biol. 132: 243‐
8. 
R
5
 
 190
 
 
 
 
Ridley  R.G.,  (2002)  Medical  need,  scientific  opportunity  and  the  drive  for 
antimalarial drugs. Nature 415: 686‐93. 
 
Ridley, R.G., Dorn, A., Vippagunta, S.R., Vennerstrom, J.L. (1997) Haematin (haem) 
olymerization  and  its  inhibition  by  quinoline  antimalarials.  Ann.  Trop.  Med. 
: ‐  
p
Parasitol. 91  559 66.
 
Rizk,  M.S.,  Shi,  X.,  Platz,  M.S.  (2006)  Lifetimes  and  reactivities  of  some 
,2‐didehydroazepines  commonly  used  in  photoaffinity  labeling  experiments  in 1
aqueous solutions. Biochemistry 45: 543‐51. 
 
Roberts, D.D., Haverstick, D.M., Dixit, V.M., Frazier, W.A., Santoro, S.A., Ginsburg, V. 
1985)  The  platelet  glycoprotein  thrombospondin  binds  specifically  to  sulfated (
glycolipids. J.  Biol.  Chem. 260: 9405‐11.  
 
osenthal PJ. (2003) Antimalarial drug discovery: old and new approaches. J. Exp. R
Biol. 206: 3735‐44.  
 
Rost, B. (1997) Protein structures sustain evolutionary drift. Fold. Des. 2: 19‐24.   
 
Russell, R.B., Saqi, M.A., Sayle, R.A., Bates, P.A., Sternberg, M.J. (1997) Recognition of 
nalogous  and  homologous  protein  folds:  analysis  of  sequence  and  structure 
onservation. J. Mol. Biol. 269: 423‐39. 
a
c
 
 
achs,  J., Malaney,  P.  (2002) The  economic  and  social  burden of malaria. Nature S
415: 680‐85. 
 
ali, A. (1995) Modeling mutations and homologous proteins. Curr. Opin. Biotechnol. S
6: 437‐51. 
 
anchez,  R.,  Sali,  A.  (1998)  Large‐scale  protein  structure  modeling  of  the 
accharomyces cerevisiae genome. PNAS 95: 13597‐602. 
S
S
 
 
 
 
Sanchez, C.P., Stein, W., Lanzer, M. (2003) Trans stimulation provides evidence for 
  drug  efflux  carrier  as  the mechanism of  chloroquine  resistance  in Plasmodium a
falciparum. Biochemistry 42: 9383‐94. 
 
auder,  J.M., Arthur,  J.W., Dunbrack, R.L.  (2000) Large‐scale comparison of protein S
 191
sequence alignment algorithms with structure alignments. Proteins  40: 6‐22. 
 
Scapin,  G.,  Grubmeyer,  C.,  Sacchettini,  J.C.  (1994)  Crystal  structure  of  orotate 
phosphoribosyltransferase. Biochemistry 33: 1287‐94. 
 
 
 
 
 
chramm, V.L.,  Shi, W.  (2001) Atomic motion  in  enzymatic  reaction  coordinates. S
Curr. Opin. Struct. Biol. 11: 657‐65.  
 
Sculley, D.G., Dawson, P.A.,  Emmerson, B.T., Gordon, R.B.  (1992) A  review of  the 
olecular  basis  of  hypoxanthine‐guanine  phosphoribosyltransferase  (HPRT) 
H 5 . 
m
deficiency.  um .Genet. 90: 19 ‐207
 
Seebregts,  C.J.,  McIntosh,  D.B.  (1989)  2',3'‐O‐(2,4,6‐trinitrophenyl)‐8‐azido‐
adenosine mono‐, di‐, and triphosphates as photoaffinity probes of the Ca2+‐ATPase 
f  sarcoplasmic  reticulum.  Regulatory/superfluorescent  nucleotides  label  the 
e  
o
catalytic sit  with high efficiency. J. Biol. Chem. 264: 2043‐52. 
 
Sidhu,A.B.,  Verdier‐Pinard,  D.,  Fidock,  D.A.  (2002)  Chloroquine  resistance  in 
lasmodium  falciparum  malaria  parasites  conferred  by  pfcrt  mutations.  Science 
10  
P
298: 2 ‐3.
 
ingh,  A.,  Thornton,  E.R.,  Westheimer,  F.H.  (1962)  The  photolysis  of S
diazoacetylchymotrypsin. J. Biol. Chem. 237: 3006‐8. 
 
inha, S.C., Smith,  J.L. (2001) The PRT protein family. Curr. Opin. Struct.   Biol. 11: S
733‐9. 
 
ippl, M.J. (1995) Knowledge‐based potentials for proteins. Curr. Opin. Struct. Biol. 5: S
229‐35. 
 
Shi,  J.,  Blundell,  T.L.,  Mizuguchi,  K.  (2001)  FUGUE:  sequence‐structure  homology 
ecognition using environment‐specific substitution tables and structure‐dependent r
gap penalties. J. Mol. Biol. 310: 243‐57. 
 
Shi, W., Li, C.M., Tyler, P.C., Furneaux, R.H., Grubmeyer, C., Schramm, V.L., Almo, S.C. 
(1999)  The  2.0  Å  structure  of  human  hypoxanthine‐guanine 
hosphoribosyltransferase  in  complex  with  a  transition‐state  analog  inhibitor. p
Nat. Struct. Biol. 6: 588‐93. 
 
Shi, W., Li, C.M., Tyler, P.C., Furneaux, R.H., Cahill, S.M., Girvin, M.E., Grubmeyer, C., 
Schramm,  V.L.,  Almo,  S.C.  (1999)  The  2.0  Å  structure  of  malarial  purine 
hosphoribosyltransferase  in  complex with a  transition‐state analogue  inhibitor. 
3
p
Biochemistry  8: 9872‐80. 
 
mith,  T.F.,  Waterman,  M.S.  (1981)  Identification  of  common  molecular S
 192
subsequences. J. Mol. Biol. 147: 195‐7. 
 
Snow,  R.W.,  Guerra,  C.A.,  Noor,  A.M.,  Myint,  H.Y.,  Hay,  S.I.  (2005)  The  global 
distribution  of  clinical  episodes  of  Plasmodium  falciparum  malaria. Nature 434: 
214‐217. 
 
 
 
 
 
Somoza,  J.R.,  Chin,  M.S.,  Focia,  P.J.,  Wang,  C.C.,  Fletterick,  R.J.  (1996)  Crystal 
tructure  of  the  hypoxanthine‐guanine‐xanthine phosphoribosyltransferase  from 
o  
s
the protozoan parasite Tritrichomonas f etus. Biochemistry 35: 7032‐40. 
 
Srinivasan,  N.,  Blundell,  T.L.  (1993)  An  evaluation  of  the  performance  of  an 
utomated  procedure  for  comparative  modelling  of  protein  tertiary  structure. a
Protein Eng. 6: 501‐12.  
for the synergistic   
    
Sri K., Vaidya, A.B. (1999) A mechanism 
ant  action of atovaquone and proguanil. Antimicrob. Agents Chemother.  
    vastava, I.
   imalarial
  43
 
 
 
: 1334‐9. 
Staines, H.M., Ellory, J.C., Chibale K. (2005) The new permeability pathways: targets 
nd  selective  routes  for  the development of new antimalarial  agents. Comb. Chem. a
High Throughput Screen. 8: 81‐8. 
 
Stoye,  J., Evers, D., Meyer, F.  (1997) Generating benchmarks  for multiple sequence 
lignments and phylogenetic reconstructions. Proc. Int. Conf. Intell. Syst. Mol. Biol. 5: a
    
303‐6. 
 
ubbayya,  I.N.,  Ray,  S.S.,  Balaram,  P.,  Balaram  H.  (1997)  Metabolic  enzymes  as 
 
S
    
potential drug targets in Plasmodium falciparum. Indian J. Med. Res. 106: 79‐94. 
 
Sujjay Subbayya,  I.N., Sukumaran, S., Shivashankar, K., Balaram, H.  (2000) Unusual 
substrate specificity of a chimeric hypoxanthine‐guanine phosphoribosyltransferase 
ontaining  segments  from  the  Plasmodium  falciparum  and  human  enzymes.  c
Biochem. Biophys. Res. Commun. 272: 596‐602. 
protection against blood stages o
 
., Surolia, A. (2001) Triclosan offers  f  
y inhibiting enoyl‐ACP reductase of Plasmodium falciparum. Nat. Med. 7:  
   Surolia, N
   malaria b
   167‐73. 
 
Sutcliffe,  M.J.,  Hayes,  F.R.,  Blundell,  T.L.  (1987)  Knowledge  based  modelling  of 
omologous proteins, part II: rules for the conformations of substituted side chains. h
Protein Eng. 1: 385‐92. 
 
wain, M.T., Kemp, G.J. (2001) Modelling of protein side‐chain conformations using 
l
S
constraint  ogic programming. Comput. Chem. 26: 85‐95. 
 
animura,  R.,  Kidera,  A.,  Nakamura, H.  (1994) Determinants  of  protein  side‐chain T
 193
packing. Protein Sci. 3: 2358‐65. 
 
Tao,  W.,  Grubmeyer,  C.,  Blanchard,  J.S.  (1996)  Transition  state  structure  of 
Salmonella  typhimurium orotate phosphoribosyltransferase. Biochemistry 35: 14‐
21. 
 
 
 
 
 
aylor,  W.R.  (1988)  A  flexible  method  to  align  large  numbers  of  biological 
 
T
sequences. J. Mol. Evol. 28: 161‐9. 
 
en Eyck, L.F.  (1985) Fast Fourier  transform calculation of electron density maps. T
Methods Enzymol. 115: 324‐37. 
 
ickle, A.,  Sharff, A., Vinkovic, M.,  Yon,  J.,  Jhoti, H.  (2004) High‐throughput protein 
  : 558‐65. 
T
crystallography and drug discovery. Chem.  Soc. Rev. 33
 
Thomas  A,  Field  MJ.  (2002)  Reaction  mechanism  of  the  HGXPRTase  from 
lasmodium  falciparum:  a  hybrid  potential  quantum  mechanical/molecular P
mechanical study. J. Am. Chem. Soc. 124: 12432‐8. 
 
homas, P.J., Qu, B.H., Pedersen, B.L.  (1995) Defective protein  folding as a basis of 
uman disease. Trends Biochem. Sci. 20: 456‐9. 
T
h
 
 
Thompson,  J.D.,  Higgins,  D.G.,  Gibson,  T.J.  (1994)  CLUSTAL  W:  improving  the 
sensitivity of progressive multiple sequence alignment through sequence weighting, 
osition‐specific  gap  penalties  and  weight  matrix  choice.  Nucleic  Acids  Res.  22: p
4673‐80.   
 
odd,  A.E.,  Orengo,  C.A.,  Thornton,  J.M.  (2001)  Evolution  of  function  in  protein T
superfamilies, from a structural perspective. J. Mol. Biol. 307: 1113‐43. 
 
rampuz,  A.,  Jereb,  M.,  Muzlovic,  I.,  Prabhu,  R.M.  (2003)  Clinical  review:  severe 
 7
T
malaria. Crit. Care : 315‐23. 
 
Udomsangpetch,  R.,  Webster,  H.K.,  Pattanapanyasat,  K.,  Pitchayangkul,  S., 
Thaithong, S. (1992) Cytoadherence characteristics of rosette-forming Plasmodium 
falciparum. Infect. Immun. 60: 4483‐90.  
 
arghese,  J.N.  (1999)  Development  of  neuraminidase  inhibitors  as  anti‐influenza 
Drug
V
virus drugs.   Dev. Res. 46: 176–96. 
 
asquez,  M  (1996)  Modeling  side‐chain  conformation.  Curr.  Opin.  Struct.  Biol.  6: V
217‐21. 
 
lijmen,  H.W.,  Karplus, M.  (1997)  PDB‐based  protein  loop  prediction:  parameters 
  ods for optimization.  .  :
V
for selection and meth J. Mol Biol. 267  975‐1001. 
 
Voigt,  C.A.,  Gordon,  D.B.,  Mayo,  S.L.  (2000)  Trading  accuracy  for  speed:  A 
uantitative  comparison  of  search  algorithms  in  protein  sequence  design.  J. Mol. 
iol. 299: 789‐803. 
 194
q
B
 
 
 
 
 
Vos,  S.,  de  Jersey,  J.,  Martin,  J.L.  (1997)  Crystal  structure  of  Escherichia  coli 
sphoribosyltransfera 3xanthine pho se. Biochemistry  6: 4125‐34. 
  
ard,  W.H.,  Holdgate,  G.A.  (2001)  Isothermal  titration  calorimetry  in  drug W
discovery. Prog. Med. Chem. 38: 309‐76. 
 
Warhurst, D.C.  (2003) Polymorphism in the Plasmodium  falciparum  chloroquine‐
resistance  transporter  protein  links  verapamil  enhancement  of  chloroquine 
ensitivity  with  the  clinical  efficacy  of  amodiaquine. s
(http://www.malariajournal.com/content/2/1/31) 
 
 
ellems, T.E., Plowe, C.V. (2001) Chloroquine‐resistant malaria. J. Infect. Dis. 184: W
770‐6. 
 
White, N.J. (2004) Antimalarial drug resistance. J. Clin. Invest. 113: 1084‐92. 
 
Wiener,  J.,  Hintz,  M.,  Altincicek,  B.,  Sanderbrand,  S.,  Weidemeyer,  C.,  Beck,  E., 
maa,  H.  (2000)  Plasmodium  falciparum:  detection  of  the  deoxyxylulose  5‐
 
Jo
phosphate reductoisomerase activity. Exp. Parasitol. 96: 182‐6.    
  
iesner,  J.,  Borrmann,  S.,  Jomaa,  H.  (2003)  Fosmidomycin  for  the  treatment  of W
malaria. Parasitol. Res. 90: 71‐6. 
 
Wilson, C.M., Serrano, A.E., Wasley, A., Bogenschutz, M.P., Shankar, A.H., Wirth, D.F. 
1989) Amplification of a gene related to mammalian mdr genes in drug‐resistant (
Plasmodium falciparum. Science 244: 1184‐6.  
 
Wilson, R.J. (2002) Progress with parasite plastids. J. Mol. Biol. 319: 257‐74. 
 
instanley,  P.A.  (2000)  Chemotherapy  for  falciparum malaria:  the  armoury,  the W
problems and the prospects. Parasitol. Today 16: 146‐53. 
 
Winstanley, P.A., Coleman,  J.W., Maggs,  J.L., Breckenridge, A.M., Park, B.K.  (1990) 
The  toxicity  of  amodiaquine  and  its  principal metabolites  towards mononuclear 
eucocytes and granulocyte/monocyte colony forming units. Br. J. Clin. Pharmacol. l
29: 479‐85. 
 
ood, T.C., Pearson, W.R.  (1999) Evolution of protein sequences and structures.  J. W
Mol. Biol. 291: 977‐95. 
 
Wright,  C.W.,  Addae‐Kyereme,  J.,  Breen,  A.G.,  Brown,  J.E.,  Cox,  M.F.,  Croft,  S.L., 
Gokcek, Y., Kendrick, H., Phillips, R.M., Pollet, P.L .(2001) Synthesis and evaluation 
of  cryptolepine analogues  for potential as new antimalarial agents.  J. Med. Chem. 
44: 3187‐94. 
 
 195
 
 
 
 
Xu, Y., Eads, J., Sacchettini, J.C., Grubmeyer, C. (1997) Kinetic mechanism of human 
hypoxanthine‐guanine phosphoribosyltransferase:  rapid phosphoribosyl  transfer 
hemistry. Biochemistry 36: 3700‐12. c
 
 
 
Xu,  Y.,  Grubmeyer,  C.  (1998)  Catalysis  in  human  hypoxanthine‐guanine 
phosphoribosyltransferase: Asp 137 acts as a general acid/base. Biochemistry 37: 
4114‐24. 
 
Yeung,  S.,  Pongtavornpinyo,  W.,  Hastings,  I.M.,  Mills,  A.J.,  White,  N.J.  (2004) 
Antimalarial  drug  resistance,  artemisinin‐based  combination  therapy,  and  the 
ontribution of modeling  to elucidating policy choices. Am.  J. Trop. Med. Hyg. 71: c
179‐86. 
 
You,  D.,  Chen,  Q.,  Liang,  Y.,  An,  J.,  Li,  R.,  Gu,  X.,  Luo,  M.,  Su,  X.D.  (2003)  Protein 
preparation,  crystallization  and  preliminary  X‐ray  crystallographic  studies  of  a 
hermostable  hypoxanthine‐guanine  phosphoribosyltransferase  from t
Thermoanaerobacter tengcongensis. Acta Crysta. D 59: 1863‐5.  
 
Young,  M.J.T.,  Platz,  M.S.  (1991)  Mechanistic  analysis  of  the  reactions  of 
a n(pentafluorophenyl)nitrene in  lka es. J. Org. Chem. 56: 6403‐06. 
 
Yuvaniyama,  J.,  Chitnumsub,  P.,  Kamchonwongpaisan,  S.,  Vanichtanankul,  J., 
Sirawaraporn, W., Taylor, P., Walkinshaw, M.D., Yuthavong, Y. (2003) Insights into 
antifolate resistance from malarial DHFR‐TS structures. Nat. Struct. Biol. 10: 357‐
65. 
 
hang,  H.,  Howard,  E.M.,  Roepe,  P.D.  (2002)  Analysis  of  the  antimalarial  drug 
p
Z
resistance  rotein Pfcrt expressed in yeast. J. Biol. Chem. 277: 49767‐75. 
 
hang,  K.,  Rathod,  P.K.  (2002)  Divergent  regulation  of  dihydrofolate  reductase 
etween malaria parasite and human host. Science 296: 545‐7. 
Z
b
 
 
 
 
 
 
 
 
 
 196
 
 
 
 
